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ABSTRACT	  
It	   is	  clear	  that	  the	  voltage-­‐gated	  proton	  channel	  HVCN1	  plays	  an	  essential	  role	   in	  a	  
range	   of	   cell	   types,	   in	   particular	   immune	   cells.	   Previous	   published	   work	   has	  
confirmed	   the	   existence	   of	   proton	   channels	   in	   both	   murine	   and	   human	  
macrophages.	   However,	   the	   role	   of	   HVCN1	   in	   macrophages	   has	   not	   been	  
investigated.	  Given	   that	   the	  current	   literature	  on	  voltage-­‐gated	  proton	  channels	   in	  
immune	  cells	  has	  found	  HVCN1	  to	  be	  involved	  in	  several	  cellular	  processes	  (such	  as	  
the	  respiratory	  burst	  and	  signalling	  events)	  it	  is	  important	  to	  establish	  its	  functional	  
role	  in	  macrophages,	  which	  are	  a	  crucial	  constituent	  of	  the	  immune	  system.	  	  
The	   aim	   of	   my	   thesis	   was	   to	   investigate	   the	   function	   of	   voltage-­‐gated	   proton	  
channels	  in	  macrophages	  with	  the	  use	  of	  mice	  with	  a	  disrupting	  mutation	  within	  the	  
Hvcn1	   gene,	   which	   results	   in	   HVCN1	   loss.	   In	   particular,	   I	   wanted	   to	   address	   how	  
Hvcn1-­‐/-­‐	   macrophages	   responded	   to	   LPS	   activation.	   I	   hypothesised	   that	   HVCN1	  
regulates	   the	   respiratory	   burst	   of	   macrophages	   and	   that	   it	   potentially	   modulates	  
mitochondrial	  ROS	  production,	  and	  in	  doing	  so,	  may	  affect	  several	  functional	  aspects	  
of	  macrophage	  biology.	  
I	   show	   here	   that	   the	   voltage-­‐gated	   proton	   channel,	   HVCN1,	   regulates	   phagocytic	  
respiratory	   burst,	   modulates	   the	  mitochondrial	   ROS	   production	   and	   inflammatory	  
response	   of	   macrophages.	   These	   cells	   also	   showed	   clear	   signs	   of	   mitochondrial	  
defect	  as	  they	  had	  attenuated	  mitochondrial	  respiration.	  Hvcn1-­‐/-­‐	  macrophages	  had	  
elevated	   basal	   levels	   of	   mitochondrial	   ROS,	   which	   resulted	   in	   the	   enhanced	  
activation	   of	   the	   redox-­‐sensitive	  MAPK	   and	  NF-­‐κB	   signaling	   pathways.	   This	   caused	  
	  	   iv 
Hvcn1-­‐/-­‐	   macrophages	   to	   produce	   increased	   cytokine	   production	   following	   LPS	  
activation.	  Our	  findings	  provide	  a	  new	  perspective	  for	  voltage-­‐gated	  proton	  channels	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1.1 THE	  IMMUNE	  SYSTEM	  
The	  immune	  system	  has	  continuously	  been	  evolved	  to	  efficiently	  detect,	  isolate	  and	  
eliminate	   infectious	   agents.	   The	   two	   arms	   of	   the	   immune	   system,	   innate	   and	  
adaptive,	  work	  together	  in	  order	  to	  successfully	  deal	  with	  those	  agents	  (Parkin	  and	  
Cohen,	  2001).	  	  
The	   innate	   immune	   system	   provides	   an	   acute	   and	   robust	   response	   to	   pathogenic	  
challenge	  as	  well	  as	   tissue	  damage.	   It	   relies	  on	  a	   limited	  number	  of	   receptors	   that	  
can	  detect	  pathogens,	  known	  as	  pattern	  recognition	  receptors	  (PPRs)	  (Lee	  and	  Kim,	  
2007).	   These	   receptors	   recognise	   conserved	   microbial	   molecules	   that	   are	  
characteristic	  of	   large	  groups	  of	  pathogens	  and	  are	  known	  as	  pathogen-­‐associated	  
molecular	  patterns	  (PAMPs)	  (Beutler,	  2004).	  The	  cells	  involved	  in	  the	  innate	  immune	  
system	   include	   macrophages,	   dendritic	   cells	   (DCs),	   mast	   cells,	   neutrophils,	  
eosinophils,	  basophils,	  natural	  killer	  (NK)	  cells	  and	  NK	  T	  cells.	  The	  cells	  of	  the	  innate	  
immune	   system	   rapidly	   generate	   an	   inflammatory	   response	   upon	   encountering	  
pathogens	  (Turvey	  and	  Broide,	  2010).	  Moreover,	  these	  cells	  are	  crucial	  for	  activating	  
and	   amplifying	   the	   adaptive	   immune	   system	   (Figure	   ).	   Antigen-­‐presenting	   cells	  
(APCs)	   phagocytose	   antigen	   and	   then	   display	   a	   fragment	   of	   the	   antigen,	   which	   is	  
bound	   to	   major	   histocompatibility	   complex	   (MHC)	   class	   II,	   on	   their	   plasma	  
membrane.	   This	   allows	   cells	   of	   the	   adaptive	   immune	   system,	   such	   as	   T	   cells,	   to	  
recognise	   and	   interact	   with	   the	   presented	   antigen	   and	   thus	   becomes	   activated	  
(Trombetta	  and	  Mellman,	  2005).	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The	  cells	  of	  the	  innate	  immune	  system	  are	  limited	  by	  the	  range	  of	  PAMPs	  that	  they	  
can	   recognise.	   In	  addition,	  pathogens	  have	   the	  ability	   to	  mutate	   in	  order	   to	  evade	  
host	   detection.	   This	   has	   propelled	   the	   evolution	   of	   the	   adaptive	   immune	   system	  
(Cooper	  and	  Alder,	  2006).	  Cells	  of	   the	  adaptive	   immune	  system	  include	  T	  cells	  and	  
antibody-­‐producing	  B	  cells.	  The	  full	  response	  of	  the	  adaptive	  immune	  system	  is	  less	  
rapid	  as	  it	  is	  mounted	  towards	  specific	  antigens.	  This	  allows	  the	  system	  to	  generate	  a	  
life-­‐long	  ‘immunological	  memory’	  and	  thus	  a	  swifter	  response	  is	  produced	  upon	  re-­‐
exposure	  to	  those	   individual	  antigens	  (Dempsey	  et	  al.,	  2003).	  B	  cells	  activation	  can	  
occur	  either	  through	  binding	  of	  antigen	  or	  though	  the	  actions	  of	  helper	  T	  cells.	  This	  
allows	   B	   cells	   to	   mature	   into	   antibody-­‐secreting	   plasma	   cells	   (Figure	   ).	   T	   cells,	  
however,	  are	  dependent	  on	  antigen	  presentation	  by	  APCs	  (via	  MHC	  II)	  or	  any	  other	  
cell	  type	  via	  MHC	  I	  (Figure	  1	  -­‐	  1)	  (Bonilla	  and	  Oettgen,	  2010).	  	  
Whilst	  this	   is	  the	  trademark	  of	  the	   immune	  system,	   it	   is	  also	  crucial	  to	  maintaining	  
homeostasis.	  The	  system	  faces	  constant	  exposure	  to	  a	  range	  of	  other	  foreign	  agents	  
(environmental,	  dietary,	  toxins	  etc.)	  and	  to	  the	  high	  turnover	  of	  cells,	  which	  includes	  
both	  those	  that	  are	  of	  an	  apoptotic	  and	  necrotic	  nature	  (Sirisinha,	  2011).	  An	  active	  
immune	   response	   to	   these	   homeostatic	   procedures	   would	   be	   both	   wasteful	   and	  
detrimental	  to	  the	  host.	  That	  is	  why	  the	  immune	  system	  has	  evolved	  in	  such	  a	  way	  
to	   allow	   maintenance	   procedures	   to	   occur	   in	   the	   absence	   of	   an	   immune	   assault	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Figure	  1	  -­‐	  1	  Innate	  and	  adaptive	  immune	  cell	  interactions	  
APCs	   ingest	  antigens	  that	  are	  then	  bound	  to	  MHC	  II	  and	  presented	  to	  T	  cell,	  which	  
activates	  these	  cells.	  T	  cells	  can	  also	  recognise	  antigens	  presented	  on	  MHC	  I	  on	  other	  
cell	  types,	  such	  as	  epithelial	  cells.	  B	  cells	  can	  act	  as	  APCs	  and	  bind	  antigen,	  but	  need	  
co-­‐stimulation	  in	  the	  form	  of	  TLR	  activation	  in	  order	  for	  themselves	  to	  be	  activated.	  
They	   can	   also	   be	   activated	   though	   the	   actions	   of	   helper	   T	   cells.	   Both	   activation	  
mechanisms	   induce	   the	   maturation	   of	   B	   cells	   into	   plasma	   cells,	   the	   antibody-­‐
producing	  cells	  of	  the	  adaptive	  immune	  system.	  Adapted	  from	  (Chaplin,	  2010).	  
	  
	  
CHAPTER	  ONE	  	  	  	  	   INTRODUCTION	  –	  MONONUCLEAR	  PHAGOCYTE	  SYSTEM	  
	   	   25 
1.2 MONONUCLEAR	  PHAGOCYTE	  SYSTEM	  
Elie	  Metchnikoff	  first	  described	  macrophages	  in	  the	  19th	  century.	  Macrophages	  were	  
originally	   classified	   as	   reticular	   cells,	   a	   type	   of	   phagocytes	   that	   were	   part	   of	   the	  
reticuloendothelia	   system	   (Kaufmann,	   2008).	   The	   system	  also	   included	   endothelial	  
cells,	  monocytes	  and	  histiocytes.	   It	  was	  believed	  that	  reticular	  cells	  and	  endothelia	  
shared	   a	   common	   tissue	   origin	   owing	   to	   initial	   studies	   on	   phagocytic	   activity	  
(Hashimoto	   et	   al.,	   2011).	  However,	   functional	   and	  morphological	   differences	  were	  
discovered	  between	  endothelial	  cells	  and	  macrophages,	  which	  led	  to	  the	  rejection	  of	  
the	  reticuloendothelial	  system.	  Since	  then,	  it	  has	  been	  recognised	  that	  macrophages	  
are	   present	   in	   virtually	   every	   tissue	   of	   the	   body.	   Tissue	  macrophages	   show	   great	  
heterogeneity,	  which	   is	   attributed	   to	   the	   their	   different	   anatomical	   locations.	   This	  
heterogeneity	   is	  due	  to	  the	  specialised	  functions	  performed	  by	  those	  macrophages	  
(Gordon	  and	  Taylor,	  2005).	  
A	  seminal	  study	  in	  1968	  provided	  evidence	  that	  distinct	  populations	  of	  macrophages	  
were	   derived	   from	  monocytes	   in	   the	   circulation	   (van	   Furth	   and	   Cohn,	   1968).	   This	  
concept	   established	   the	   early	  mononuclear	   phagocyte	   system	   (MPS)	   (van	   Furth	   et	  
al.,	  1972).	  The	  idea	  of	  the	  MPS	  as	  such	  a	  strict	  linear	  model	  was	  disputed	  by	  others	  
who	   found	   evidence	   for	  macrophage	   proliferation	   in	   the	   tissues	   (Melnicoff	   et	   al.,	  
1988)	  and	  the	  existence	  of	  macrophages	  in	  the	  early	  yolk	  sac	  (Naito	  et	  al.,	  1996).	  The	  
MPS	   includes	   monocytes,	   macrophages	   and	   DCs.	   The	  MPS	   has	   been	   found	   to	   be	  
crucial	   in	   numerous	   host	   functions	   that	   are	   relevant	   in	   infection,	   inflammation,	  
autoimmunity,	  organ	   transplantation	  and	  cancer	   (Wynn	  et	  al.,	  2013).	  All	  blood	  cell	  
types	  are	  generated	  from	  hematopoietic	  stem	  cells	  (HSCs).	  Successive	  commitment	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steps	   from	   the	  HSCs	  give	   rise	   to	   common	  myeloid	  progenitors	   (MPs),	   granulocyte-­‐
macrophage	  progenitors	  (GMPs)	  and	  macrophage/DC	  progenitors	  (Fogg	  et	  al.,	  2006).	  
It	   is	  thought	  that	  cells	  are	  committed	  to	  the	  mononuclear	  phagocyte	  lineage	  at	  the	  
MDP	   stage,	   where	   the	   fates	   of	   other	   cell	   types	   (lymphoid,	   erythrocyte,	  
megakaryocyte	  and	  granulocyte)	  have	  already	  been	  precluded	  (Iwasaki	  and	  Akashi,	  
2007).	   MDPs	   differentiate	   into	   monocytes	   (Ly6C-­‐	   and	   Ly6C+)	   or	   common	   DC	  
progenitors	   (CDP).	  The	  majority	  of	   lymphoid	  and	  non-­‐lymphoid	   tissue	  DCs,	   such	  as	  
plasmacytoid	  DCs	  (pDCs),	  are	  derived	  from	  CDPs	  (Naik	  et	  al.,	  2007).	   In	  comparison,	  
monocytes	  can	  differentiate	  into	  macrophages/DCs	  or	  participate	  as	  effector	  cells	  in	  
immune	  responses.	  Monocytes	  are	  generally	  found	  in	  the	  bone	  marrow,	  circulation	  
and	   spleen.	   They	   can	   migrate	   into	   tissues	   to	   replenish	   resident	   myeloid	   cell	  
populations	   under	   both	   physiological	   and	   pathophysiological	   situations	   (Auffray	   et	  
al.,	  2009).	  
In	   humans,	   monocytes	   have	   been	   found	   to	   show	  morphological	   heterogeneity	   in	  
terms	   of	   size	   and	   granularity.	   This	   apparent	   heterogeneity	   led	   to	   studies	   that	  
identified	  differential	  expression	  of	  surface	  markers	  that	  gave	  rise	  to	  the	  recognition	  
of	  monocyte	  subsets	  (Ziegler-­‐Heitbrock	  et	  al.,	  1993).	  The	  two	  main	  subsets	  are	  based	  
on	   the	   expression	   of	   cluster	   of	   differentiation	   (CD)	   14	   (which	   forms	   part	   of	   the	  
receptor	   for	   lipopolysaccharide	   [LPS])	   and	   CD16,	   also	   known	   as	   Fc	   receptor	   γRIII.	  
Classical	  monocytes	   are	  described	  as	  CD14highCD16-­‐	  whilst	   non-­‐classical	  monocytes	  
are	  identified	  as	  CD14lowCD16+.	  Each	  subset	  shows	  distinct	  expression	  of	  a	  range	  of	  
other	   receptors,	   in	   particular	   the	   chemokine	   receptors.	   For	   example,	   classical	  
monocytes	  express	  CC-­‐chemokine	  receptor	  (CCR)	  2,	  whereas	  the	  non-­‐classical	  subset	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expresses	   CX3CR1.	   During	   inflammation	   classical	  monocytes	   invade	   tissue	   through	  
interaction	  of	  CCR2/CCL2	  in	  a	  VCAM1-­‐dependent	  manner.	   In	  contrast,	  non-­‐classical	  
monocytes	   invade	   through	   interaction	   of	   CX3CR1/CCL3	   in	   an	   ICAM1-­‐dependent	  
manner	  (Weber	  et	  al.,	  2000).	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1.3 CELLULAR	  ORIGINS	  OF	  TISSUE-­‐RESIDENT	  MACROPHAGES	  
The	  importance	  of	  macrophages	  in	  the	  innate	  immune	  system	  has	  been	  recognised	  
for	  decades.	  Macrophages	  are	  often	  the	  first	  type	  of	  cell	  to	  encounter	  a	  pathogen	  or	  
foreign	   substance.	   They	   have	   the	   ability	   to	   ingest	   pathogens	   and	   particles	   via	  
phagocytosis,	   one	   of	   their	   most	   distinctive	   properties	   (Wynn	   et	   al.,	   2013).	  
Macrophages	  can	  detect	  these	  pathogens	  using	  a	  number	  of	  PRRs	  such	  as	  the	  toll-­‐
like	   receptors	   (TLRs).	   In	   addition,	   they	   have	   an	   arsenal	   of	   antimicrobial	   effector	  
mechanisms	  to	  eliminate	  pathogens	  including	  oxidation,	  antimicrobial	  peptides	  and	  
enzymatic	  degradation	  (Rees,	  2010).	  Macrophages	  are	  also	   important	   in	  amplifying	  
the	   adaptive	   immune	   response	   through	   their	   antigen-­‐presenting	   abilities	   (Bonilla	  
and	  Oettgen,	  2010).	  
Tissue-­‐resident	  macrophage	  populations	   can	  be	   found	   in	   the	  majority	  of	   tissues	   in	  
the	   body	   (Table	   1	   -­‐	   1).	   There	   is	   great	   heterogeneity	   in	   the	   tissue-­‐resident	  
macrophages	  and	  this	   is	   important	  as	  they	  perform	  specific	  functions	  in	  the	  tissues	  
that	  they	  occupy	  in	  order	  to	  maintain	  homeostasis.	  The	  microanatomical	  niches	  that	  
tissue-­‐resident	   macrophages	   are	   positioned	   in	   allow	   them	   to	   provide	   defence	  
against	   pathogens,	   aid	   in	   tissue	   repair	   after	   tissue	   injury	   and	   maintain	   tissue	  
homeostasis	  through	  clearance	  of	  apoptotic/necrotic	  cells	  (Elliott	  and	  Ravichandran,	  
2010).	  	  
As	   previously	   described,	   the	   foundational	   dogma	   states	   that	   tissue-­‐resident	  
macrophages	   are	   constitutively	   replenished	   by	   circulating	  monocytes	   in	   the	   adult.	  
However,	  recent	  findings	   into	  the	  origin	  of	  tissue-­‐resident	  macrophage	  populations	  
have	  found	  evidence	  that	  challenges	  this	  model.	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Tissue	   Cell	  type	   Function	  
Central	  nervous	  system	   Microglia	  
Neural	  survival,	  immune	  
surveillance	  
Bone	  




Gastrointestinal	  tract	   Intestinal	  macrophages	   Intestinal	  homeostasis	  
Liver	   Kupffer	  cells	  
Clearance	  of	  
microorganisms,	  cell	  
debris	  and	  aged	  
erythrocytes	  






Dermal	  macrophages	   Immune	  surveillance	  









Red	  pulp	  macrophages	   Erythrocyte	  clearance	  and	  
iron	  metabolism	  
White	  pulp	  macrophages	   Clearance	  of	  apoptotic	  
cells	  
	  
Table	  1	  -­‐	  1	  Distinct	  locations	  and	  functions	  of	  tissue	  macrophages.	  
Select	  examples	  of	   tissue-­‐resident	  macrophages	  and	   their	   functions.	  Adapted	   from	  
Davies	  et	  al.	  (2013)	  (Davies	  et	  al.,	  2013)	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Embryonic	   progenitors	   from	   the	   yolk	   sac	   have	   been	   found	   to	   give	   rise	   to	   major	  
macrophage	   populations,	   such	   as	   the	   central	   nervous	   system	   (CNS)-­‐resident	  
macrophages	  (Ginhoux	  et	  al.,	  2010),	  Kupffer	  cells,	  and	  Langerhans	  cells	  (Schulz	  et	  al.,	  
2012).	  	  
A	   number	   of	   macrophage	   populations	   in	   tissues	   have	   also	   been	   found	   to	   be	  
maintained	  long-­‐term	  without	  the	  input	  from	  hematopoietic	  stem	  cells	  (Hashimoto	  
et	   al.,	   2013,	   Ajami	   et	   al.,	   2007,	   Yona	   et	   al.,	   2013).	   Hashimoto	   et	   al.	   used	   fate-­‐
mapping	  models,	   such	   as	  Mx1/S100a4-­‐cre	   x	   R26Tomato,	   to	   find	   that	   tissue-­‐resident	  
macrophages	   expressed	   minimal	   levels	   of	   tdTomato,	   which	   indicates	   a	   lack	   of	  
monocyte	  contribution	  to	  tissue-­‐resident	  macrophages.	  This	  was	  further	  confirmed	  
with	   the	  use	  of	  parabiotic	   approaches.	   The	  authors	  also	  used	  a	  genotoxic	  ablation	  
approach	  to	  deplete	  lung	  macrophages	  and	  found	  that	  re-­‐population	  was	  mainly	  due	  
to	   cell	   proliferation	   in	   situ.	   Finally	   they	   observed	   that	  mice	   given	   a	   bone	  marrow	  
transplantation	   of	   GM-­‐CSF	   receptor-­‐deficient	   progenitors	   still	   managed	   to	   expand	  
their	  tissue-­‐resident	  macrophages	  (Hashimoto	  et	  al.,	  2013).	  
Recent	   studies	   have	   observed	   significant	   macrophage	   proliferation	   during	   tissue	  
stress,	   such	   as	   infection.	   Jenkins	   et	   al.	   found	   that	   during	   helminth	   infection	   very	  
small	   numbers	   of	  monocytes	   accumulated	   in	   the	   peritoneal	   cavity	   of	   the	   animals.	  
Despite	   this	   there	   was	   a	   significant	   infiltration	   of	   alternatively	   activated	  
macrophages.	  They	  further	  confirmed	  this	  by	  repeating	  the	  experiment	  and	  this	  time	  
giving	   the	   animals	   clodronate-­‐loaded	   liposomes,	   which	   deplete	   monocytes.	   They	  
found	  that	  this	  did	  not	  affect	  the	  number	  of	  alternatively	  activated	  macrophages	  in	  
the	   peritoneal	   cavity.	   The	   authors	   found	   that	   the	   large	   increase	   in	   macrophages	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numbers	   in	   the	   peritoneal	   cavity	   were	   due	   to	   local	   proliferation	   and	   highly	  
dependent	   on	   IL-­‐4	   availability.	   IL-­‐4-­‐deficient	   animals	   infected	   in	   the	   same	  manner	  
had	  significantly	  fewer	  proliferating	  macrophages	  in	  the	  cavity	  (Jenkins	  et	  al.,	  2011).	  	  
Notably,	   the	   long-­‐held	  view	  that	  monocytes	  rapidly	  differentiate	   into	  macrophages	  
upon	   entering	   tissues	   is	   now	   being	   revised	   as	   recent	   evidence	   has	   shown	   that	  
monocytes	  can	  enter	  steady-­‐state	  nonlymphoid	  organs	  and	  re-­‐enter	  the	  circulation	  
without	  differentiating	  (Jakubzick	  et	  al.,	  2013,	  Gautier	  et	  al.,	  2012).	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1.4 MACROPHAGE	  ACTIVATION	  
Macrophages	  display	  remarkable	  plasticity	  and	  can	  thus	  rapidly	  respond	  to	  injury	  or	  
infection	  by	  changing	  their	  physiology	  to	  adapt	  to	  a	  particular	  situation	  (Mosser	  and	  
Edwards,	   2008).	   The	   activation	   phenotype	   of	   recruited	   macrophages	   is	   mainly	  
determined	  by	  soluble	  cues	  generated	  by	  the	  surrounding	  microenvironment	  (Figure	  
1	   -­‐	   2).	   Two	   general	  macrophage	   activation	   phenotypes	   have	  been	   recognised	   that	  
mirror	   T	   helper	   polarisation	   (TH1/TH2):	   the	   classically	   activated	   (M1)	   macrophage	  
phenotype	  and	  the	  alternatively	  activated	  (M2)	  macrophage	  phenotype	  (Mills	  et	  al.,	  
2000).	   Regulatory	   macrophages	   have	   also	   been	   described	   as	   a	   third	   macrophage	  
phenotype	  (Gerber	  and	  Mosser,	  2001).	  
1.4.1 CLASSICAL	  MACROPHAGE	  ACTIVATION	  
Macrophages	   were	   originally	   polarised	   towards	   the	   M1	   phenotype	   with	   the	  
combination	   of	   two	   signals,	   interferon	   (IFN)-­‐γ	   and	   tumour-­‐necrosis	   factor	   (TNF)	  
(O'Shea	  and	  Murray,	  2008).	  Bacterial	   components,	   such	  as	   LPS,	   in	   the	  presence	  of	  
IFN-­‐γ	   can	   also	   lead	   to	   classical	   activation	   of	   macrophages.	   M1	   macrophages	   are	  
characterised	  by	   the	  production	  of	   reactive	  oxygen	  and	  nitrogen	  species,	   secretion	  
of	  large	  amounts	  of	  pro-­‐inflammatory	  cytokines	  (in	  particular	  interleukin	  [IL]-­‐12)	  and	  
mediators	  (Galli	  et	  al.,	  2011).	  Classically	  activated	  macrophages	  also	  have	  an	  efficient	  
antigen	   presenting	   capacity	   and	   promote	   the	   induction	   of	   TH1	   cells	   through	  
stimulation	  by	  IL-­‐12	  and	  interaction	  with	  MHC	  II.	  
Both	  innate	  and	  adaptive	  immune	  cells	  can	  produce	  IFN-­‐γ	  and	  an	  important	  source	  
of	  IFN-­‐γ	  is	  provided	  by	  NK	  cells,	  which	  produce	  the	  cytokine	  in	  response	  to	  stress	  and	  
infection.	  However,	  NK	  cells	  only	  transiently	  produce	  IFN-­‐γ	  and	  cannot	  sustain	  large	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populations	   of	   classical	   macrophages.	   	   In	   order	   to	   maintain	   classically	   activated	  
macrophages	   and	   support	   host	   defences,	   TH1	   cells	   provide	   the	   necessary	   levels	   of	  
the	  cytokine	  (Biswas	  and	  Mantovani,	  2010).	  
Whilst	   the	   pro-­‐inflammatory	   cytokines	   that	   are	   produced	   by	   classically	   activated	  
macrophages	   play	   a	   crucial	   role	   in	   host	   defence,	   they	   also	   have	   the	   potential	   to	  
cause	  widespread	  damage	   to	   the	  host	   tissue	  by	  maintaining	   inflammation	   through	  
the	   recruitment	   of	   additional	   inflammatory	   immune	   cells	   (Langrish	   et	   al.,	   2005,	  
Veldhoen	  et	  al.,	  2006).	  Indeed,	  classically	  activated	  macrophages	  have	  been	  found	  to	  
have	   distinct	   roles	   in	   mediating	   the	   immunopathology	   of	   several	   autoimmune	  
diseases	   such	   as	   inflammatory	   bowel	   disease	   (Hontecillas	   et	   al.,	   2011)	   and	  
rheumatoid	  arthritis	   (RA)	   (Szekanecz	  and	  Koch,	  2007).	  Therefore,	   it	   is	  vital	   that	  the	  
activation	  of	  M1	  macrophages	  is	  tightly	  regulated.	  
1.4.2 ALTERNATIVE	  MACROPHAGE	  ACTIVATION	  
Alternatively	   activated	   macrophages	   were	   originally	   described	   as	   a	   population	   of	  
macrophages	  responding	  to	  the	  TH2	  cytokine,	   IL-­‐4	  (Stein	  et	  al.,	  1992).	   It	   is	  believed	  
that	  that	   IL-­‐4	   is	  one	  of	  the	  first	   innate	  cytokines	  to	  be	  released	  during	  tissue	  injury	  
(Loke	  et	  al.,	  2007).	  Mast	  cells	  and	  basophils	  are	  the	  main	  early	  sources	  of	  innate	  IL-­‐4	  
(Kuroda	   et	   al.,	   2009),	   although	  other	   cell	   types	   have	   also	   been	   implicated	   such	   as	  
polymorphonuclear	  neutrophils	  (Brandt	  et	  al.,	  2000).	  
Alternatively	  activated	  macrophages	  participate	   in	  TH2-­‐type	  immune	  responses	  and	  
the	   signature	   cytokines	   found	   in	   such	   a	   response	   are	   IL-­‐4	   and	   IL-­‐13	   (Raes	   et	   al.,	  
2007).	  Indeed,	  it	  has	  been	  shown	  that	  the	  M2	  phenotype	  can	  be	  induced	  in	  vitro	  in	  
response	  to	  IL-­‐4	  and/or	  IL-­‐13.	  Macrophages	  treated	  in	  such	  a	  manner	  cannot	  present	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antigen	  to	  T	  cells,	  produce	  almost	  no	  pro-­‐inflammatory	  cytokines	  and	  generate	  very	  
low	  levels	  of	  reactive	  oxygen	  species	  (ROS)	  (Edwards	  et	  al.,	  2006).	  
Alternatively	   activated	   macrophages	   are	   characterised	   by	   high	   expression	   of	  
mannose	   and	   scavenger	   receptors,	   enhanced	   phagocytic	   ability,	   increased	  
production	  of	   IL-­‐10	  and	  high	  arginase	  activity	   (Gordon	  and	  Taylor,	   2005).	  Arginase	  
allows	   the	   conversion	   of	   arginine	   to	   ornithine,	   which	   serves	   as	   a	   precursor	   to	  
collagen	   and	   polyamines,	   and	   thus	   contributes	   to	   the	   production	   of	   extracellular	  
matrix	   related	   proteins	   (Kreider	   et	   al.,	   2007).	   These	   characteristics	   imply	   that	   the	  
primary	  function	  of	  alternatively	  activated	  macrophages	  is	  related	  to	  wound	  healing,	  
which	  is	  why	  they	  are	  also	  referred	  to	  as	  “wound-­‐healing	  macrophages”	  (Mosser	  and	  
Edwards,	  2008).	  Indeed,	  alternatively	  activated	  macrophages	  have	  the	  ability	  to	  limit	  
inflammation,	  aid	  in	  tissue	  repair	  and	  also	  exhibit	  some	  immunoregulatory	  functions	  
(Wynn	  and	  Barron,	  2010).	  
Similarly	   to	   the	   uncontrolled	   activity	   of	   classically	   activated	   macrophages	   in	  
autoimmune	  disorders,	  the	  actions	  of	  alternatively	  activated	  macrophages	  can	  also	  
be	  detrimental	  to	  the	  host	  tissue.	  In	  particular,	  it	  is	  the	  deregulation	  of	  their	  matrix-­‐
enhancing	   activity	   that	   has	   been	   implicated	   in	   disease	   states	   such	   as	   chronic	  
schistosomiasis	  (Hesse	  et	  al.,	  2001)	  and	  asthma	  (Munitz	  et	  al.,	  2008).	  During	  chronic	  
schistosomiasis,	   Th2	   cytokines	   IL-­‐4	   and	   IL-­‐13	   increase	   the	   number	   of	   alternatively	  
activated	   macrophages	   that	   cause	   fibrotic	   pathology	   in	   the	   form	   of	   increased	  
collagen	   deposition	   (Barron	   and	   Wynn,	   2011).	   Similarly	   in	   asthma,	   alternatively	  
activated	   macrophages	   have	   been	   found	   to	   exacerbate	   the	   condition	   through	  
increased	   collagen	   deposition.	   In	   addition,	   alternatively	   activated	   macrophages	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secrete	  TGFβ	  that	  causes	  goblet	  cells	   to	  secrete	   increased	  amounts	  mucus	  (Hussell	  
and	   Bell,	   2014).
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Figure	  1	  -­‐	  2	  Macrophage	  activation	  states	  	  
In	   response	   to	   stimuli	   such	   as	   LPS,	   IFNγ	   and	   TNF,	  macrophages	  become	   classically	  
activated.	  This	  phenotype	   is	  associated	  with	  pro-­‐inflammatory	  cytokine	  production	  
and	   microbicidal	   activity.	   IL-­‐4	   secreted	   by	   granulocytes	   can	   induce	   alternatively	  
activated	   macrophages,	   which	   are	   associated	   with	   wound-­‐healing	   activities.	  
Regulatory	   macrophages	   are	   induced	   in	   the	   presence	   of	   Il-­‐10	   and	   other	   anti-­‐
inflammatory	  factors.	  Adapted	  from	  (Mosser	  and	  Edwards,	  2008).	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1.4.3 REGULATORY	  MACROPHAGE	  ACTIVATION	  
Regulatory	   macrophages	   can	   be	   induced	   by	   TLR	   agonists	   in	   the	   presence	   of	  
immunoglobulin	  G	  (Ig)G	  immune	  complexes	  (Gerber	  and	  Mosser,	  2001),	  engulfment	  
of	  apoptotic	  cells	  (Erwig	  and	  Henson,	  2007),	  prostaglandins	  (Strassmann	  et	  al.,	  1994)	  
and	  stimulation	  by	  IL-­‐10	  (Martinez	  et	  al.,	  2008).	  
Regulatory	  macrophages	  are	  characterised	  by	  their	  production	  of	  IL-­‐10	  and	  tumour	  
growth	   factor	   (TGF)-­‐β,	   poor	   antigen	  presenting	   capacity,	   and	   induction	  of	   TH2	   and	  
regulatory	   T	   cell	   (Treg)	   responses	   (Edwards	   et	   al.,	   2006).	   These	   characteristics	   gear	  
regulatory	  macrophages	   towards	  dampening	   immune	  responses	  and	   inflammation.	  
However,	   unlike	   alternatively	   activated	   macrophages,	   regulatory	   macrophages	   do	  
not	   produce	   extracellular	   matrix	   related	   proteins	   and	   have	   a	   better	   antigen	  
presenting	  ability	  in	  comparison	  (Edwards	  et	  al.,	  2006).	  
It	  is	  believed	  that	  there	  is	  a	  spectrum	  of	  macrophage	  activation	  phenotypes	  despite	  
the	   description	   of	   distinct	   subpopulations	   of	   macrophages.	   Macrophages	   show	   a	  
high	  degree	  of	  plasticity	  and	  have	  been	  found	  to	  readily	  change	  from	  one	  functional	  
phenotype	   to	  another	   in	   response	   to	  new	  environmental	   cues	   (Stout	  et	  al.,	   2005).	  
Both	   injury	   and	   pathological	   conditions	   are	   associated	   with	   dynamic	   changes	   in	  
macrophage	   phenotypes.	   Classically	   activated	   macrophages	   are	   frequently	  
associated	   with	   initiating	   and	   maintaining	   inflammation	   and	   the	   macrophage	  
population	  is	  found	  to	  switch	  to	  the	  alternative	  activation	  to	  resolve	  inflammation	  or	  
to	   lead	   to	  a	   chronic	   condition.	  The	   re-­‐education	  of	  what	   is	  essentially	   a	   terminally	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differentiated	   cell	   allows	   macrophages	   to	   respond	   to	   environmental	   signals	   and	  
adapt	  to	  the	  situation	  at	  hand	  (Sica	  and	  Mantovani,	  2012).	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1.5 MACROPHAGES	  IN	  TISSUE	  HOMEOSTASIS	  
One	  of	  the	  most	  important	  functions	  of	  macrophages	  is	  that	  of	  immune	  surveillance,	  
which	   they	  are	  able	   to	  perform	  since	   they	  are	  strategically	   located	   throughout	   the	  
body.	  They	  constantly	   scan	   their	  environment	   for	   signs	  of	   tissue	   injury	  or	   invading	  
pathogens	   (Lech	   et	   al.,	   2012).	   Once	   a	   danger	   signal	   is	   detected	   by	   cell	   surface	  
receptors	   and/or	   phagocytosed	   it	   is	   readily	   conveyed	   by	   macrophages	   to	  
lymphocytes	  and	  other	   immune	  cells,	  which	  are	  stimulated	  by	  the	  macrophages	  to	  
respond	   (Underhill	   and	   Ozinsky,	   2002).	   For	   example,	   when	   a	   macrophage	  
encounters	  a	  pathogen	   it	   is	   ingested	  and	  enveloped	   in	  a	  phagosome	  to	  quarantine	  
the	   threat.	  A	   lysosome	  will	   then	   fuse	  with	   the	  phagosome	   in	  order	   to	  destroy	   the	  
pathogen.	   The	   phagolysosome	   achieves	   this	   by	   releasing	   ROS	   and	   enzymes	   that	  
damage	  and	  digest	  the	  pathogen	  (Aderem	  and	  Underhill,	  1999).	   It	  should	  be	  noted	  
that	   certain	   pathogens	   have	   developed	   specific	   mechanisms	   to	   prevent	   their	  
destruction,	  either	  through	  escaping	  the	  phagolysosome	  or	  neutralising	  the	  released	  
enzymes/ROS.	   L.	   monocytogenes	   escape	   by	   lysing	   the	   phagolysosome	   membrane	  
through	  the	  secretion	  of	  the	  enzyme	  phospholipase	  C.	  S.	  aureus	  neutralises	  the	  ROS	  
released	   by	   the	   phagolysosome	   through	   its	   own	   secretion	   of	   catalse	   and	   SOD	  	  
(Rosenberger	  and	  Finlay,	  2003).	  
In	  addition	  to	  their	  vital	  role	  in	  warding	  off	   infections,	  tissue	  resident	  macrophages	  
maintain	   tissue	   homeostasis	   by	   phagocytosing	   toxins,	   apoptotic	   and	   necrotic	   cells	  
(Henson	  and	  Hume,	  2006).	  For	  example,	  in	  the	  liver	  the	  function	  of	  Kupffer	  cells	  is	  to	  
clear	  erythrocytes,	  pathogens	  and	  toxic	  materials	   from	  the	  circulation	  (Bilzer	  et	  al.,	  
2006),	   whereas	   alveolar	   macrophages	   are	   ideally	   located	   in	   the	   lung	   in	   order	   to	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assist	   in	   the	   removal	  of	   allergens	   (Kirby	  et	  al.,	   2009).	   Following	   infection	  or	   injury,	  
tissue	   resident	   macrophages	   also	   maintain	   tissue	   homeostasis	   by	   suppressing	  
inflammation	  mediated	  by	  inflammatory	  monocytes	  (Fujiwara	  and	  Kobayashi,	  2005).	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1.6 MACROPHAGES	  IN	  TISSUE	  INJURY	  
A	  highly	  debated	  question	  in	  the	  macrophage	  biology	  field	  at	  the	  moment	  is	  whether	  
tissue	  resident	  macrophages	  within	  any	  given	  organ	  can	  sufficiently	  deal	  with	  tissue	  
injury	  or	  if	  it	  is	  essential	  to	  recruit	  inflammatory	  monocytes	  to	  the	  tissue	  to	  replenish	  
the	   myeloid	   numbers	   (Brancato	   and	   Albina,	   2011).	   In	   many	   infections	   and	   tissue	  
injury	   situations	   the	   resident	   population	   of	   macrophages	   are	   overwhelmed	   and	  
cannot	   efficiently	  mediate	   both	   defence	   against	   pathogens	   as	   well	   as	   subsequent	  
tissue	   repair.	   The	   foundational	   dogma	   thus	   far	   has	   dictated	   that	   in	   situations	   of	  
tissue	   injury,	   monocytes	   are	   recruited	   to	   the	   damaged	   tissue	   and	   terminally	  
differentiate	  into	  a	  spectrum	  of	  macrophages	  (Weidenbusch	  and	  Anders,	  2012).	  
The	  increased	  production	  of	  monocytes	  and	  neutrophils	  is	  driven	  by	  tissue	  stress	  in	  
the	  form	  of	  both	  acute	  and	  chronic	  inflammation	  as	  well	  as	  sterile	  inflammation	  (Shi	  
and	  Pamer,	  2011).	   The	  processes	  of	  production	  and	  migration	   to	   the	   site	  of	   injury	  
are	   heavily	   dependent	   on	   cytokines	   and	   chemokines	   such	   as	  macrophage	   –colony	  
stimulating	  factor	  (M-­‐CSF),	  granulocyte/macrophage	  colony	  stimulating	  factor	  (GM-­‐
CSF)	  and	  CC-­‐chemokine	  ligand	  (CCL)2	  (Serbina	  et	  al.,	  2008).	  As	  mentioned	  previously,	  
monocytes	  are	  generally	  thought	  to	  adopt	  two	  different	  phenotypes	  after	  exiting	  the	  
bone	  marrow	  (Geissmann	  et	  al.,	  2010).	   Importantly,	  only	  the	  Ly6Chi	  monocyte	  pool	  
expresses	  the	  CCR2	  and	  can	  thus	  respond	  to	  CCL2.	  Large	  pools	  of	  LY6Chi	  monocytes	  
are	  found	  in	  the	  subcapsular	  red	  pulp	  of	  the	  spleen	  and	  these	  are	  readily	  mobilised	  
to	  migrate	  to	  inflammatory	  sites	  (Swirski	  et	  al.,	  2009).	  
Following	   tissue	   injury,	   the	   initial	  macrophages	   responding	   to	   the	   insult	   exhibit	   an	  
inflammatory	   phenotype	   in	   order	   to	   be	   able	   to	   efficiently	   deal	   with	   the	   invading	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pathogen	   (Novak	  and	  Koh,	  2013).	  These	  classically	  activated	  macrophages	  produce	  
large	   amounts	   of	   pro-­‐inflammatory	   mediators	   and	   ROS	   that	   drive	   inflammatory	  
responses	   forward	   (Galli	   et	   al.,	   2011).	   However,	   an	   excessive	   production	   of	   pro-­‐
inflammatory	  mediators	   could	   lead	   to	   collateral	   tissue	   damage	   and	   it	   is	   therefore	  
essential	   that	   it	   be	   balanced	   to	   protect	   the	   surrounding	   tissue.	   Alternatively	  
activated	  macrophages	  and	  regulatory	  macrophages	  are	  crucial	   in	   these	  settings	   in	  
order	   to	   limit	   inflammation	   by	   antagonising	   the	   classically	   activated	   macrophage	  
responses,	   initiate	  wound	  healing	  and	   restore	   tissue	  homeostasis	   (Sindrilaru	  et	  al.,	  
2011).	   Tissue	   repair	   is	   also	   aided	   by	   macrophage-­‐derived	   TGF-­‐β,	   which	   induces	  
differentiation	   of	   fibroblasts	   into	   myofibroblasts,	   and	   production	   of	   the	  
immunoregulatory	  cytokine	  IL-­‐10	  (Gordon	  and	  Taylor,	  2005).	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1.7 MACROPHAGES	  IN	  DISEASE	  
Macrophages	   play	   important	   roles	   in	   the	   pathogenesis	   of	   many	   chronic	   diseases,	  
such	   as	   RA	   (McInnes	   and	   Schett,	   2011)	   and	   fibrosis	   (Wynn	   and	   Barron,	   2010).	   A	  
number	  of	  factors	  control	  the	  contribution	  of	  the	  macrophages	  to	  the	  disease	  state	  
and	  as	  such	  their	  involvement	  varies	  greatly	  in	  different	  stages	  of	  the	  disease.	  	  
A	   great	   deal	   of	   evidence	   shows	   that	   macrophages	   are	   intimately	   involved	   in	   the	  
pathogenesis	   of	   fibrotic	   diseases	   (Wynn	   and	   Barron,	   2010).	   In	   these	   instances,	  
macrophages	   are	   found	   to	   produce	   ‘pro-­‐fibrotic’	   mediators	   such	   as	   TGFβ1	  
(Broekelmann	   et	   al.,	   1991)	   and	   platelet-­‐derived	   growth	   factor	   (PDGF)	   (Nagaoka	   et	  
al.,	   1990).	   These	   mediators	   activate	   local	   fibroblasts,	   which	   regulate	   extracellular	  
matric	  deposition.	  Increased	  matrix	  deposition	  by	  these	  cells	  leads	  to	  fibrosis,	  which	  
can	   severly	   impair	   the	   function	   of	   the	   surrounding	   tissue	   (Wynn,	   2008).	  
Macrophages	  also	  produce	  matrix	  metalloproteases	   (MMPs),	  which	  are	   involved	   in	  
extracellular	  matrix	  (ECM)	  turnover	  (Wynn	  and	  Barron,	  2010).	  
In	  RA	  autoantibodies	  are	  produced	   that	   trigger	   the	  activation	  of	  macrophages	  and	  
mast	  cells	  through	  Fc	  receptor	  binding,	  which	  leads	  to	  local	  inflammation.	  	  (McInnes	  
and	  Schett,	  2011).	  Due	  to	  the	  constant	  presence	  of	  autoantibodies,	  this	  leads	  to	  the	  
development	  of	  chronic	  inflammation	  and	  this	  causes	  significant	  tissue	  damage	  (Ma	  
and	  Pope,	  2005).	  These	  macrophages	  produce	  many	  of	  the	   inflammatory	  cytokines	  
that	  are	  recognised	  as	  propagators	  of	  autoimmune	  inflammation,	  such	  as	  IL-­‐18,	  IL-­‐23	  
and	  TNFα	  (Murray	  and	  Wynn,	  2011).	  For	  example,	  TNFα	  production	  by	  macrophages	  
triggers	   cytokine	   secretion	   by	   synovial	   cells	   that	   can	   lead	   to	   the	   development	   of	  
chronic	  polyarthritis	  (Kawane	  et	  al.,	  2006).	  A	  great	  deal	  of	  bone	  loss	  is	  also	  observed	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with	   RA	   due	   to	   unrestrained	   osteoclast	   function.	   CSF-­‐1	   and	   receptor	   activator	   of	  
nuclear	   factor	   kabba-­‐B	   ligand	   (RANKL)	   is	   locally	   produced	   in	   affected	   tissues	   and	  
leads	  to	  the	  recruitment	  and	  differentiation	  of	  monocytes	  into	  osteoclasts,	  which	  in	  
turn	  trigger	  the	  bone	  loss	  (Hamilton,	  2008,	  Dougall	  et	  al.,	  1999).	  	  	  
Macrophages	  are	  found	  in	  great	  numbers	  in	  tumours	  and	  have	  been	  associated	  with	  
pathogenic	   roles	   in	   tumourigenesis	   (Qian	   and	   Pollard,	   2010).	   Studies	   have	   shown	  
that	  macrophages	  can	  promote	  the	  progression	  of	  tumours	  though	  the	  secretion	  of	  
various	  mediators	  such	  as	  members	  of	  the	  vascular	  endothelial	  growth	  factor	  (VEGF)	  
family,	  which	  are	  involved	  in	  increasing	  the	  vascular	  density	  (Murdoch	  et	  al.,	  2008).	  
Macrophages	  have	  also	  been	   implied	   in	   facilitating	   tumour	  metastasis	   through	   the	  
regulation	   of	   ECM	   turnover	   with	   their	   production	   of	   proteases	   such	   as	   MMPs	  
(Mason	   and	   Joyce,	   2011).	   Several	   studies	   have	   highlighted	   the	   importance	   of	  
macrophages	   in	   tumourigenesis	   with	   the	   use	   of	   tumour	   xenografts	   where	  
macrophage	   ablation,	   in	   the	   form	  of	   CSF-­‐1	   blockade,	   led	   to	   a	   decrease	   in	   tumour	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1.8 VOLTAGE-­‐GATED	  PROTON	  CHANNELS	  
Proton	   currents	   were	   originally	   identified	   in	   snail	   neurons	   by	   Thomas	   and	  Meech	  
(1982)	  in	  the	  early	  1980s	  and	  have	  since	  been	  recorded	  in	  a	  variety	  of	  cells	  (Thomas	  
and	  Meech,	   1982);	   the	  most	   recent	  being	  mouse	  eosinophils	   (Zhu	  et	   al.,	   2013).	   In	  
2006,	   two	   independent	   groups	   discovered	   the	   Human	   Voltage-­‐gated	   Channel	   1	  
(Hvcn1)	  gene	  by	  clonal	  studies	  in	  mouse	  (Sasaki	  et	  al.,	  2006)	  and	  human	  (Ramsey	  et	  
al.,	   2006).	   The	   gene	   encodes	   a	   protein	   of	   273	   amino	   acids,	   which	   has	   a	   striking	  
resemblance	   to	   the	   voltage-­‐sensing	   domains	   of	   other	   ion	   channels.	   The	   HVCN1	  
protein	   forms	   the	   four	   transmembrane	   segments	   (S1-­‐S4)	   of	   a	   voltage-­‐sensing	  
domain	   observed	   in	   other	   voltage-­‐gated	   channels	   (Figure	   1	   –	   3);	   however,	   it	   does	  
not	  form	  a	  pore	  domain	  as	  it	  lacks	  the	  S5-­‐S6	  segments	  (Koch	  et	  al.,	  2008).	  	  
Voltage-­‐gated	   proton	   channels	   are	   extremely	   selective	   for	   protons	   (H+),	   with	   no	  
evident	   permeability	   to	   other	   cations.	   Several	   studies	   into	   the	   structure	   of	   the	  
proton	   channel	   have	   provided	   evidence	   that	   it	   is	   a	   dimer,	   with	   a	   separate	  
permeation	   pathway	   in	   each	   monomer	   (Hong	   et	   al.,	   2013,	   Tombola	   et	   al.,	   2010,	  
Musset	  et	  al.,	  2010a).	  These	  same	  studies	  also	  showed	  that	  the	  proton	  channel	  could	  
function	  as	  a	  monomer	  with	  the	  same	  functions	  as	  the	  dimer;	  however,	  it	  has	  been	  
established	   that	   the	   two	  monomers	  do	  not	   function	   independently	   to	   conduct	  H+.	  
Interestingly,	  the	  monomers	  cooperate	  during	  gating	  and	  thus	   increase	  the	  voltage	  
sensitivity	  of	  the	  channel	  two-­‐fold	  (Qiu	  et	  al.,	  2013).	  	  
Small	  peptides	  found	  in	  toxins	  from	  insects	  and	  animals	  can	  block	  most	  ion	  channels,	  
however,	   there	  are	  no	  known	  selective	   inhibitors	  of	  voltage-­‐gated	  proton	  channels	  
(Musset	   et	   al.,	   2010b).	   Despite	   being	   non-­‐selective,	   zinc	   (Zn2+)	   is	   the	  most	   potent	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inhibitor	  of	  voltage-­‐gated	  proton	  channels	  (Mahaut-­‐Smith,	  1989).	  Other	  cations	  have	  
also	  been	  found	  to	  be	  effective	  (DeCoursey	  et	  al.	  2007).	  The	  HVCN1	  protein	  has	  two	  
His	   residues	   that	   are	   accessible	   by	   extracellular	   molecules.	   Ramsey	   et	   al.	   (2006)	  
showed	   that	   by	   mutating	   either	   histidine	   (His)140	   or	   His193	   to	   alanine	   (Ala)	  
significantly	  affected	  Zn2+	   inhibition	  and	   the	  double	  mutant	  more	  or	   less	  abolished	  
Zn2+	   sensitivity	   (Ramsey	   et	   al.,	   2006).	  More	   recent	   studies	   have	   shed	   light	   on	   the	  
exact	  mechanism	  of	  this	  inhibition.	  Zn2+	  binds	  simultaneously	  to	  the	  His	  residues	  at	  









Figure	  1	  -­‐	  3	  Structure	  of	  the	  HVCN1	  protein	  
The	  figure	  shows	  the	  four	  transmembrane	  segment	  (S1-­‐S4)	  structure	  of	  HVCN1.	  The	  
four	   segments	   form	   the	   pore	   that	   allows	   the	   extrusion	   of	   protons.	   Adapted	   from	  
Berger	  and	  Isacoff	  (2011)	  (Berger	  and	  Isacoff,	  2011).	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Proton	   channels	   have	   been	   characterized,	   through	   electrophysiological	   studies,	   to	  
function	   in	   the	   plasma	  membrane.	  Other	   studies	   have	   shown	  evidence	   for	   proton	  
channel	   expression	  on	  other	  organelles	   as	  well.	  One	   such	   study	  used	   fluorescence	  
ratio	  imaging	  to	  study	  the	  factors	  that	  contribute	  to	  the	  establishment	  of	  the	  steady	  
state	   Golgi	   power	   of	   hydrogen	   (pH)	   in	   intact	   and	   permeabilised	   mammalian	   cells	  
(Vero	  cells,	  which	  are	  kidney	  epithelial	   cells	   from	  African	  green	  monkey)	   (Schapiro	  
and	  Grinstein,	  2000).	  They	  observed	  a	  net	  loss	  of	  H+	  from	  the	  Golgi	  that	  was	  neither	  
due	   to	   H+/cation	   antiporters	   or	   symporters.	   This	   H+	   conductive	   pathway	   was	  
sensitive	  to	  both	  voltage	  changes	  and	  Zn2+	  inhibition,	  thus	  suggesting	  the	  activity	  of	  
HVCN1.	   Okochi	   et	   al.	   (2009)	   studied	   phagosomal	   membrane	   fractions	   from	  
neutrophils	   and	   used	   immunoblotting	   to	   demonstrate	   that	   the	   fraction	   contained	  
the	   subunits	   of	   nicotinamide	   adenine	   dinucleotide	   phosphate	   (NADPH)	   oxidase	  
(gp91,	   p22,	   p47	   and	  p67)	   as	  well	   as	  HVCN1	   (Okochi	   et	   al.,	   2009).	   Recently,	   it	  was	  
shown	   that	   voltage-­‐gated	   proton	   channels	   are	   expressed	   in	   intracellular	  
compartment	  membranes	  in	  HeLa	  cells	  (Li	  et	  al.,	  2010).	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1.9 THE	  ROLE	  OF	  HVCN1	  IN	  IMMUNE	  CELLS	  
Only	   a	   few	   studies	   have	   investigated	   the	   phenotypes	   of	   immune	   cells	   deficient	   of	  
voltage-­‐gated	   proton	   channels.	   Below	   is	   a	   description	   of	   what	   work	   has	   been	  
previously	   conducted	   on	   a	   particular	   immune	   cell	   type	   and	   the	   findings	   of	   those	  
investigations.	  	  
1.9.1 POLYMORPHONUCLEAR	  LEUKOCYTES	  
1.9.1.1 NEUTROPHILS	  
Decoursey	   et	   al.	   were	   the	   first	   to	   report	   the	   need	   for	   proton	   channels	   in	   NADPH	  
oxidase-­‐mediated	   respiratory	  burst	   in	  phagocytes.	  Neutrophils	  were	   shown	   to	   rely	  
on	  proton	  channels	  in	  order	  to	  produce	  superoxide	  upon	  membrane	  depolarisation.	  
This	  was	  evident	  as	  the	  respiratory	  burst	  in	  neutrophils	  was	  impaired	  in	  the	  presence	  
of	  Zn2+	  (DeCoursey	  et	  al.,	  2003).	  
Okochi	  et	  al.	  investigated	  this	  further	  by	  focusing	  on	  the	  phagosomal	  compartments,	  
where	   the	   superoxide	   is	   produced	   to	   eliminate	   pathogens.	   They	   were	   able	   to	  
confirm	   that	  Hvcn1-­‐/-­‐	   neutrophils	   have	   significantly	   reduced	   ROS	   production	   upon	  
PMA	  stimulation.	  They	  also	   found	   that	  phagosomal	  membrane	   fractions	  contained	  
NADPH	  oxidase	  subunits	  as	  well	  as	  the	  HVCN1	  protein	  (Okochi	  et	  al.,	  2009).	  	  
Similarly,	   Ramsey	   et	   al.	   found	   that	   proton	   channels	   are	   required	   for	   high-­‐level	  
NADPH	   oxidase-­‐dependent	   ROS	   production.	   The	   study	   also	   wanted	   to	   determine	  
whether	  the	  impaired	  respiratory	  burst	  observed	  in	  Hvcn1-­‐/-­‐	  neutrophils	  would	  affect	  
bacterial	   clearance.	  WT	   and	  Hvcn1-­‐/-­‐	   BMCs	  were	   given	   live	   Staphylococcus	   aureus.	  
Both	   cell	   types	   achieved	   greater	   than	   90%	   clearance	   of	   the	   bacteria	   added.	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Furthermore,	   no	   difference	   was	   observed	   in	   the	   phagocytic	   capacity	   of	   both	   cell	  
types	  when	   given	   fluorescently	   labelled	  S.	   aureus	   or	  E.	   coli.	   The	   study	  next	   tested	  
whether	  this	  was	  true	  in	  an	  in	  vivo	  setting	  by	  inoculating	  the	  mice	  with	  S.	  aureus	  or	  
Pseudomonas	   aeurginosa.	   Hvcn1-­‐/-­‐	  mice	   displayed	   bacterial	   clearance	   to	   the	   same	  
extent	  as	  their	  WT	  littermates	  (Ramsey	  et	  al.,	  2009).	  	  
Voltage-­‐gated	  proton	  channels	  have	  also	  been	  found	  to	  maintain	  pH	  in	  neutrophils	  
during	   phagocytosis	   (Morgan	   et	   al.,	   2009).	   During	   the	   phagocytosis	   of	   opsonised	  
zymosan,	  human	  neutrophils	   initially	  displayed	  a	  sharp	  decrease	   in	   intracellular	  pH	  
(pHi)	   after	  which	   a	   slow	   recovery	   to	   starting	   pHi	  was	   achieved.	   In	   the	  presence	  of	  
Zn2+	   there	  was	   an	   even	   greater	   decrease	   in	   pHi,	  which	  was	   sustained	   and	   lead	   to	  
inhibition	  of	  the	  NADH	  oxidase	  complex.	  These	  observations	  were	  mirrored	  in	  bone	  
marrow	  phagocytes	  from	  Hvcn1-­‐/-­‐	  mice.	  	  
A	   similar	   study	   suggested	   that	   the	   acid-­‐extruding	   role	   of	   HVCN1	   sustains	   calcium	  
entry	   in	  neutrophils,	  which	   in	  turn	  controls	  cell	  migration	  (El	  Chemaly	  et	  al.,	  2010).	  
The	  study	  found	  that	  Hvcn1-­‐/-­‐	  neutrophils	  produced	  less	  superoxide	  and	  had	  a	  more	  
acidic	   cytosol	   than	  WT	  mice.	  The	  absence	  of	  proton	  channels	  also	  greatly	   reduced	  
the	   influx	   of	   calcium	   (Ca2+)	   ions,	   which	   are	   important	   in	   the	   regulation	   of	   actin	  
depolymerisation.	  Indeed,	  impaired	  actin	  depolymerisation	  was	  observed	  in	  Hvcn1-­‐/-­‐	  
neutrophils	  as	  well	  as	  a	  migration	  defect	  in	  these	  cells.	  	  
1.9.1.2 EOSINOPHILS	  
Both	  human	  and	  mouse	  eosinophils	  have	  been	  found	  to	  possess	  a	  voltage-­‐gated	  H+	  
conductance	   (Gordienko	   et	   al.,	   1996,	   Zhu	   et	   al.,	   2013).	   Voltage-­‐clamp	   studies	   of	  
human	  eosinophils	  showed	  that	  voltage	  activation	  of	  the	  membrane	  resulted	   in	  an	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outward	   current.	   This	   was	   sustained	   even	   following	   simultaneous	   replacement	   of	  
potassium	   (K+),	   sodium	   (Na+)	   and	   chloride	   (Cl-­‐)	  with	  mostly	   impermeant	   ions,	   thus	  
indicating	   that	   the	   conductance	   was	   highly	   selective	   for	   H+	   ions.	   Increasing	  
intracellular	  H+	  [H+]i	  through	  acidification	  of	  the	  pipette	  solution	  led	  to	  augmentation	  
of	   the	   H+	   current	   whilst	   extracellular	   application	   of	   Zn2+	   reversibly	   inhibited	   the	  
proton	  current	  (Gordienko	  et	  al.,	  1996).	  
Zhu	  et	  al.	  investigated	  HVCN1	  in	  regards	  to	  eosinophils	  effector	  functions	  in	  order	  to	  
further	   understand	   its	   role.	   The	   protein	   expression	   of	   HVCN1	   was	   confirmed	   in	  
mouse	   eosinophils	   by	   both	   quantitative	   polymerase	   chain	   reaction	   (qPCR)	   and	  
immunoblot.	   Similar	   to	   other	   Hvcn1-­‐/-­‐	   immune	   cells,	   Hvcn1-­‐/-­‐	   mouse	   eosinophils	  
produced	   less	   ROS	   following	   phorbol	   12-­‐myristate	   13-­‐acetate	   (PMA)	   stimulation.	  
ROS	  production	  was	  inhibited	  in	  both	  WT	  and	  Hvcn1-­‐/-­‐	  cells	  in	  the	  presence	  of	  either	  
Zn2+	  or	  dyphenylene	  iodonium	  (DPI).	  Since	  migration	  in	  vitro	  had	  been	  shown	  to	  be	  
impaired	   in	   Hvcn1-­‐/-­‐	   neutrophils	   due	   to	   impaired	   calcium	   responses,	   the	   authors	  
decided	   to	   investigate	  whether	   this	  was	   true	   for	   eosinophils.	   This	  was	   assessed	   in	  
vitro	   with	   the	   use	   of	   the	   eosinophil-­‐specific	   chemoattractant,	   eotaxin-­‐1.	   No	  
differences	   were	   observed	   between	   WT	   and	   Hvcn1-­‐/-­‐	   eosinophils	   in	   their	  
chemotactic	   ability	   towards	   exotoxin-­‐1.	   Using	   a	   model	   of	   peritonitis,	   injection	   of	  
thioglycollate	  medium	  recruited	  the	  same	  number	  of	  eosinophils	  into	  the	  peritoneal	  
cavity	   in	   both	   WT	   and	   Hvcn1-­‐/-­‐	   mice,	   suggesting	   that	   HVCN1	   deficiency	   does	   not	  
affect	  eosinophil	  migration	  in	  vivo	  (Zhu	  et	  al.,	  2013).	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1.9.1.3 BASOPHILS	  
Basophils	   are	   closely	   related	   to	   eosinophils	   and	   neutrophils,	   however	   they	   do	   not	  
express	   the	  NADPH	  oxidase.	  As	  discussed	  previously,	   there	   is	   a	   close	   link	  between	  
HVCN1	   and	   NADPH	   oxidase;	   therefore,	   Musset	   et	   al.	   studied	   the	   effect	   of	   cell	  
activation	   on	   proton	   channels	   in	   basophils	   (Musset	   et	   al.,	   2008).	   They	   found	   that	  
human	   basophils	   had	   functional	   voltage-­‐gated	   proton	   channels	   that	   responded	   to	  
PMA	   and	   IgE	   stimulation,	   thus	   suggesting	   a	   link	   between	   proton	   channels	   and	  
activation	   of	   basophils	   by	   allergens	   through	   the	   IgE	   receptor.	   Activation	   of	   proton	  
channels	  by	  PMA	  or	   IgE	  was	   inhibited	   in	   the	  presence	  of	  Zn2+.	   Inhibition	  of	  proton	  
channel	   activation	   also	   negatively	   affected	   histamine	   release.	   With	   the	   use	   of	   a	  
ratiometric	   fluorescent	   dye	   it	   was	   established	   that	   IgE	   activation	   produced	  
intracellular	  acidification	  that	  was	  exacerbated	  with	  the	  addition	  of	  Zn2+.	  The	  authors	  
thus	   suggested	   that	   proton	   channels	   prevent	   excessive	   intracellular	   acidification	  
during	  IgE-­‐mediated	  responses	  and	  that	  this	  might	  play	  a	  role	  in	  histamine	  release.	  
1.9.2 MONONUCLEAR	  LEUKOCYTES	  
1.9.2.1 B	  CELLS	  
Voltage-­‐gated	  proton	  currents	  were	  first	  described	  in	  human	  peripheral	  blood	  B	  cells	  
(Schilling	   et	   al.,	   2002).	   Electrophysiological	   recordings	   found	   marked	   changes	   in	  
channel	   expression	   in	   lymphocytes	   following	   24h	   of	   stimulation	   with	   PMA	   by	  
measuring	   the	   proton	   current.	   The	   mean	   proton	   current	   amplitude	   of	   PMA-­‐
stimulated	   B	   cells	  was	   halved	   compared	   to	   that	   of	   unstimulated	   cells.	   Taking	   into	  
consideration	   the	   roughly	   30%	   increase	   in	   size	   following	   stimulation	   with	   PMA	  
meant	  that	   the	  mean	  H+	  current	  density	  of	  CD19+	  B	  cells	  decreased	  by	  about	  70%.	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The	  authors	  argued	  that	  the	  function	  of	  voltage-­‐gated	  proton	  currents	  in	  B	  cells	  was	  
to	   repolarise	   the	   membrane	   during	   superoxide	   anion	   production,	   but	   offered	   no	  
functional	  conclusion	  to	  the	  observed	  decrease	  in	  H+	  current	  density.	  
Suenaga	  et	  al.	  (2007)	  described	  another	  similar	  gene	  around	  the	  same	  time	  that	  the	  
Hvcn1	   gene	  was	  discovered	   (Suenaga	  et	   al.,	   2007).	   They	   identified	  a	  B	   cell-­‐specific	  
tetraspanning	   (BTS)	  molecule	   that	  was	   found	   to	  be	   involved	   in	  B	  cell	  development	  
and	  proliferation.	  qPCR	  analysis	  of	   various	   tissues	   showed	   that	  BTS	  was	  expressed	  
predominantly	  in	  the	  spleen,	  in	  particular	  in	  follicular	  B	  cells.	  FLAG-­‐tagged	  BTS	  in	  an	  
immature	  B	  cell	  line	  suggested	  that	  the	  protein	  was	  expressed	  predominantly	  within	  
the	  cells.	  The	  authors	   investigated	  this	  further	  by	  co-­‐staining	  with	  mitochondrial	  or	  
lysosomal	  markers,	  but	  found	  no	  localisation	  with	  either	  organelle.	  
Functional	  assays	  revealed	  that	  the	  growth	  retardations	  observed	  in	  BTS	  expressing	  
B	   cell	   lines	   was	   due	   inhibition	   of	   cell	   cycle	   progression	   and	   not	   induction	   of	  
apoptosis.	  The	  authors	  also	   identified	   the	  N	   terminus	  of	   the	  BTS	   to	  be	   responsible	  
for	   its	   inhibitory	   function.	   Upon	   BCR	   stimulation	   with	   anti-­‐IgM	   F(ab’)2,	   BTS	  
expression	  was	  down-­‐regulated.	  Following	  on	  from	  the	  in	  vitro	  data,	  transgenic	  mice	  
with	   high	   BTS	   expression	   were	   generated	   to	   investigate	   its	   functions	   in	   vivo.	  
Similarly,	  they	  found	  inhibition	  of	  B	  cell	  development	  in	  the	  transgenic	  mice.	  It	  was	  
later	  discovered	  that	  the	  BTS	  gene	  and	  Hvcn1	  gene	  are	  one	  and	  the	  same.	  
Boyd	   et	   al.	   (2009)	   identified	   the	  HVCN1	   protein	   in	   a	   shotgun	   proteomic	   screen	   of	  
plasma	  membrane	  proteins	  expressed	  in	  purified	  B	  cells	  from	  mantle	  cell	  lymphoma	  
patients	   (Boyd	   et	   al.,	   2009).	   However,	   their	   qPCR	   data	   showed	   that	  Hvcn1	   mRNA	  
levels	   were	   similar	   in	   both	   normal	   B	   and	   MCL	   cells.	   The	   authors’	   unpublished	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observations	   hinted	   at	   the	   potential	   involvement	   of	   HVCN1	   in	   class	   switch	  
recombination	  in	  B	  cells.	  	  
Expanding	  on	  these	  previous	  studies,	  Capasso	  et	  al.	   (2010)	   investigated	  the	  role	  of	  
HVCN1	  in	  the	  initial	  phase	  of	  B	  cell	  activation	  (Capasso	  et	  al.,	  2010).	  They	  observed	  
abundant	  expression	   in	  resting	  naïve	  and	  memory	  B	  cells,	  but	  a	  downregulation	  of	  
HVCN1	   expression	   in	   B	   cells	   activated	   by	   CD154	   in	   the	   presence	   of	   IL-­‐4.	   A	   co-­‐
localisation	   of	   HVCN1	   with	   the	   B	   cell	   receptor	   (BCR)	   following	   activation	   was	  
confirmed	   through	   confocal	   microscopy,	   electron	   microscopy	   and	   subcellular	  
fractionation	   methods.	   Internalised	   BCR	   co-­‐localised	   with	   HVCN1	   and	   late	  
endosomal	   markers.	   Extensive	   co-­‐immunoprecipitation	   and	   immunoblot	   analysis	  
suggested	   functional	   interactions	   between	   the	   components	   of	   BCR	   signalling	   and	  
HVCN1.	  
The	  study	  assessed	  the	  ROS	  generating	  ability	  of	  Hvcn1-­‐/-­‐	  B	  cells	   in	  the	  steady	  state	  
and	   after	   BCR	   activation.	   Surprisingly,	  Hvcn1-­‐/-­‐	   B	   cells	   had	   greater	   levels	   of	   ROS	   at	  
steady	  state	  than	  their	  wild-­‐type	  counterpart.	  Rotenone,	  an	  inhibitor	  of	  the	  electron	  
transport	   chain	   (ETC),	   diminished	   the	   basal	   ROS	   levels	   of	   the	   Hvcn1-­‐/-­‐	   B	   cells	   to	  
similar	  amounts	   found	   in	   the	  wild	   type	  cells;	  however,	  DPI	   (an	   inhibitor	  of	  NADPH	  
oxidase)	   failed	   to	   diminish	   basal	   ROS	   levels.	   The	   authors	   thus	   suggested	   a	  
mitochondrial	   source	   for	   the	  differential	   basal	   ROS	   found,	   but	   did	  not	   explore	   the	  
significance	  of	  this	  observation	  further.	  ROS	  production	  was	  significantly	  impaired	  in	  
Hvcn1-­‐/-­‐	  B	  cells	  following	  PMA	  or	  F(ab’)2	  activation	  and	  this	  also	  impaired	  local	  SH2-­‐
containing	   protein	   tyrosine	   phosphatase-­‐1	   (SHP-­‐1)	   oxidation,	   which	   is	   crucial	   for	  
initiation	  of	   signalling	  cascades	  downstream	  of	   the	  BCR.	  However,	   SHP-­‐1	  oxidation	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was	  found	  to	  be	  four-­‐fold	  greater	  in	  unstimulated	  Hvcn1-­‐/-­‐	  B	  cells	  compared	  to	  wild	  
type	  cells.	  	  
This	   diminished	   SHP-­‐1	   oxidation	   was	   shown	   to	   have	   a	   detrimental	   effect	   on	   BCR	  
downstream	  signalling.	  The	  tyrosine	  kinase	  Syk,	  a	  crucial	  SHP-­‐1	  target,	  was	  activated	  
to	   a	   lesser	   extent	   in	   the	  Hvcn1-­‐/-­‐	   B	   cells.	   The	   same	  was	   true	   for	   activation	   of	   Akt,	  
which	   is	   heavily	   involved	   in	   cellular	   metabolism.	   To	   this	   end,	   mitochondrial	  
respiration	  and	  glycolysis	  was	  assessed	  in	  the	  B	  cells	  and	  it	  was	  observed	  that	  after	  
BCR	  activation	  Hvcn1-­‐/-­‐	  B	  cells	  showed	  lower	  rates	  of	  oxidative	  phosphorylation	  and	  
glycolysis	  compared	  to	  their	  wild	  type	  counterparts.	  
Finally,	   the	   authors	   challenged	   wild	   type	   and	   Hvcn1-­‐/-­‐	   mice	   with	   immunogens	   to	  
assess	   B	   cell	   responses.	   Whilst	   they	   did	   not	   find	   any	   impairment	   of	   B	   cell	  
development,	  they	  did	  observe	  defective	  antibody	  responses	  in	  Hvcn1-­‐/-­‐	  mice.	  
1.9.2.2 T	  CELLS	  
Schilling	  et	  al.	  (2002)	  were	  also	  the	  first	  to	  describe	  voltage-­‐gated	  proton	  currents	  in	  
human	   peripheral	   blood	   T	   cells	   (Schilling	   et	   al.,	   2002).	   H+	   currents	   measured	   in	  
unstimulated	   human	   peripheral	   blood	   lymphocytes	   revealed	   that	   the	   mean	   H+	  
current	  density	  in	  CD19+	  B	  cells	  was	  100-­‐fold	  greater	  than	  in	  CD3+	  T	  cells.	  However,	  
unlike	  B	  cells,	  PMA-­‐stimulated	  peripheral	  blood	  T	  cells	  had	  a	  13-­‐fold	   increase	   in	  H+	  
current	  amplitude.	  Normalising	  this	  to	  cell	  capacity	  meant	  that	  T	  cells	  increased	  their	  
H+	  current	  density	  8-­‐fold	  following	  PMA	  stimulation.	  The	  implication	  is	  that	  the	  need	  
for	   voltage-­‐gated	   proton	   channels	   is	   much	   greater	   after	   activation.	   The	   authors	  
suggested	  that	  H+	  channels	  might	  be	  required	  to	  maintain	  an	  alkaline	  pHi	   in	  T	  cells	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during	   proliferation,	   antigen	   presentation	   and	   cytokine	   release	   as	   intracellular	  
acidification	  can	  inhibit	  IL-­‐2	  release	  .	  
More	  recently,	  it	  was	  shown	  that	  mouse	  T	  cells	  express	  the	  HVCN1	  protein	  (Sasaki	  et	  
al.,	  2013).	  The	  same	  study	  also	  found	  that	  in	  the	  Hvcn1-­‐/-­‐	  mice	  there	  were	  a	  greater	  
proportion	  of	  activated	  T	  cells	   (CD4+CD44high	  and	  CD8+CD44high),	  both	   in	   the	  steady	  
state	   and	   after	   infection	   with	   lymphocytic	   choriomeningitis	   virus.	   However,	   no	  
difference	  was	  observed	  in	  the	  proportion	  of	  CD4+	  and	  CD8+	  T	  cells	  in	  the	  thymus	  or	  
the	  ability	  of	  CD4+	  cells	  to	  differentiate	  into	  Th1/Th17	  cells.	  
The	  authors	  investigated	  ROS	  production	  in	  mouse	  T	  cells	  as	  T	  cells	  have	  been	  shown	  
to	   express	   a	   phagocyte-­‐type	  NADPH	  oxidase	   that	   is	   activated	   after	   T	   cell	   receptor	  
stimulation	   (Jackson	   et	   al.,	   2004).	   By	   stimulating	   CD4+	   and	   CD8+	   T	   cells	  with	   PMA	  
they	  observed	  that	  the	  kinetics	  of	  superoxide	  production	  had	  two	  distinct	  phases	  or	  
‘peaks’	   in	   these	  cell	   types.	  The	   first	   ‘peak’	  was	   reached	  after	  5min	  and	   the	  second	  
‘peak’	  after	  30min.	  Hvcn1-­‐/-­‐	  T	  cells	  only	  managed	  to	  produce	  superoxide	  for	  the	  first	  
phase.	   The	   two	   phases	   were	   abolished	   in	   the	   presence	   of	   Apocynin	   (a	   specific	  
NADPH	   oxidase	   inhibitor)	   in	   both	   wild	   type	   and	   Hvcn1-­‐/-­‐	   T	   cells.	   The	   authors	  
suggested	  that	  HVCN1	  is	  important	  in	  the	  second	  phase	  of	  superoxide	  production	  in	  
T	  cells	  and	  not	  necessary	  for	  the	  first	  phase.	  They	  stressed	  that	  further	  investigations	  
were	   needed	   to	   identify	   the	   mechanism	   by	   which	   HVCN1	   contributes	   to	   ROS	  
production	  in	  T	  cells.	  
1.9.2.3 DENDRITIC	  CELLS	  
Szteyn	   et	   al.	   (2012)	   recently	   demonstrated	   the	   functional	   expression	   of	   HVCN1	   in	  
mouse	  bone	  marrow-­‐derived	  DCs	   (BMDCs)	   (Szteyn	  et	   al.,	   2012).	  Whole	   cell	   patch-­‐
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clamp	  experiments	  revealed	  Zn2+-­‐sensitive	  currents	  that	  were	  highly	  selective	  for	  H+.	  
Acute	   treatment	   of	   BMDCs	   with	   LPS	   increased	   HVCN1	   channel	   activity,	   whereas	  
incubation	  with	  LPS	  for	  24h	  had	  the	  opposite	  effect.	  H+	  currents,	  ROS	  production	  and	  
Hvcn1	   mRNA	   levels	   were	   all	   reduced	   at	   the	   later	   time	   point;	   however,	   HVCN1	  
protein	  abundance	  was	  not	  affected.	  
Ligation	  of	  TLR4	  by	  LPS	  on	  DCs	  induces	  maturation	  in	  these	  cells,	  which	  leads	  to	  the	  
downregulation	  of	  endocytic	  ability	   in	  the	  fully	  matured	  DCs	  (Zanoni	  and	  Granucci,	  
2010,	  West	  et	  al.,	  2004).	  Szteyn	  et	  al.	  (2012)	  argued	  that	  the	  loss	  of	  endocytic	  ability	  
in	  mature	  DCs	  might	  be	  due	  to	  the	  inhibition	  of	  H+	  currents	  observed	  after	  24h	  with	  
LPS;	   however,	   the	   authors	   did	   not	   address	   the	   discrepancy	   between	   unaffected	  
HVCN1	  protein	   levels	   and	   reduced	  H+	   currents	   at	  24h	  post-­‐treatment	   Szteyn	  et	   al.	  
(2012)	  .	  
1.9.2.4 MACROPHAGES	  
The	   existence	   of	   H+	   conductance	   in	   macrophages	   was	   first	   shown	   in	   a	   study	   of	  
murine	  peritoneal	  macrophages	  (Kapus	  et	  al.,	  1993).	  A	  suspension	  of	  thioglycollate-­‐
elicited	   peritoneal	   macrophages	   was	   used	   to	   measure	   the	   cytosolic	   pH	  
fluorimetrically	  using	  BCECF.	  This	  was	  conducted	  in	  the	  absence	  of	  Na+	  and	  HCO3-­‐	  to	  
minimise	  the	  activity	  of	  other	  H+	  transporting	  systems.	  The	  cytosols	  of	  the	  cells	  were	  
acid-­‐loaded	  and	  pHi	  was	  recorded.	  Recovery	  of	  pHi	  was	  found	  to	  be	  inhibited	  in	  the	  
presence	  of	   extracellular	   Zn2+,	   thus	   suggesting	   the	   involvement	  of	   a	  H+	   conductive	  
pathway.	   Patch-­‐clamping	   of	   single	   cells	   provided	   further	   evidence	   of	   H+	   currents.	  
These	  currents	  were	  found	  to	  be	  voltage-­‐gated	  and	  pH-­‐sensitive.	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In	   a	   set	   of	   similar	   experiments,	   Holevinsky	   et	   al.	   (1994)	   identified	   H+	   currents	   in	  
human	  monocyte-­‐derived	  macrophages	  (HMDMs)	  (Holevinsky	  et	  al.,	  1994).	  Currents	  
were	  characterised	  following	  an	  elevation	  in	  intracellular	  Ca2+	  [Ca2+]i	  using	  whole-­‐cell	  
voltage	  clamp	  recordings.	  [Ca2+]i	  elevation	  was	  achieved	  by	  exposing	  cells	  to	  the	  Ca2+	  
ionophore,	   A23187,	   in	   the	   presence	   of	   extracellular	   Ca2+.	   The	   setup	   of	   these	  
experiments	  was	  chosen	  as	   it	  mimics	  macrophage	  activation.	  Changes	   in	  [Ca2+]i	  are	  
closely	   followed	   by	   changes	   in	  membrane	   potential	   and	   pHi,	  which	   are	   associated	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1.10 	  CELLULAR	  METABOLISM	  
There	  are	  two	  main	  stages	  of	  catabolic	  reactions	  in	  mammalian	  cells.	  Glycolysis	  is	  the	  
first	   stage	   and	   occurs	   in	   the	   cytoplasm	   of	   the	   cell.	   At	   this	   stage,	   adenosine	  
triphosphate	  (ATP)	  and	  NADPH	  are	  generated	  by	  breaking	  down	  glucose	  and	  other	  
sugars	  through	  a	  series	  of	  enzymatic	  reactions.	  A	  small	  amount	  of	  ATP	  and	  NADH	  are	  
formed	   through	   this	   process,	   especially	   in	   comparison	   to	   the	   catabolic	   processes	  
that	  take	  place	  within	  the	  mitochondria	  (Lunt	  and	  Vander	  Heiden,	  2011).	  
The	  second	  stage	  is	  oxidative	  phosphorylation	  (OXPHOS)	  and	  involves	  catabolism	  of	  
pyruvate,	   the	   end	   stage	   product	   of	   glycolysis.	   Pyruvate	  molecules	   are	   transported	  
into	   the	   matrix	   of	   mitochondria	   where	   they	   are	   oxidised	   in	   a	   series	   of	   chemical	  
reactions	  termed	  the	  tricarboxylic	  acid	  (TCA)	  cycle	  (Papa	  et	  al.,	  2012).	  This	  process	  is	  
chemically	  linked	  to	  the	  last	  part	  of	  cellular	  respiration,	  namely	  the	  respiratory	  chain.	  
Protein	   complexes	   situated	   in	   the	   intermembrane	   wall	   of	   mitochondria	   form	   the	  
electron	   transport	   chain	   (ETC)	   and	   facilitate	   the	   movement	   of	   electrons	   in	   redox	  
reactions,	   which	   release	   electrochemical	   energy	   that	   is	   used	   to	   generate	   ATP.	  	  
Complete	   oxidation	   of	   glucose	   in	   this	   manner	   produces	   large	   amounts	   of	   ATP	  
(Schultz	  and	  Chan,	  2001).	  
Cells	  also	  have	  the	  ability	  to	  catabolise	  other	  substrates,	  such	  as	  fatty	  acids	  through	  
β-­‐oxidation	  and	  glutamine	  through	  glutaminolysis,	  which	  fuel	  OXPHOS	  and	  replenish	  
the	  TCA	  cycle	  (Fernie	  et	  al.,	  2004).	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1.10.1 	  GLYCOLYSIS	  
Glucose	  is	  a	  major	  source	  of	  cellular	  energy	  and	  takes	  place	  in	  all	  of	  the	  cells	  of	  the	  
body.	   The	   enzymes	   that	   are	   involved	   in	   the	   glycolytic	   pathway	   are	   found	   in	   the	  
cytoplasm	  of	  the	  cell.	  Glycolysis	  comprises	  several	  metabolic	  reactions	  by	  which	  one	  
molecule	  of	   glucose	   is	   catabolised	   to	   two	  molecules	  of	  pyruvate	   (Lunt	  and	  Vander	  
Heiden,	  2011).	  The	  pathway	  is	  generally	  divided	  into	  two	  specific	  phases:	  
1. Energy	  investment	  phase	  
2. Energy	  generating	  phase	  
In	  the	  energy	  investment	  phase,	  glucose	  is	  phosphorylated	  by	  hexokinase	  to	  glucose	  
6-­‐phosphate	   (G6P)	   (Figure	   1	   -­‐	   4).	   This	   reaction	   consumes	   ATP,	   but	   promotes	   the	  
continuous	   transport	   of	   glucose	   molecules	   into	   the	   cell	   by	   maintaining	   a	   low	  
intracellular	  concentration	  of	  glucose	  (Kim	  and	  Dang,	  2005).	  Due	  to	  the	  lack	  of	  G6P	  
transporters	   and	   the	  molecule’s	   negative	   charge	   it	   cannot	   leave	   cross	   the	   plasma	  
membrane	  through	  active	  transport	  or	  passive	  diffusion.	  Next,	  another	  molecule	  of	  
ATP	   is	   consumed	   to	   convert	   G6P	   to	   fructose	   1,6-­‐bisphosphate	   (F1,6-­‐BP)	   through	  
sequential	   reactions	   that	   are	   catalysed	   by	   the	   enzymes	   glucose-­‐6-­‐phospho	  
isomerase	  (PGI),	  and	  phosphofructokinase	  (PFK)	  (Vander	  Heiden	  et	  al.,	  2011).	  	  
In	  the	  energy-­‐yielding	  phase,	  F1,6-­‐BP	  is	  further	  converted	  sequentially	  into	  pyruvate	  
through	  the	  use	  of	  catabolic	  enzymes	  and	  thus	  	  generates	  of	  four	  molecules	  of	  ATP	  
and	   two	   molecules	   of	   NADH.	   This	   process	   consumes	   two	   adenosine	   diphosphate	  
(ADP)	   and	   two	  NAD+	  molecules	   (Fernie	   et	   al.,	   2004).	   The	   reactions	   in	   the	   energy-­‐
yielding	  phase	  occur	  twice	  as	  two	  molecules	  of	  glyceraldehyde	  3-­‐phosphate	  (GADP)	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are	  produced	  in	  the	  energy	  investment	  phase	  and	  thus	  there	  is	  a	  net	  gain	  of	  two	  ATP	  
and	  two	  NADPH	  molecules	  (Greiner	  et	  al.,	  1994).	  
Glycolysis	   can	   occur	   in	   the	   presence	   (aerobic)	   or	   absence	   (anaerobic)	   of	   oxygen.	  
Anaerobic	   glycolysis	   involves	   the	   conversion	   of	   pyruvate	   to	   lactate	   by	   the	   enzyme	  
lactate	   dehydrogenase	   (Vander	   Heiden	   et	   al.,	   2009).	   This	   reaction	   also	   produces	  
NAD+,	  which	   is	   used	   to	  maintain	   the	   glycolytic	   pathway	   in	   the	   absence	   of	   oxygen	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Figure	  1	  -­‐	  4	  The	  glycolysis	  pathway	  
The	  figure	  shows	  the	  catabolism	  of	  glucose	  into	  pyruvic	  acid.	  The	  process	  uses	  two	  
ATP	  molecules,	  but	  generates	  4	  ATP	  molecules	  and	  2	  NADH	  molecules;	  thus	  giving	  a	  
net	  gain	  of	  two	  ATP	  and	  two	  NADH.	  Adapted	  from	  Fernie	  et	  al.	  (2004).	  
	  
	  
1.10.2 	  OXIDATIVE	  PHOSPHORYLATION	  
The	   mitochondria	   have	   a	   four-­‐layered	   structure,	   which	   includes	   the	   outer	  
mitochondrial	   membrane,	   intermembrane	   space,	   inner	   mitochondrial	   membrane	  
the	  matrix	  (Lenaz	  and	  Genova,	  2009).	  Mitochondria	  generate	  large	  amounts	  of	  ATP	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mitochondrial	  membrane	  and	  consists	  of	  five	  multiprotein	  complexes	  (Figure	  1	  -­‐	  5)	  
(Saraste,	   1999).	   These	   proteins	   make	   up	   the	   ETC	   and	   include	   complex	   I	   (NADH	  
dehydrogenase),	   complex	   II	   (succinate	   dehydrogenase),	   complex	   II	   (ubiquinol	  
cytochrome	  c	   reductase),	   complex	   IV	   (cytochrome	  c	  oxidase),	   and	   complex	  V	   (ATP	  
synthase)	   (Fernie	   et	   al.,	   2004).	   The	   system	   also	   comprises	   two	   electron	   carriers,	  
namely	  coenzyme	  Q	  and	  cytochrome	  c.	  The	  function	  of	   the	  ETC	   is	   the	  transport	  of	  
electrons	  and	  protons	  through	  the	  inner	  mitochondrial	  membrane	  to	  allow	  complex	  
V	  to	  produce	  ATP.	  All	  of	   the	  complexes,	  except	   for	  complex	   II,	  are	  encoded	  by	  the	  
mitochondrial	  genome	  (Smeitink	  et	  al.,	  2001).	  	  
Electrons	   enter	   the	   ETC	   through	   the	   donation	   from	  NADH	   to	   complex	   I	   and	   flavin	  
adenine	   dinucleotide	   (FADH2)	   to	   complex	   II	   (Papa	   et	   al.,	   2012).	   The	   negatively	  
charged	  electrons	  pass	  through	  the	  electron	  carriers	  and	  other	  complexes	  and	  thus	  
generate	  a	  proton-­‐motive	  force	  (Figure	  1	  -­‐	  5).	  This	  allows	  positively	  charged	  protons	  
to	  be	  pumped	  from	  the	  mitochondrial	  matrix	  though	  complexes	  I,	  II	  and	  IV	  into	  the	  
intermembrane	  space	  (Schultz	  and	  Chan,	  2001).	  This	  results	   in	  a	  negative	  charge	  in	  
the	  mitochondrial	  matrix	   and	   a	   positive	   charge	   in	   the	   intermembrane	   space,	   thus	  
creating	   a	   mitochondrial	   membrane	   potential	   across	   the	   inner	   mitochondrial	  
membrane	   (Echtay	   et	   al.,	   2002).	   Complex	   V	   pumps	   the	   protons	   back	   into	   the	  
mitochondrial	   matrix	   and	   in	   doing	   so	   generates	   ATP	   from	   ADP	   and	   inorganic	  
phosphate	  (Pi)	  (Schultz	  and	  Chan,	  2001).	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Figure	  1	  -­‐	  5	  Oxidative	  phosphorylation	  and	  the	  electron	  transport	  chain.	  
A	   proton-­‐motive	   force	   is	   generated	   by	   electrons	   passing	   through	   the	   ETC,	   which	  
causes	  H+	  to	  be	  pumped	  into	  the	  intermembrane	  space	  of	  mitochondria.	  Complex	  V	  
(ATP	   synthase)	   pumps	   H+	   back	   into	   the	   matrix	   of	   mitochondria	   and	   in	   doing	   so	  
generates	  energy	  that	  it	  uses	  to	  produce	  ATP	  molecules.	  Adapted	  from	  (Fernie	  et	  al.,	  
2004).	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1.11 	  IMMUNOMETABOLISM	  
The	  field	  of	  immune	  cell	  metabolism	  has	  greatly	  expanded	  in	  recent	  years,	  as	  there	  
has	  been	  a	  greater	  appreciation	  and	  understanding	  of	  cross	  talk	  between	  immunity	  
and	  metabolism	   (Mathis	  and	  Shoelson,	  2011).	  Several	   studies	  have	   focused	  on	   the	  
interaction	  of	   immune	  cells	  with	  organs	  that	  control	  whole-­‐body	  metabolism,	  such	  
as	   the	   liver	   and	   adipose	   tissue	   (Odegaard	   and	   Chawla,	   2013).	   Other	   studies	   have	  
specifically	   focused	   on	   the	   regulation	   of	   immune	   responses	   through	   metabolic	  
pathways	  within	  the	  immune	  cells	  (Pearce	  and	  Pearce,	  2013).	  	  
Cells	   can	   utilise	   distinct	   metabolic	   pathways	   to	   achieve	   their	   metabolic	   goals;	  
however,	   these	  pathways	  also	  converge	  at	  several	   levels	   (Lunt	  and	  Vander	  Heiden,	  
2011).	  This	   is	  further	  complicated	  given	  that	  commitment	  to	  a	  particular	  metabolic	  
fate	   is	   influenced	  by	  both	   substrate	   availability	   and	   signalling	  pathways	  elicited	  by	  
extracellular	   stimuli,	   such	  as	  cytokines	  and	  microbial	   components	   (Kominsky	  et	  al.,	  
2010).	   Current	   studies	   are	   thus	   interested	   in	   elucidating	   the	   process	   by	   which	  
immune	   cells	   commit	   to	   a	   particular	   metabolic	   fate	   and	   also	   the	   immunological	  
consequences	  of	  utilising	  one	  pathway	  over	  another.	  
1.11.1 	  GRANULOCYTES	  
Myeloid	  cells	  are	   thought	   to	  primarily	  use	  glycolysis	   to	  generate	   the	  ATP	  that	   they	  
need	  for	  cellular	  processes	  (Kominsky	  et	  al.,	  2010).	  Early	  studies	  into	  the	  metabolism	  
of	  neutrophils	  found	  them	  to	  be	  highly	  dependent	  on	  aerobic	  glycolysis	  to	  generate	  
ATP	   (Sbarra	   and	   Karnovsky,	   1959,	   Valentine	   and	   Beck,	   1951).	   Indeed,	   neutrophils	  
have	  been	  found	  to	  have	   little	  mitochondrial	  biomass	  and	  consume	  small	  amounts	  
of	  oxygen	  (van	  Raam	  et	  al.,	  2006).	  Neutrophils	  increase	  their	  consumption	  of	  oxygen	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and	  glucose	  upon	  binding	  of	  TLR	  ligands	  or	  phagocytosis	  of	  particles	  (Borregaard	  and	  
Herlin,	   1982).	   This	   increase	   in	   their	   oxygen	   consumption	   rate	   does	   not	   reflect	   the	  
oxidation	   of	   glucose	   in	   the	  mitochondria,	   rather	   an	   increase	   in	   the	   activity	   of	   the	  
pentose	  phosphate	  pathway	  (PPP)	  (Dale	  et	  al.,	  2008).	  The	  PPP	  is	  an	  anabolic	  process	  
that	   oxidises	   glucose	   to	   produce	   NADPH	   and	   five-­‐carbon	   sugars	   such	   as	   ribose-­‐5-­‐
phosphate,	  which	   is	  used	   crucial	   for	   the	   synthesis	  of	  nucleic	   acids	  and	  nucleotides	  
(Wamelink	  et	  al.,	  2008).	  As	  mentioned	  previously,	  NADPH	  is	  important	  in	  the	  process	  
of	  the	  respiratory	  burst	   in	  order	  to	  produce	  ROS	  to	  eliminate	  pathogens	  (Lambeth,	  
2004).	  The	  few	  studies	  that	  have	  investigated	  the	  metabolism	  of	  eosinophils	  (Sher	  et	  
al.,	  1983,	  Venge	  et	  al.,	  2003)	  and	  basophils	  (Sumbayev	  et	  al.,	  2009)	  have	  found	  these	  
cells	   to	  be	  metabolically	   similar	   to	  neutrophils.	   It	  has	  been	  suggested	   that	   the	   low	  
mitochondrial	   activity	   of	   granulocytes	   reflects	   their	   terminally	   differentiated	   state	  
and	  their	  inability	  to	  proliferate	  in	  the	  periphery	  (Pearce	  and	  Pearce,	  2013).	  	  	  
1.11.2 	  DENDRITIC	  CELLS	  
DCs	  can	  be	  activated	  by	  a	  number	  of	  pathogen-­‐associated	  molecular	  patterns,	  such	  
as	  LPS	  and	  double-­‐stranded	  ribonucleic	  acid	  (RNA),	  which	  allows	  them	  to	  respond	  to	  
foreign	  particles	  or	  changes	  in	  their	  microenvironment.	  DCs	  play	  an	  important	  part	  in	  
the	   immune	   system	   as	   they	   can	   prime	   T	   cell	   responses	   as	   well	   as	   initiate	  
inflammation	   (Banchereau	   et	   al.,	   2000).	   Similar	   to	   macrophages,	   DCs	   can	   be	  
replenished	  in	  the	  tissues	  from	  the	  monocyte	  pool	  during	  inflammation.	  Therefore,	  
there	   are	  metabolic	   similarities	   between	  monocyte-­‐derived	  macrophages	   and	   DCs	  
(Geissmann	  et	  al.,	  2010).	  At	  steady	  state,	  DCs	   largely	  use	  mitochondrial	  respiration	  
to	   generate	   energy,	   but	   upon	   activation	   they	   switch	   to	   glycolysis.	   This	   switch	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involves	  the	  increased	  expression	  of	  the	  glucose	  transporter	  GLUT1	  (Krawczyk	  et	  al.,	  
2010).	   The	   glycolytic	   switch	   in	   DCs	   can	   be	   limited	   in	   the	   presence	   of	   IL-­‐10,	   thus	  
suggesting	   that	   glycolytic	   metabolism	   is	   essential	   for	   pro-­‐inflammatory	   effects	  
(Krawczyk	  et	  al.,	  2010).	  It	  has	  been	  shown	  in	  DCs	  that	  the	  decrease	  in	  mitochondrial	  
respiration	  after	  TLR4	  activation	  was	  due	  to	   inhibition	  of	  oxidative	  phosphorylation	  
by	  nitric	  oxide	  (NO),	  which	  constitutes	  part	  of	  the	  glycolytic	  shift	  observed	  in	  myeloid	  
cells	  after	  activation	  (Everts	  et	  al.,	  2012).	  NO	  achieves	  this	  by	  competing	  with	  oxygen	  
to	  inhibit	  cytochrome	  c	  oxidase,	  an	  electron	  acceptor	  of	  the	  ETC.	  This	  is	  followed	  by	  
a	  decrease	  of	  glucose	  into	  the	  TCA	  cycle	  and	  an	  increase	  in	  lactate	  production,	  thus	  
myeloid	  cells	  depend	  on	  aerobic	  glycolysis	  alone	  to	  survive	  (Everts	  et	  al.,	  2012).	  
1.11.3 	  T	  CELLS	  
T	   cells	   differ	   from	   innate	   immune	   cells	   in	   that	   they	   have	   the	   ability	   to	   proliferate	  
upon	   activation.	   Similar	   to	   other	   immune	   cells,	   effector	   T	   cells	   also	   switch	   to	  
glycolytic	  metabolism	  once	  they	  have	  been	  activated	  (Jones	  and	  Thompson,	  2007).	  
However,	  they	  also	  maintain	  mitochondrial	  respiration	  albeit	  at	  a	  lower	  rate	  (Fox	  et	  
al.,	   2005).	   It	   has	   been	   shown	   that	   other	   T	   cell	   subset	   use	   different	   metabolic	  
processes.	  Memory	   T	   cells	   rely	   on	  mitochondrial	   fatty	   acid	   oxidation	   over	   aerobic	  
glycolysis	   and	   this	   is	   crucial	   for	   their	   development.	   They	   also	   have	   a	   greater	  
mitochondrial	  biomass	  compared	  to	  effector	  T	  cells	  (Pearce	  et	  al.,	  2009).	  Regulatory	  
T	   cells	   have	   been	   found	   to	   use	  mitochondrial	   respiration	   and	   fatty	   acid	   oxidation	  
both	  for	  their	  development	  and	  survival	  (Michalek	  et	  al.,	  2011).	  In	  contrast,	  aerobic	  
glycolysis	  is	  crucial	  for	  the	  generation	  of	  T	  helper	  17	  cells	  (Shi	  et	  al.,	  2011).	  Although	  
there	   is	  a	  growing	  understanding	  of	  metabolic	  reprogramming	  in	  T	  cells,	   it	  remains	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unclear	  exactly	  why	  T	  cell	   subsets	   rely	  on	  different	  metabolic	  phenotypes	   for	   their	  
differentiation	  (Pearce	  and	  Pearce,	  2013).	  	  
1.11.4 	  B	  CELLS	  
Studies	  have	  observed	  shared	  metabolic	  characteristics	  between	  B	  cells	  and	  T	  cells	  
such	  as	  a	  switch	  to	  aerobic	  glycolysis	  upon	  activation	  (Doughty	  et	  al.,	  2006)	  as	  well	  as	  
an	   increased	   glucose	   uptake	   (Dufort	   et	   al.,	   2007).	   However,	   much	   less	   is	   known	  
about	  the	  metabolic	  reprogramming	  of	  B	  cells	  in	  comparison.	  It	  has	  been	  suggested	  
that	   plasma	   cells	   and	   memory	   B	   cells	   may	   mirror	   the	   metabolic	   phenotypes	   of	  
effector	  T	  cells	  and	  memory	  T	  cells,	  respectively.	  This	  could	  be	  relevant	  as	  the	  two	  
sets	  of	  cells	  are	  similar	   in	  terms	  of	  their	   lifespan	  and	  functional	  capacity	  (Pearce	  et	  
al.,	  2013).	  	  
1.11.5 	  MACROPHAGES	  
Macrophages	   display	   a	   shift	   towards	   aerobic	   glycolysis	   in	   response	   to	   IFNγ	   or	   TLR	  
ligands	  whilst	  no	  such	  effect	  is	  observed	  in	  response	  to	  IL-­‐4	  (Rodriguez-­‐Prados	  et	  al.,	  
2010).	  The	  increased	  glycolytic	  flux	  observed	  with	  classically	  activated	  macrophages	  
is	   necessary	   in	   order	   to	   rapidly	   trigger	  microbicidal	   activity	   and	   also	   to	   withstand	  
hypoxic	   microenvironments	   (Biswas	   and	   Mantovani,	   2012).	   In	   response	   to	   IL-­‐4,	  
macrophages	  polarise	  towards	  the	  alternative	  phenotype	  and	  maintain	  the	  OXPHOS	  
metabolism	   in	   order	   to	   have	   sustained	   energy	   for	   tissue	   repair	   and	   remodelling.	  
Alternatively	   activated	   macrophages	   also	   display	   increased	   fatty	   acid	   oxidation,	  
which	   is	   important	   in	  controlling	  membrane	   fluidity	  necessary	   for	   the	  processes	  of	  
phagocytosis	  (Vats	  et	  al.,	  2006).	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1.12 	  REDOX	  REGULATION	  OF	  CELLULAR	  SIGNALLING	  
1.12.1 	  SOURCES	  OF	  REACTIVE	  OXYGEN	  SPECIES	  
Most	   ROS	   are	   partially	   reduced	   forms	   of	   molecular	   oxygen	   and	   many	   oxidative	  
enzymes	   are	   capable	   of	   generating	   small	   amounts	   of	   ROS	  during	   normal	   function.	  
Xanthine	  oxidases,	  cytochrome	  P-­‐450,	  nitric	  oxide	  synthases	  and	  NADPH-­‐dependent	  
oxidases	  are	  amongst	  the	  enzymes	  that	  can	  produce	  ROS	  (Nathan	  and	  Cunningham-­‐
Bussel,	  2013).	  Electron	  leak	  in	  the	  ETC	  complexes	  during	  cellular	  respiration	  can	  also	  
produce	   ROS	   (Murphy,	   2009).	   The	  mitochondria	   and	   the	   NADPH	   oxidase	   complex	  
produce	  the	  greatest	  amount	  of	  ROS.	  Whilst	  mitochondria	  constantly	  produce	  ROS	  
as	  a	  by-­‐product	  of	  cellular	   respiration,	   the	  NADPH	  oxidase	  complex	  only	  generates	  
ROS	  during	  the	  respiratory	  burst	  in	  phagocytes	  (Lambeth,	  2004).	  	  
The	  respiratory	  burst	  is	  an	  example	  of	  deliberate	  generation	  of	  ROS	  and	  the	  NADPH	  
oxidase	  complex	  catalyses	  the	  reaction.	  Phagocytes	  are	  able	  to	  distinguish	  between	  
pathogens	   and	   self	   through	   the	   use	   of	   specific	   phagocytic	   receptors,	   such	   as	  
mannose	   receptors	   (Aderem	  and	  Underhill,	   1999).	   For	  example,	  mannose-­‐residues	  
found	  on	  pathogens	  are	  recognised	  by	  mannose	  receptors	  on	  APCs	  and	  the	  binding	  
of	   the	   two	   leads	   to	   the	   mobilisation	   of	   the	   actin	   cytoskeleton	   and	   thus	  
internalisation	   of	   the	   pathogen.	   The	   phagocytic	   cell	   thus	   forms	   a	   phagosome	   by	  
fusing	  its	  cell	  membrane	  around	  the	  pathogen	  as	  part	  of	  the	  internalisation	  process.	  
(Lambeth,	   2004).	   Once	   the	   pathogen	   is	   engulfed,	   the	   phagocyte	   assembles	   the	  
NADPH	   oxidase	   enzymatic	   complex	   on	   its	   plasma	   membrane	   (Figure	   1	   -­‐	   6).	   The	  
recruited	  cytosolic	  components	  (p40	  phox,	  p47	  phox,	  p67	  phox	  and	  Rac)	  are	  bound	  by	  the	  
membrane-­‐bound	  components,	  gp91	  phox	  and	  p22	  phox	  (Bylund	  et	  al.,	  2010).	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Figure	  1	  -­‐	  6	  The	  phagocytic	  respiratory	  burst.	  
The	  components	  of	  the	  NADPH	  oxidase	  complex	  assemble	  on	  the	  phagosome	  once	  a	  
pathogen	   has	   been	   engulfed.	   The	   complex	   catalyses	   the	   reduction	   of	   O2	   into	   O2-­‐.	  
HVCN1	  provides	  charge	  compensation	  by	  extruding	  H+	  into	  the	  phagosome.	  Several	  
potent	   ROS	   are	   generated	   within	   the	   phagosome,	   such	   as	   HOCl.	   Adapted	   from	  
(DeCoursey,	  2010).	  
	  
gp91	  phox	  creates	  an	  electron	  transport	  chain	  that	  passes	  electrons	  from	  intracellular	  
NADPH	  out	   to	   the	   phagosome	   that,	  with	   the	   addition	   of	   intraphagosomal	   oxygen,	  
produces	   superoxide	  anion	   (O2-­‐);	  which	   is	   the	  precursor	   for	   several	  ROS	   (Babior	  et	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al.,	   2002).	   Dismutation	   of	   O2-­‐	   produces	   hydrogen	   peroxide	   (H2O2)	   that	  
myeloperoxidases	  convert	  to	  hypochlorous	  acid	  (HOCl).	  The	  bacteria	  is	  thus	  killed	  by	  
the	  high	  levels	  of	  intraphagosomal	  ROS	  (Winterbourn,	  2008).	  
The	  electrogenic	  activity	  of	  translocating	  electrons	  to	  the	  phagosome	  by	  the	  NADPH	  
oxidase	   would	   depolarise	   the	   plasma	   membrane.	   Depolarisation	   would	   give	   the	  
membrane	   a	   positive	   charge,	   at	   which	   NADPH	   oxidase	   would	   cease	   to	   function	  
(Murphy	   and	   DeCoursey,	   2006).	   Charge	   compensation	   is	   achieved	  mainly	   through	  
voltage-­‐gated	  proton	  channels,	  by	  diminishing	  cytosolic	  acidification	  caused	  by	   the	  
enzyme	  complex	  and	  hexose	  monophosphate	  shunt.	  Cytosolic	  acidification	  can	  also	  
inhibit	  the	  action	  of	  NADPH	  oxidase,	  which	  has	  an	  optimal	  activity	  at	  pHi	  7.5	  (Morgan	  
et	  al.,	  2009).	  	  
Mitochondrial	   ROS	   is	   generated	   from	   the	   ETC,	   which	   is	   located	   on	   the	   inner	  
mitochondrial	  membrane,	  during	  the	  process	  of	  OXPHOS	  (Murphy,	  2009).	  Whilst	  the	  
ETC	  is	  highly	  efficient	  in	  transporting	  electrons	  through	  the	  various	  complexes,	  there	  
is	  some	  leakage	  of	  electrons	  during	  the	  process.	  This	  leakage	  takes	  place	  at	  the	  sites	  
of	  complex	  I	  (Hirst	  et	  al.,	  2008)	  and	  complex	  III	   (Zhang	  et	  al.,	  1998),	  which	  leads	  to	  
the	  reduction	  of	  O2	  to	  form	  O2-­‐	  (Figure	  1	  -­‐	  7).	  Approximately	  2	  %	  of	  O2	  consumed	  by	  
the	   mitochondria	   during	   OXPHOS	   generates	   O2-­‐.	   Complex	   I	   leaks	   O2-­‐	   into	   the	  
mitochondrial	  matrix	  (Kussmaul	  and	  Hirst,	  2006)	  and	  the	  O2-­‐	  leaked	  from	  complex	  III	  
goes	  into	  both	  the	  mitochondrial	  matrix	  and	  the	  intermembrane	  space	  (Muller	  et	  al.,	  
2004).	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Figure	  1	  -­‐	  7	  Mitochondrial	  ROS	  production.	  	  
Electron	  leaks	  at	  Complex	  I	  and	  Complex	  III	  allow	  the	  reduction	  of	  O2	  to	  occur,	  which	  
produces	  O2-­‐.	  ROS	  produced	  at	  the	  site	  of	  Complex	  I	  are	  released	  into	  the	  matrix	  of	  
mitochondria.	  In	  contrast,	  ROS	  produced	  at	  the	  site	  of	  Complex	  III	  are	  released	  into	  
both	  the	  mitochondrial	  matrix	  and	  the	  intermembrane	  space.	  Adapted	  from	  (Fernie	  
et	  al.,	  2004).	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1.12.2 	  ANTIOXIDANT	  SYSTEMS	  AND	  REGULATION	  OF	  MITOCHONDRIAL	  
ROS	  
Mitochondrial	   ROS	   have	   high	   reactivity	   and	   toxicity	   and	   there	   are	   therefore	   a	  
number	  of	  antioxidant	  enzyme	  systems	  that	  have	  been	  evolved	  by	  mammalian	  cells	  
to	   scavenge	   ROS	   as	   they	   are	   generated	   (Winterbourn,	   2008).	   The	   mitochondrial	  
antioxidant	   enzymes	   are	   encoded	   by	   the	   nuclear	   chromosomal	   genes	   and	   are	  
thereafter	  transported	  into	  the	  mitochondria	  after	  protein	  translation	  in	  the	  cytosol	  
(Handy	  and	  Loscalzo,	  2012).	  	  
One	   of	   the	  most	   important	   antioxidant	   enzyme	   systems	   is	   that	   of	   the	   superoxide	  
dismutase	  (SOD)	  family	  of	  enzymes.	  There	  are	  three	  isoforms	  of	  SOD	  including	  SOD1,	  
SOD2	   and	   SOD3	   (Miao	   and	   St	   Clair,	   2009).	   SOD1	   can	   be	   found	   in	   the	   nucleus,	  
intermembrane	   space	  of	  mitochondria,	   and	   the	   cytosol.	   SOD2	   is	  only	  expressed	   in	  
the	  mitochondrial	  matrix,	  whilst	  SOD3	   is	   located	   in	   the	  extracellular	  space	   (Okado-­‐
Matsumoto	  and	  Fridovich,	  2001).	  Superoxide	  that	   is	  produced	  from	  the	  ETC	  during	  
OXPHOS	   is	   dismutated	   into	   H2O2	   by	   SOD1	   and	   SOD2	   in	   the	   mitochondrial	  
intermembrane	   space	   and	   matrix	   of	   the	   mitochondria,	   respectively	   (Cadenas	   and	  
Davies,	   2000).	   SOD2	   is	   however	   the	   most	   physiologically	   relevant	   antioxidant	  
enzyme	  of	  the	  three.	  This	  is	  made	  evident	  by	  the	  finding	  that	  in	  contrast	  to	  the	  other	  
isoforms,	  SOD2-­‐deficiency	  causes	  early	  neonatal	  death	  in	  mice	  (Li	  et	  al.,	  1995).	  	  
Glutathione	   peroxidases	   (GPx)	   catalyses	   the	   reduction	   of	   H2O2	   into	   water	   using	  
reduced	  glutathione	  (GSH)	  as	  a	  cofactor.	  In	  this	  process,	  GSH	  is	  oxidised	  into	  oxidised	  
glutathione	  (GSSG)	  (Winterbourn,	  2008).	  The	  majority	  of	  GPx	  is	  found	  in	  the	  cytosol,	  
but	   some	   can	   be	   found	   in	   both	   the	   matrix	   and	   intermembrane	   space	   of	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mitochondria	  (Mari	  et	  al.,	  2009).	  NADPH	  can	  be	  used	  as	  a	  substrate	  to	  recycle	  GSSG	  
back	   into	   GSH	   with	   the	   help	   of	   the	   enzyme	   glutathione	   reductase	   (GR).	   This	  
antioxidant	   enzyme	   system	   is	   therefore	   highly	   dependent	   on	   the	   bioavailabilty	   of	  
NADPH	   pools	   (Mari	   et	   al.,	   2013).	   Genetically	   engineered	   GPx	   knockout	  mice	   have	  
been	   found	   to	   be	   phenotypically	   normal	   and	   to	   have	   a	   normal	   lifespan,	   thus	  
indicating	  that	  these	  enzymes	  are	  not	  critical	  for	  survival	  (Muller	  et	  al.,	  2007).	  	  
Peroxiredoxins	  (Prx)	  are	  another	  family	  of	  antioxidant	  enzymes	  and	  they	  regulate	  the	  
levels	  of	  peroxides	  (Wood	  et	  al.,	  2003).	  Peroxides	  are	  compounds	  that	  contain	  O22-­‐,	  
such	  as	  H2O2,	  or	  an	  oxygen-­‐oxygen	  single	  bond.	  Prx	   is	   located	   in	  the	  mitochondrial	  
matrix	   as	   well	   as	   the	   cytosol.	   Certain	   cytokines,	   such	   as	   TNF,	   can	   induce	   the	  
production	  of	  peroxides	  and	  therefore	  Prx	  mediate	  signal	  transduction	  through	  their	  
regulation	  of	  the	  peroxide	  pools	  (Rhee	  et	  al.,	  2000).	  	  
Catalase	  is	  a	  heme-­‐containing	  enzyme	  that	  reduces	  H2O2	  to	  water.	  It	  uses	  NADPH	  as	  
a	  cofactor,	  which	  supplies	  electrons	  to	  the	  reaction	  to	  prevent	  the	  inactivation	  of	  the	  
enzyme	  by	  H2O2	  (Kirkman	  et	  al.,	  1999).	  NADPH	  has	  also	  been	  found	  to	  stabilise	  the	  
enzyme	   complex	   and	   optimise	   its	   activity.	   Catalase	   is	   highly	   efficient	   at	   reducing	  
H2O2,	  however	  it	  is	  not	  believed	  to	  play	  a	  central	  role	  in	  modulating	  ROS	  levels	  as	  the	  
enzyme	  is	  mainly	  found	  in	  the	  peroxisomes	  (Li	  et	  al.,	  2013).	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1.12.3 	  REDOX	  SIGNALLING	  	  
Until	  recently,	  ROS	  where	  thought	  to	  exclusively	  cause	  damaging	  effects	  on	  cellular	  
proteins	   and	   lack	   a	   physiological	   function.	   However,	   ROS	   are	   now	   appreciated	   to	  
function	  as	  signalling	  molecules	  that	  can	  modulate	  cellular	  processes	  through	  redox-­‐
dependent	   signalling	   (Sena	   and	   Chandel,	   2012).	   Early	   investigations	   showed	   that	  
hydrogen	  peroxide	  was	  required	  for	  growth	  factor,	  mitogen-­‐activated	  protein	  kinase	  
(MAPK)	   and	   nuclear	   factor	   kappa-­‐light-­‐chain-­‐enhancer	   of	   activated	   B	   cells	   (NF-­‐κB)	  
signalling	   (Finkel,	   1998).	   These	   were	   followed	   by	   reports	   that	   suggested	   that	  
hydrogen	  peroxide	  could	  inhibit	  phosphatases	  by	  cysteine	  oxidation,	  thus	  providing	  
a	   potential	   biochemical	   mechanism	   for	   ROS	   as	   signalling	   molecules	   (Rhee	   et	   al.,	  
2000).	   Recent	   studies	   have	   shown	   that	   mitochondrial	   ROS	   can	   activate	   c-­‐Jun	   N-­‐
terminal	  kinase	  (JNK)	  (Kamata	  et	  al.,	  2005)	  and	  NF-­‐κB	  signalling	  pathways.	  	  
A	   great	   deal	   of	   evidence	   indicates	   that	   ROS	   can	   regulate	   signalling	   pathways	   by	  
causing	   reversible	   protein	   modifications.	   Hydrogen	   peroxide	   oxidation	   of	   cysteine	  
groups	   can	   alter	   the	   deoxyribonucleic	   acid	   (DNA)	   binding	   activity	   of	   transcription	  
factors,	   protein-­‐protein	   interactions	   and	   affect	   the	   catalytic	   activity	   of	   enzymes	  
(Brandes	  et	  al.,	  2009).	  Phosphatases	  are	  particularly	  susceptible	  to	  regulation	  by	  ROS	  
as	  they	  posses	  a	  reactive	  cysteine	  in	  their	  catalytic	  domains.	  These	  enzymes	  inhibit	  
protein	  kinases	  through	  the	  processes	  of	  dephosphorylation,	  thus	  oxidation	  of	  their	  
cysteine	   residue	   inhibits	   the	  enzymatic	  activity	  of	  phosphatases	   (Janssen-­‐Heininger	  
et	   al.,	   2008).	   Some	   notable	   examples	   of	   susceptible	   phosphatases	   are	   protein	  
tyrosine	  phosphatase	  1b	  (PTP1b)	  (Lee	  et	  al.,	  1998),	  phosphatase	  and	  tensin	  homolog	  
(PTEN)	  (Kwon	  et	  al.,	  2004)	  and	  MAPK	  phosphatases	  (Levinthal	  and	  Defranco,	  2005).	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MAPKs	   are	   crucial	   for	   relaying	   extracellular	   signals	   to	   the	   nucleus	   and	   accomplish	  
this	  through	  a	  number	  of	  phosphorylation	  events,	  which	  are	  negatively	  regulated	  by	  
MAPK	  phosphatases	   (Cargnello	   and	  Roux,	   2011).	   Three	   subgroups	  of	  MAPKs	   exist:	  
the	   extracellular	   signal	   regulated	   kinases	   (ERKs),	   the	   JNKs,	   and	   the	   p38	   MAPKs.	  
MAPKs	  are	  involved	  in	  several	  cellular	  functions	  such	  as	  cell	  survival,	  differentiation	  
and	   inflammatory	   responses	   (Boutros	   et	   al.,	   2008).	   A	   number	   of	   studies	   have	  
demonstrated	   ROS-­‐induced	   MAPK	   activation	   and	   this	   is	   further	   evident	   as	  
antioxidants	  have	  been	  shown	  to	  inhibit	  MAPK	  activation	  after	  cell	  stimulation	  (Ding	  
et	   al.,	   2010).	   ROS	   have	   also	   been	   indicated	   in	   the	   pro-­‐inflammatory	   cytokine	  
production	  of	  macrophages	  through	  their	  activation	  of	  MAPKs	  (Kasahara	  et	  al.,	  2011,	  
Emre	  et	  al.,	  2007).	  
The	  NF-­‐κB	  signalling	  pathway	  plays	  a	  highly	  important	  role	  in	  the	  immune	  system	  as	  
it	   regulates	   the	  expression	  of	  a	  number	  of	  genes	   involved	   in	   inflammation	  such	  as	  
those	   for	   cytokines	  and	  growth	   factors	   (Li	   and	  Verma,	  2002).	   The	  members	  of	   the	  
NF-­‐κB	   family	  are	   found	   in	   the	  cytoplasm	  of	  cells	  bound	  to	   IκB	   family	  proteins.	  This	  
prevents	  the	  NF-­‐κB	  proteins	  to	  translocate	  to	  the	  nucleus,	  thus	  inhibiting	  activation	  
of	   the	   pathway	   (Hayden	   and	   Ghosh,	   2004).	   NF-­‐κB	   signalling	   can	   occur	   through	   a	  
classical	   or	   alternative	   pathway.	   In	   the	   classical	   pathway	   of	   NF-­‐κB	   activation,	  
stimulation	  of	  the	  TLR4,	  for	  example,	  activates	  the	  IκB	  kinase	  (IKK)	  β	  complex.	  This	  in	  
turn	   phosphorylates	   IκB	   proteins,	   which	   are	   targeted	   for	   degradation	   by	   the	  
ubiquitin	   ligases.	   In	   the	  case	  of	   the	  alternative	  activation,	   IKKα	  phosphorylates	   the	  
p100	  NF-­‐κB	  protein,	  which	  is	  processed	  by	  the	  proteasome	  (Bonizzi	  and	  Karin,	  2004).	  
Several	   novel	   mechanisms	   have	   been	   reported	   for	   ROS-­‐induced	   NF-­‐κB	   activation	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such	  as	  tyrosine	  phosphorylation	  of	  IκB,	  activation	  of	  IKK	  and	  serine	  phosphorylation	  
of	   p65	   (Takada	   et	   al.,	   2003).	   Studies	   have	   shown	   that	   ROS	   can	   regulate	   the	  
production	  of	  cytokines,	  such	  as	  TNF,	  in	  macrophages	  through	  its	  actions	  on	  the	  NF-­‐
κB	  signalling	  pathway(Rose	  et	  al.,	  2000)	  (Bulua	  et	  al.,	  2011).	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1.13 	  THESIS	  AIMS	  
It	   is	  clear	  that	  the	  voltage-­‐gated	  proton	  channel	  HVCN1	  plays	  an	  essential	  role	   in	  a	  
range	   of	   cell	   types,	   in	   particular	   immune	   cells.	   Previous	   published	   work	   has	  
confirmed	   the	   existence	   of	   proton	   channels	   in	   both	   murine	   and	   human	  
macrophages.	   However,	   the	   role	   of	   HVCN1	   in	   macrophages	   has	   not	   been	  
investigated.	  Given	   that	   the	  current	   literature	  on	  voltage-­‐gated	  proton	  channels	   in	  
immune	  cells	  has	  found	  HVCN1	  to	  be	  involved	  in	  several	  cellular	  processes	  (such	  as	  
the	  respiratory	  burst	  and	  signalling	  events)	  it	  is	  important	  to	  establish	  its	  functional	  
role	  in	  macrophages,	  which	  are	  a	  crucial	  constituent	  of	  the	  immune	  system.	  	  
The	   aim	   of	   my	   thesis	   was	   to	   investigate	   the	   function	   of	   voltage-­‐gated	   proton	  
channels	  in	  macrophages	  with	  the	  use	  of	  mice	  with	  a	  disrupting	  mutation	  within	  the	  
Hvcn1	   gene,	   which	   results	   in	   HVCN1	   loss.	   In	   particular,	   I	   wanted	   to	   address	   how	  
Hvcn1-­‐/-­‐	   macrophages	   responded	   to	   LPS	   activation.	   I	   hypothesised	   that	   HVCN1	  
regulates	   the	   respiratory	   burst	   of	   macrophages	   and	   that	   it	   potentially	   modulates	  
mitochondrial	  ROS	  production,	  and	  in	  doing	  so,	  may	  affect	  several	  functional	  aspects	  
of	  macrophage	  biology.	  The	  specific	  aims	  of	  the	  present	  work	  were:	  
1. Elucidate	   the	   involvement	   of	   HVCN1	   in	   the	   ROS	   producing	   processes	   of	  
macrophages	  
2. Determine	   the	   subcellular	   localisation	   of	   HVCN1	   in	   macrophages	   and	  
investigate	  its	  potential	  functional	  role	  in	  regards	  to	  its	  specific	  location.	  
3. Assess	   the	   impact	   of	   HVCN1-­‐deficiency	   on	   the	   metabolic	   processes	   of	  
macrophages.	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4. Investigate	   cell	   signalling	   pathways	   in	   order	   to	   gain	   insight	   into	   other	  
potential	  cellular	  functions	  associated	  with	  HVCN1	  loss.	  
5. 	  Study	  characteristic	  macrophage	  functions	  to	  gain	  a	  global	  understanding	  of	  
the	  role	  of	  voltage-­‐gated	  proton	  channels	  in	  these	  cells.	  	  
My	  thesis	  provides	  a	  novel	  perspective	  on	  the	  role	  of	  voltage-­‐gated	  proton	  channels	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2.1 TRANSGENIC	  ANIMALS	  
C57BL/6	  mice	  were	  purchased	  from	  Charles	  River	  (Canterbury,	  UK)	  aged	  6-­‐8	  weeks	  
and	  Hvcn1-­‐/-­‐	  mice	  were	  bred	  in-­‐house	  on	  a	  C57BL/6	  background.	  Hvcn1-­‐/-­‐	  mice	  were	  
generated	  in	  the	  lab	  of	  David	  Clapham	  and	  backcrossed	  against	  C57BL/6	  mice	  for	  8	  
generations.	  Hvcn1-­‐/-­‐	  mice	  were	  screened	  by	  genomic	  PCR	  using	  primers	  specific	  for	  
Hvcn1	   intron	   3	   and	   β-­‐galactosidase.	   Mice	   were	   maintained	   in	   our	   pathogen-­‐free	  
Biological	   Services	   Unit	   at	   the	   Barts	   Cancer	   Institute,	   London.	   Mice	   were	   used	  
according	  to	  the	  established	  institutional	  welfare	  guidelines	  under	  the	  authority	  of	  a	  
UK	   Home	   Office	   project	   licence	   (PL	   70/5541)	   (Guidance	   on	   Operation	   of	   Animals	  
Scientific	   Procedures	   Act	   1986).	   Experimental	   protocols	   and	   procedures	  were	   also	  
approved	   by	   the	   UK	   Home	   Office	   and	   performed	   under	   the	   following	   personal	  
licence	  number:	  PIL	  70/22431.	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2.2 TISSUE	  CULTURE	  
2.2.1 GENERATION	  OF	  BONE	  MARROW-­‐DERIVED	  MACROPHAGES	  
Mice	  were	  culled	  by	  cervical	  dislocation	  and	  the	  tibiae	  and	  femurs	  of	  WT	  and	  HVCN1-­‐
/-­‐	  mice	  were	  collected	  and	  the	  bone	  marrow	  progenitor	  cells	  were	  flushed	  out	  with	  
20	   ml	   of	   Dulbecco’s	   Modified	   Eagle’s	   Medium	   (DMEM;	   PAA	   –	   E15-­‐S10)	  
supplemented	  with	  10	  %	  v/v	  heat-­‐inactivated	  (HI)	   foetal	  bovine	  serum	  (FBS;	  PAA	  –	  
A15-­‐102)	   and	  1	  %	   v/v	  penicillin/streptomycin	   (PAA	  –	  P11-­‐010)	   using	   a	   27G	  needle	  
under	   sterile	   conditions.	   The	   cell	   suspensions	  were	   centrifuged	   at	   1500	   rpm	   for	   5	  
minutes.	  The	  cells	  were	  resuspended	  in	  10	  ml	  of	  medium	  and	  passed	  through	  a	  70	  
μm-­‐wide	  cut-­‐off	  strainer.	  7	  x	  106	  cells	  were	  seeded	  in	  100	  x	  20	  mm	  non-­‐treated	  cell	  
culture	  plates	   in	   25	  ml	   of	  medium.	  A	   final	   concentration	  of	   20	  ng/ml	  macrophage	  
colony	  stimulating	  factor	   (eBioscience	  14-­‐8983-­‐80)	  was	  added	  to	  each	  plate,	  which	  
were	  then	  allowed	  to	  incubate	  at	  37	  ˚C	  and	  5	  %	  CO2.	  After	  3	  days,	  the	  medium	  was	  
supplemented	  with	  a	  final	  concentration	  of	  20	  ng/ml	  M-­‐CSF.	  On	  day	  6/7	  of	  culture,	  
non-­‐adherent	  cells	  were	  removed	  by	  washing	  with	  phosphate	  buffered	  saline	  (PBS;	  
PAA	   –	   H15-­‐002).	   Adherent	   cells	   were	   collected	   by	   adding	   15	   ml	   cell-­‐dissociation	  
buffer	  (Life	  Tech	  –	  13151-­‐014),	  incubating	  at	  37	  ˚C	  and	  5	  %	  CO2	  for	  30	  minutes	  and	  
then	  displacing	  the	  cells	  with	  cell	  scrapers.	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2.3 PROTEIN	  ANALYSIS	  
2.3.1 PROTEIN	  EXTRACTION	  
BMDMs	  were	  seeded	  into	  6-­‐well	  plates	  at	  1	  x	  106	  cells/well	  and	  incubated	  overnight	  
at	   37	   ˚C	   and	   5	   %	   CO2.	   Cells	   were	   then	   either	   untreated	   or	   given	   100ng/ml	   LPS	  
(invivogen	  –	  tlrl-­‐eklps)	  for	  0	  to	  60	  min	  and	  were	  allowed	  to	  incubate	  at	  37	  ˚C	  and	  5	  %	  
CO2.	   In	  some	  experiments,	  cells	  were	  pre-­‐treated	  with	  100	  μM	  Mito-­‐TEMPO	  (Santa	  
Cruz	  –	  sc-­‐221945)	  or	  10	  μM	  Apocynin	  (Sigma	  –	  W508454)	  for	  1	  hour.	  
Once	  the	  given	  time	  point	  had	  been	  reached,	  the	  wells	  were	  washed	  once	  with	  PBS,	  
placed	  on	  ice	  and	  given	  50	  μl	  supplemented	  radioimmunoprecipitation	  (RIPA)	  buffer	  
(Sigma	   -­‐	   R0278).	   This	   buffer	   had	   been	   supplemented	   with	   Complete	   Protease	  
Inhibitor	  Cocktail	  (Roche	  -­‐	  11836153001)	  and	  phosphatase	  inhibitor	  cocktail	  2	  and	  3	  
(Sigma	   -­‐	   P5726	   and	   P004).	   Plates	   were	   incubated	   on	   ice	   for	   at	   least	   15	   minutes	  
whereupon	   the	   cell	   lysates	  were	  harvested	  by	   scrapping	  with	   a	   rubber	  policeman.	  
Lysates	  were	   collected	   into	   1.5	  ml	   Eppendorf	   tubes	   and	  were	   centrifuged	   at	   1320	  
rpm	  for	  30	  min	  at	  4	   ˚C	  to	  pellet	   the	  cell	  debris.	  Lysates	  were	  then	  transferred	   into	  
new	  1.5	  ml	  Eppendorf	  tubes	  and	  stored	  at	  -­‐20	  ˚C	  until	  use.	  
2.3.2 PROTEIN	  QUANTIFICATION	  
The	   concentration	   of	   protein	   was	   determined	   using	   the	   bicinchoninic	   acid	   (BCA)	  
protein	  assay.	  The	   first	   step	   is	   the	  biuret	   reaction,	  which	   involves	   the	   reduction	  of	  
Cu2+	   to	   Cu+	   by	   proteins	   in	   an	   alkaline	   environment.	   This	   produces	   a	   light	   blue	  
complex.	   In	   the	   second	   step,	   the	   chelation	   of	   two	   molecules	   of	   BCA	   with	   one	  
cuprous	   ion	   results	   in	   a	   purple-­‐coloured	   reaction	   product.	   The	   water-­‐soluble	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BCA/copper	  complex	  exhibits	  a	  strong	  linear	  absorbance	  at	  595	  nm	  with	  increasing	  
protein	  concentrations.	  
A	  stock	  solution	  of	  bovine	  serum	  albumin	  (BSA;	  Sigma	  –	  A9418)	  was	  diluted	  in	  PBS	  to	  
generate	  a	  standard	  curve	  ranging	  from	  0	  to	  1	  mg/ml.	  10	  μL	  BSA	  standard,	  sample	  or	  
control	   were	   pipetted	   into	   a	   96-­‐well	   plate.	   Working	   reagent	   was	   prepared	   by	  
combining	  one	  part	  of	  Copper	  (II)	  sulfate	  solution	  (Sigma	  -­‐	  C2284;)	  with	  50	  parts	  BCA	  
solution	   (Sigma	   -­‐	  B9643).	  200	  μL	  of	  working	   reagent	  was	  dispensed	   into	  each	  well	  
and	  the	  plate	  was	   incubated	  at	  37	  ˚C	   for	  30	  minutes.	  The	  optical	  density	   (OD)	  was	  
read	   at	   595nm	   using	   a	   spectrophotometer	   and	   the	   protein	   concentrations	   of	   the	  
samples	  were	  calculated	  using	  the	  known	  concentrations	  of	  the	  BSA	  standard	  curve.	  
2.3.3 WESTERN	  BLOT	  
In	   order	   to	   identify	   proteins	   within	   a	   sample	   they	   need	   to	   be	   chemically	   and	  
physically	  denatured	  followed	  by	  separation,	  according	  to	  their	  molecular	  weight,	  in	  
a	   Bis-­‐Tris	   buffered	   sodium	   dodecyl	   sulfate	   (SDS)	   polyacrylamide	   gel.	   Once	   the	  
proteins	   have	   been	   separated	   they	   can	   then	   be	   transferred	   onto	   a	   polyvinylidine	  
fluoride	  (PVDF)	  membrane	  to	  allow	  detection	  with	  antibodies.	  
Samples	   (20	  μg)	  were	  mixed	  with	  NuPAGE	  LDS	  Sample	  Buffer	   (Life	  Tech	   -­‐	  NP0007)	  
and	  NuPAGE	  Sample	  Reducing	  Agent	  (Life	  Tech	  -­‐	  NP0004).	  They	  were	  then	  heated	  to	  
75	   ˚C	   for	   10	  minutes	   followed	  by	   brief	   centrifugation	   to	   collect	   any	   condensation.	  
Samples	  remained	  at	  room	  temperature	  until	  they	  were	  loaded	  onto	  the	  gel.	  Novex	  
Sharp	   Pre-­‐stained	   protein	   standard	   (Life	   Tech	   -­‐	   LC5800)	   was	   run	   on	   all	   gels.	  
Prestained	   molecular	   weight	   standards	   allow	   monitoring	   of	   electrophoresis,	  
determination	   of	   the	   apparent	   mass	   (kDA)	   of	   proteins	   of	   interest	   and,	   to	   some	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extent,	  confirmation	  of	  protein	  transfer	  onto	  PVDF.	  Novex	  Bis-­‐Tris	  gels	  were	  run	  by	  
electrophoresis	  in	  NuPAGE	  MOPS	  SDS	  Running	  Buffer	  (Life	  Tech	  -­‐	  NP0001).	  NuPAGE	  
Antioxidant	  (Life	  Tech	  -­‐	  NP0005)	  was	  added	  to	  the	  upper	  (cathode)	  buffer	  chamber.	  
The	  antioxidant	  prevents	  the	  reoxidation	  of	  sensitive	  amino	  acids	  by	  migrating	  with	  
the	   reduced	  proteins	   to	  maintain	   reducing	  conditions.	  Gels	  were	   run	  at	  a	  constant	  
voltage	  of	  150	  V	  for	  1	  hour	  and	  30	  minutes.	  
Resolved	  proteins	  were	  transferred	  to	  PVDF	  membranes	  by	  XCell	  II	  Blot	  Module	  tank	  
transfer	   (Life	   Tech	   -­‐	   LC2005	   and	   EI9051,	   respectively).	   PVDF	   membranes	   are	  
hydrophobic	  and	  were	  therefore	  hydrated	  in	  methanol	  for	  one	  minute	  prior	  to	  use.	  
The	   gel	   and	   PVDF	   membrane	   were	   sandwiched	   between	   Whatmann	   paper	   and	  
sponge	  pads	  (Life	  Tech	  -­‐	  LC2005	  and	  EI9052,	  respectively).	  	  The	  transfer	  module	  was	  
immersed	  in	  NuPAGE	  Transfer	  Buffer	  (Life	  Tech	  -­‐	  NP0006-­‐1)	  and	  electrotransfer	  was	  
performed	  at	  a	  constant	  voltage	  of	  30	  V	  for	  1	  hour.	  
Membranes	  were	  blocked	  with	  5	  %	  milk	  powder	  in	  tris	  buffered	  saline	  (TBS)	  with	  0.1	  
%	   v/v	   Tween-­‐20	   (TBS-­‐T)	   for	   1	  hour	   at	   room	   temperature	  on	  a	   rocking	  platform	   to	  
prevent	   non-­‐specific	   antibody	  binding.	   Primary	   antibodies	  were	  diluted	   in	   the	   5	  %	  
milk	   solution	   and	   allowed	   to	   incubate	   with	   the	   membranes	   over	   night	   at	   4	   ˚C.	  
Membranes	  were	  washed	  3	   x	  5	  minutes	   in	  TBS-­‐T	  and	  were	   then	   incubated	   in	  5	  %	  
milk	   solution	   containing	   horseradish	   peroxidises	   (HRP)-­‐conjugated	   secondary	  
antibodies	   for	   1	   hour.	   Following	   a	   further	   three	   washes,	   a	   substrate	   for	   HRP	  
(Amersham	  ECL	  Western	  Blotting	  Detection	  Reagents,	  GE	  Healthcare	  -­‐	  RPN2106)	  was	  
added	   to	   the	   membranes	   and	   this	   was	   followed	   by	   exposure	   onto	   Super	   RX	  
autoradiography	  films	  (Fujifilm	  -­‐	  P10M000266A)	  to	  detect	  the	  emitted	  light.	  HRP	  can	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catalyse	  the	  oxidation	  of	  luminol	  to	  3-­‐aminophthalate,	  which	  causes	  emission	  of	  low	  
intensity	  light.	  Certain	  chemicals,	  such	  as	  p-­‐indophenol,	  can	  enhance	  this	  reaction	  in	  
order	  to	  increase	  light	  emission.	  This	  is	  referred	  to	  as	  enhanced	  chemiluminescence	  
(ECL).	   The	   amount	   of	   protein	   is	   thus	   semi-­‐quantitatively	   determined	   because	   the	  
intensity	  of	  light	  emitted	  is	  a	  measure	  of	  the	  number	  of	  enzyme	  molecules	  reacting.	  
Membranes	   could	   be	   incubated	   with	   a	   different	   primary	   antibody	   by	   stripping	   of	  
previous	  antibodies.	  This	  was	  achieved	  by	  incubation	  in	  Re-­‐blot	  solution	  (Millipore	  -­‐	  
2504)	  for	  5	  minutes	  at	  room	  temperature,	  followed	  by	  a	  5	  minute	  incubation	  in	  5	  %	  
milk	  solution.	  At	  this	  point,	  membranes	  were	  blocked	  in	  5	  %	  milk	  solution	  for	  1	  hour	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All	  primary	  and	  secondary	  antibodies	  used	  are	   listed	  below	  in	  Table	  2	  -­‐1	  and	  2	  -­‐	  2,	  
respectively.	  	  
Antibody	   Supplier	   Cat.	  Ref.	   Isotype	   Dilution	  
Β-­‐actin	   Sigma	  Aldrich	   A1978	   Mouse	  IgG1	   1:5000	  
HVCN1	   Abcam	   105344	   Rabbit	  IgG	   1:500	  
SOD2	   Abcam	   68155	   Rabbit	  IgG	   1:1000	  
p-­‐p44/p42	   Cell	  Signalling	   4370	   Rabbit	  IgG	   1:1000	  
p44/p42	   Cell	  Signalling	   4695	   Rabbit	  IgG	   1:1000	  
p-­‐SAPK/JNK	   Cell	  Signalling	   4668	   Rabbit	  IgG	   1:1000	  
SAPK/JNK	   Cell	  Signalling	   9258	   Rabbit	  IgG	   1:1000	  
p-­‐p38	  MAPK	   Cell	  Signalling	   4511	   Rabbit	  IgG	   1:1000	  
P38	  MAPK	   Cell	  Signalling	   8690	   Rabbit	  IgG	   1:1000	  
p-­‐IκBα	   Cell	  Signalling	   2859	   Rabbit	  IgG	   1:1000	  
IκBα	   Cell	  Signalling	   4812	   Rabbit	  IgG	   1:1000	  
p-­‐IKKα/β	   Cell	  Signalling	   2078	   Rabbit	  IgG	   1:1000	  
IKKβ	   Cell	  Signalling	   2370	   Rabbit	  IgG	   1:1000	  
	  
Table	  2	  -­‐	  1	  Primary	  antibodies	  used	  for	  Western	  Blot.	  	  
Table	  describes	  the	  primary	  antibodies	  used	  for	  Western	  Blot	  and	  lists	  the	  relevant	  
details	  of	  each	  antibody.	  	  
	  
Antibody	   Supplier	   Cat.	  Ref.	   Dilution	  
Anti-­‐mouse	  IgG	  HRP	   GE	  Healthcare	   NXA931	   1:5000	  
Anti-­‐rabbit	  IgG	  HRP	   GE	  Healthcare	   NA934	   1:2000	  
	  
Table	  2	  -­‐	  2	  Secondary	  antibodies	  used	  for	  Western	  Blot.	  
Table	  describes	  the	  secondary	  antibodies	  for	  Western	  Blot	  and	  lists	  the	  relevant	  
details	  of	  each	  antibody.	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2.3.4 ENZYME-­‐LINKED	  IMMUNOSORBENT	  ASSAY	  (ELISA)	  
BMDMs	   were	   seeded	   into	   96-­‐well	   plates	   at	   5	   x	   104	   cells/well	   and	   incubated	  
overnight	  at	  37	  ˚C	  and	  5	  %	  CO2.	  Cells	  were	  then	  either	  untreated	  or	  given	  100	  ng/ml	  
LPS	   for	   3	   to	   48	   hours.	   In	   some	   experiments,	   cells	   were	   pre-­‐treated	   with	   100	   μM	  
Mito-­‐TEMPO	  or	  10	  μM	  Apocynin	  for	  1	  hour.	  
The	  supernatant	  was	  collected	  by	  centrifugation	  of	  the	  microplates	  at	  1200	  rpm	  for	  
5	   minutes	   to	   remove	   any	   dead	   cells	   or	   debris	   and	   then	   the	   supernatant	   was	  
transferred	   into	   new	   microplates	   and	   stored	   at	   -­‐80	   ˚C.	   The	   supernatant	   was	  
subjected	  to	  no	  more	  than	  two	  freeze/thaw	  cycles.	  
ELISA	  kits	  were	  used	  to	  measure	  the	  levels	  of	  IL-­‐10	  (555252),	  IL-­‐6	  (555240),	  IL12p70	  
(555256)	  and	  TNFα	  (558534)	  protein	  according	  to	  the	  manufacturer’s	  guidelines	  (all	  
BD	  Biosciences).	  
Briefly,	   96-­‐well	   ELISA	   microplates	   were	   coated	   with	   50μl	   capture	   antibody	   (anti-­‐
mouse	  monoclonal	  Ab)	   in	  PBS	  and	   incubated	  over	  night	  at	  4	   ˚C.	   ELISA	  microplates	  
were	  washed	  three	  times	  with	  PBS	  supplemented	  with	  0.05	  %	  Tween-­‐20	  (PBS/T)	  and	  
then	   unspecific	   binding	  was	   blocked	  with	   the	   addition	   of	   100	   μl	   blocking	   solution	  
(PBS	  with	   10	  %	   FBS)	   to	   each	  well	   and	   incubated	   for	   1	   hour	   at	   room	   temperature.	  
ELISA	   microplates	   were	   washed	   three	   times	   with	   PBS/T	   and	   50	   μl	   of	   standards,	  
samples,	   and	   control	   supernatants	   were	   added	   to	   the	   wells	   and	   the	   microplates	  
were	  incubated	  for	  2	  hours	  at	  room	  temperature.	  Plates	  were	  washed	  for	  a	  total	  of	  
five	  times	  after	  which	  50	  μl	  of	  working	  detector	  solution	  was	  added	  to	  each	  well	  and	  
plates	   were	   incubated	   for	   1h	   at	   room	   temperature.	   The	   solution	   consisted	   of	  
detection	   antibody	   (biotinylated	   anti-­‐mouse	   monoclonal	   Ab)	   and	   streptavidin-­‐
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horseradish	  peroxidase	  conjugate	  (SAv-­‐HRP).	  Plates	  were	  washed	  for	  a	  total	  of	  seven	  
times	   followed	   by	   addition	   of	   50	   μl	   substrate	   solution	   (tetramethylbenzidine	   and	  
hydrogen	  peroxide;	  BioLegend	  -­‐	  421101)	  and	  were	  then	  allowed	  to	  incubate	  at	  room	  
temperature	   in	   the	  dark	   for	   5-­‐15	  minutes.	   The	   enzyme	   reaction	  was	  quenched	  by	  
adding	  25	  μl	  stop	  solution	  (1	  M	  H3PO4)	  to	  each	  well.	  The	  absorbance	  was	  read	  at	  450	  
nm	   with	   570	   nm	   within	   30	   minutes	   of	   stopping	   the	   reaction	   on	   a	  
spectrophotometer.	  Protein	  concentrations	  (pg/ml)	  were	  calculated	  using	  the	  known	  
concentrations	  of	  the	  cytokine	  standard	  curve.	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2.4 NUCEIC	  ACIDS	  
2.4.1 TOTAL	  RNA	  ISOLATION	  
BMDMs	   were	   seeded	   into	   24-­‐well	   plates	   at	   2	   x	   105	   cells/well	   and	   incubated	  
overnight	  at	  37	  ˚C	  and	  5	  %	  CO2.	  Cells	  were	  then	  either	  untreated	  or	  given	  100	  ng/ml	  
LPS	   for	   6	   hours	   and	   were	   allowed	   to	   incubate	   at	   37	   ˚C	   and	   5	   %	   CO2.	   In	   some	  
experiments,	   cells	  were	  pre-­‐treated	  with	  100	  μM	  Mito-­‐TEMPO	  or	  10	  μM	  Apocynin	  
for	  1	  hour.	  
RNeasy	  technology	  (Qiagen	  –	  74104)	  was	  used	  to	  purify	  RNA	  from	  adherent	  BMDMs	  
according	  to	  the	  manufacturer’s	  guidelines.	  
Cells	  were	   lysed	  directly	   by	   the	   addition	  of	   350	  μl	   of	   RLT	  buffer	   to	   each	  well.	   The	  
lysate	   was	   pipetted	   onto	   a	   QIAshredder	   spin	   column	   (Qiagen	   –	   79656)	   and	  
centrifuged	  for	  2	  minutes	  at	  1300	  rpm.	  An	  equal	  volume	  of	  70	  %	  ethanol	  was	  added	  
to	  the	  homogenized	  lysate	  and	  mixed	  well	  by	  pipetting	  in	  order	  to	  provide	  adequate	  
binding	  conditions.	  The	  lysate	  was	  transferred	  onto	  an	  RNeasy	  spin	  column	  to	  allow	  
the	   total	   RNA	   to	   bind	   to	   the	   membrane	   of	   the	   column	   and	   centrifuged	   for	   15	  
seconds	  at	  1300	  rpm	  to	  wash	  off	  contaminants	  (flow-­‐through	  was	  discarded).	  350	  μl	  
of	   buffer	   RW1	   was	   used	   to	   wash	   the	  membrane-­‐bound	   RNA	   by	   centrifugation	   at	  
1300	  rpm	  for	  15	  seconds	  (flow-­‐through	  discarded).	  On-­‐column	  DNase	  digestion	  was	  
achieved	  using	  the	  RNase-­‐free	  DNase	  Set	  to	  digest	  potentially	  contaminating	  DNA.	  A	  
solution	  of	  10	  μl	  DNase	  I	  and	  70	  μl	  of	  buffer	  RDD	  was	  applied	  directly	  onto	  the	  spin	  
column	  membrane	   and	   then	   incubated	   for	   15	  minutes	   at	   room	   temperature.	   This	  
was	  followed	  by	  another	  wash	  with	  350	  μl	  of	  buffer	  RW1	  at	  1300	  rpm	  for	  15	  seconds	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(flow-­‐through	  discarded),	  after	  which	  the	  spin	  column	  membrane	  was	  washed	  twice	  
with	  500	  μl	  of	  buffer	  RPE	  at	  1300	  rpm	  for	  30	  seconds	  each.	  A	  small	  volume	  (30-­‐50	  μl)	  
of	   RNase-­‐free	  water	  was	   used	   to	   elute	   the	   high-­‐quality	   RNA	   at	   1300	   rpm	   for	   one	  
minute.	  The	  resultant	  RNA	  was	  stored	  at	  -­‐80	  ˚C.	  
2.4.2 RNA	  QUANTIFICATION	  AND	  QUALITY	  CONTROL	  	  
RNA	   concentrations	   were	   determined	   using	   the	   ND-­‐100	   spectrophotometer	  
(Nanodrop	  Technologies).	  Two	  ratios	  of	  absorbance	  were	  considered	  when	  assessing	  
the	  purity	  of	  RNA:	  
-­‐ The	   ratio	   of	   sample	   absorbance	   at	   260	   and	   280	   nm	   (260/280).	   RNA	   is	  
absorbed	   at	   260	   nm	   and	   contaminants	   are	   absorbed	   at	   280	   nm.	   A	   sample	  
ratio	   with	   a	   value	   of	   2.0	   is	   considered	   to	   be	   ‘pure’.	   A	   lower	   ratio	   would	  
indicate	  the	  presence	  of	  protein	  or	  other	  contaminants.	  -­‐ A	   ratio	   of	   sample	   absorbance	   at	   260	   and	   230	   nm	   (260/230).	   Similarly	   as	  
described	  above,	  a	  sample	  ratio	  of	  2.0	  is	  considered	  to	  be	  ‘pure’.	  Lower	  ratios	  
may	  indicate	  the	  presence	  of	  contaminants	  that	  absorb	  at	  230nm.	  
2.4.3 cDNA	  SYNTHESIS	  
M-­‐MLV	   Reverse	   Transcriptase	   (Promega	   –	   M1705)	   was	   used	   according	   to	   the	  
manufacturer’s	   guidelines	   to	   perform	   cDNA	   synthesis.	   1	   μg	   of	   random	   primers	  
(Invitrogen	  –	  48190-­‐011)	  was	  added	  to	  1	  μg	  of	  DNase-­‐treated	  RNA	  in	  a	  final	  volume	  
of	  14	  μl.	  Primer	  annealing	  and	  breakdown	  of	  secondary	  structures	  was	  achieved	  by	  
incubating	  samples	  at	  75	  ˚C	  for	  5	  minutes	  and	  then	  snap-­‐cooled	  on	  ice	  for	  a	  further	  5	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minutes	   to	   prevent	   the	   structures	   from	   reforming.	   The	   following	   reagents	   were	  
added	  to	  each	  sample:	  
-­‐ 200	  units	  M-­‐MLV	  Reverse	  Transcriptase	  -­‐ 5	  μl	  M-­‐MLV	  buffer	  (Promega	  –	  M5313)	  -­‐ 5	  nM	  dNTPs	  (Applied	  Biosystems	  –	  N8080007)	  -­‐ 0.6	  μl	  RNasin	  Ribonuclease	  inhibitor	  (Promega	  –	  N2111)	  
The	  samples	  were	  allowed	  to	  incubate	  for	  10	  minutes	  at	  room	  temperature	  followed	  
by	  60	  minutes	  at	  40	  ˚C	  for	  the	  cDNA	  synthesis.	  The	  final	  sample	  volume	  was	  adjusted	  
to	  100	  μl	  with	  deionised	  water	  and	  stored	  at	  -­‐80	  ˚C.	  
2.4.4 QUANTITATIVE	  REAL	  TIME	  POLYMERASE	  CHAIN	  REACTION	  (qRT-­‐
PCR)	  
Taqman	  Gene	  Expression	  Assays	  contain	  forward/reverse	  primers	  and	  a	  fluorogenic	  
probe	  coupled	  to	  a	  reporter	   fluorescent	  dye	  at	  the	  5’	  end	  (FAM/VIC)	  and	  an	  MGB-­‐
nonfluorescent	  quencher	  on	   the	  3’	  end	   (TAMRA).	  At	   the	  beginning	  of	   the	   reaction	  
the	   fluorescence	   from	   the	   dye	   is	   quenched	   by	   the	   quencher,	   as	   the	   probe	   is	   still	  
intact.	  Once	  the	  primers	  and	  probe	  anneal	  to	  the	  their	  specific	  target	  sequences,	  the	  
probe	   is	   cleaved	   by	   the	   enzymatic	   activity	   of	   DNA	   polymerase	   (5’	   end)	   and	   thus	  
separating	   the	  dye	   from	   the	  quencher.	   Each	   cycle	  of	  PCR	   increases	   the	  amount	  of	  
free	   dye	   molecules;	   therefore,	   the	   fluorescent	   intensity	   is	   proportional	   to	   the	  
amount	  of	  amplicon	  produced.	  
Each	   qRT-­‐PCR	   reaction	   consisted	   of	   500	   ng	   of	   cDNA,	   10	   μl	   Master	   Mix	   (Applied	  
Biosystems	  –	  4364340),	  1	  μl	  Taqman	  assay	  for	  the	  gene	  of	  interest	  (Table	  2	  -­‐	  3),	  1	  μl	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Taqman	   assay	   for	   the	   eukaryote	   18S	   gene	   (Applied	   Biosystems	   –	   4310893E)	   and	  
DNase-­‐free	  water	  to	  a	  final	  volume	  of	  25	  μl.	  The	  reaction	  mixture	  was	  transferred	  to	  
MicroAmp	   optical	   96-­‐well	   reaction	   plates	   (Applied	   Biosystems	   –	   4306737)	   and	  
amplified	  using	  a	  StepOne	  Real-­‐Time	  PCR	  system	  (Applied	  Biosystems).	  	  
The	  thermal	  cycler	  conditions	  were	  as	  follows:	  
Step	  1:	  50˚C	  for	  2min	  
Step	  2:	  95˚C	  for	  10min	  
Step	  3:	  95˚C	  for	  15s	  
Step	  4:	  60˚C	  for	  1min	  
Step	  5:	  Repeat	  steps	  3	  and	  4	  for	  39	  cycles	  
	  
Gene	   Cat.	  Ref.	   Amplicon	  size	  (base	  pairs)	  
18S	   4310893E	   187	  
Hvcn1	   Mm01199507	   56	  
	  
Table	  2	  -­‐	  3	  Primers	  used	  for	  qRT-­‐PCR.	  
Table	  describes	  primers	  used	  for	  qRT-­‐PCR	  and	  lists	  the	  relevant	  details	  of	  each	  
primer.	  	  
	  
CHAPTER	  TWO	  	  	  	  	   MATERIALS	  AND	  METHODS	  
	   93 
Data	  was	   collected	   and	   analysed	   using	   the	   StepOne	   Software	   version	   2.1	   (Applied	  
Biosystems)	  to	  determine	  the	  threshold	  cycle	  (Ct)	  values	  for	  each	  sample.	  Data	  was	  
further	  analysed	  using	  the	  Comparative	  Ct	  Method	  (2-­‐ΔΔCt):	  
ΔCt	  =	  Ct	  (target	  gene)	  –	  Ct	  (18S)	  
ΔΔCt	  =	  ΔCt	  (test	  sample)	  –	  ΔCt	  (control/reference	  sample)	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2.5 CELLULAR	  BIOENERGETICS	  	  
2.5.1 XF	  CELL	  TECHNOLOGY	  
The	  XF24	  Extracellular	  Flux	  Analyser	  is	  an	  instrument	  that	  measures	  in	  real	  time	  the	  
uptake	   and	   excretion	   of	   primary	   metabolites.	   It	   simultaneously	   monitors	   the	   two	  
major	   energy	   pathways	   of	   a	   cell,	   glycolysis	   and	   oxidative	   phosphorylation;	   thus,	   it	  
can	   determine	   the	  metabolic	   phenotype	   of	   cells.	   The	   instrument	   achieves	   this	   by	  
measuring	   the	   oxygen	   consumption	   rate	   (OCR)	   and	   extracellular	   acidification	   rate	  
(ECAR)	   in	   the	   media	   surrounding	   the	   cells	   cultured	   in	   the	   XF24	   Cell	   Culture	  
Microplate	  (Seahorse	  Biosciences	  –	  100777-­‐004).	  
Each	   XF	   assay	   kit	   contains	   a	   disposable	   sensor	   cartridge	   that	   has	   24	   pairs	   of	  
embedded	   fluorophores.	   One	   fluorophore	   measures	   oxygen	   whilst	   the	   other	  
measures	  protons.	  The	  measurement	  is	  accomplished	  by	  the	  sensor	  cartridge	  being	  
lowered	   to	   200	   μm	   above	   the	   cells,	   thus	   creating	   a	   transient	   microchamber.	   The	  
microchamber	   allows	   the	   detection	   of	   changes	   in	   oxygen	   and	   protons	   as	   well	   as	  
repetitive	  measurements	  of	  the	  same	  cell	  population.	  When	  the	  instrument	  detects	  
a	  10	  %	  drop	  in	  oxygen/proton	  concentration,	  the	  sensor	  cartridge	  rises	  allowing	  the	  
medium	   to	   restore	   the	   cells	   to	   baseline.	   Each	   sensor	   cartridge	   has	   four	   reagent	  
injection	   ports	   that	   enable	   the	   sequential	   addition	   of	   compounds	   during	   an	  
experiment.	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2.5.2 XF	  CELL	  ASSAY	  
XF	  Calibrant	  Solution	  (Seahorse	  Biosciences	  –	  102353-­‐004)	  was	  added	  to	  the	  wells	  of	  
the	   Extracellular	   Flux	  Assay	  plate	   (Seahorse	  Biosciences	   –	   100850-­‐001),	  which	  was	  
then	  incubated	  over	  night	  at	  37	  ˚C	  in	  a	  non-­‐CO2	  incubator.	  
BMDMs	  were	   seeded	   into	   24-­‐well	   XF	   Cell	   Culture	   plates	   at	   2	   x	   105	   cells/well	   and	  
incubated	  overnight	  at	  37	  ˚C	  and	  5	  %	  CO2.	  Cells	  were	  then	  either	  untreated	  or	  given	  
100	  ng/ml	  LPS	   for	  24	  hours.	   In	   some	  experiments,	   cells	  were	  pre-­‐treated	  with	  100	  
μM	  Mito-­‐TEMPO	  for	  1	  hour.	  
Oligomycin	   A,	   Carbonyl	   cyanide-­‐4-­‐(trifluoromethoxy)phenylhydrazone	   (FCCP),	  
Rotenone	  and	  Antimycin	  A	  were	  added	  to	  the	  reagent	  injection	  ports	  of	  the	  plate	  at	  
a	  10x	  working	  concentration	  (Table	  2	  -­‐	  4).	  At	  the	  start	  of	  the	  XF	  assay,	  the	  instrument	  
calibrated	  all	  24	  pairs	  of	  fluorophores	  to	  the	  known	  pH	  and	  oxygen	  concentration	  in	  
the	  XF	  Calibrant	  solution.	  In	  the	  meantime,	  the	  prepared	  XF	  Cell	  Culture	  Microplate	  
was	  washed	  twice	  with	  XF	  Assay	  medium	  and	  incubated	  for	  20	  minutes	  at	  37	  ˚C	  in	  a	  
non-­‐CO2	  incubator.	  Once	  the	  calibration	  had	  finished,	  the	  XF	  Cell	  Culture	  Microplate	  
was	  inserted	  into	  the	  instrument.	  The	  assay	  conditions	  were	  as	  follows:	  
Step	  1:	  Equilibrate	  (12min)	  
Step	  2:	  4x	  Baseline	  measurements	  (24min)	  
Step	  3:	  Inject	  Port	  A	  
Step	  4:	  3x	  Post-­‐injection	  measurements	  (18min)	  
Step	  5:	  Repeat	  steps	  3	  and	  4	  for	  injection	  ports	  B	  and	  C.	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Table	  2	  -­‐	  4	  Compounds	  used	  for	  the	  XF	  assay.	  	  
Table	  describes	  the	  compounds	  used	  for	  the	  XF	  assay	  and	  lists	  the	  relevant	  details	  of	  
each	  compound.	  	  
	  
	  
Compound	   Company	   Cat.	  Ref.	   Concentration	  
Oligomycin	  A	   Sigma	   75351	   1	  μM	  
FCCP	   Sigma	   C2920	   1	  μM	  
Rotenone	   Sigma	   R8875	   1	  μM	  
Antimycin	  A	   Sigma	   A8674	   1	  μM	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2.6 FLOW	  CYTOMETRY	  
Flow	  cytometry	  was	  performed	  using	  an	  LSRFortessa	  cell	  analyser	   (BD	  Biosciences)	  
and	  FACSDiva	  software	  version	  6.2.	  The	  fluorescence	  of	  at	   least	  10,000	  events	  was	  
acquired	   for	  each	  sample.	  Data	  were	  analysed	  with	  the	  FlowJo	  software	   (Tree	  Star	  
Inc).	  
The	  basic	  concept	  of	  flow	  cytometry	  is	  that	  individual	  cells	  are	  passed	  through	  a	  light	  
beam	  and	  this	  causes	  the	  ray	  of	  light	  to	  be	  scattered.	  The	  fluorophores	  used	  to	  label	  
the	  cells	  are	  excited	  by	  the	  light	  beam	  and	  thus	  emit	  a	  light	  at	  a	  longer	  wavelength	  
than	   the	   light	   source.	   This	   emitted	   light	   is	   detected	   and	   converted	   into	   electric	  
signals.	  Each	  individual	  cell	  is	  shown	  as	  an	  event	  on	  a	  graphical	  scale.	  
The	  excitation/emission	  for	  4’,6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI;	  Life	  Tech	  –	  D1306)	  
is	  358/461	  nm.	  	  
	  
2.6.1 MITOCHONDRIAL	  BIOMASS	  
MitoTracker	  Green	  FM	  (Life	  Tech	  -­‐	  M7514)	  is	  a	  green-­‐fluorescent	  mitochondrial	  stain	  
that	   localises	   to	  mitochondria	  regardless	  of	  mitochondrial	  potential.	  Once	  this	  cell-­‐
permeant	  probe	  enters	  a	  cell	   it	   is	  sequestered	  in	  the	  mitochondria,	  where	  it	  reacts	  
with	  thiols	  on	  proteins	  and	  peptides	  to	  form	  a	  fluorescent	  conjugate.	  
BMDMs	  were	  seeded	  at	  5	  x	  105	  cells/well	   into	  6-­‐well	  plates	  and	  incubated	  at	  37	  ˚C	  
and	  5	  %	  CO2	  over	  night.	  Cells	  were	  then	  either	  untreated	  or	  given	  100	  ng/ml	  LPS	  for	  
24	  hours	  and	  were	  allowed	  to	  incubate	  at	  37	  ˚C.	  Supernatant	  was	  discarded	  and	  cells	  
were	  washed	  once	  in	  PBS.	  A	  25	  nM	  solution	  of	  MitoTracker	  Green	  FM	  was	  prepared	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in	  PBS	  and	  cells	  were	  stained	  with	  this	  solution	  for	  15	  minutes	  at	  37	  ˚C	  and	  5	  %	  CO2.	  
Cells	  were	  washed	  three	  times	   in	  PBS	  and	  were	  then	  collected	  into	  flow	  cytometry	  
tubes	   by	   scrapping	   gently	   with	   a	   rubber	   policeman.	   Tubes	   were	   kept	   on	   ice	   until	  
analysis	   by	   flow	   cytometry.	   Immediately	   prior	   to	   analysis	  DAPI	  was	   added	   to	   each	  
tube	  at	  a	  final	  concentration	  of	  2.5	  μg/ml.	  
The	  excitation/emission	  for	  MitoTracker	  Green	  FM	  is	  490/516	  nm.	  	  
2.6.2 INTRACELLULAR	  ROS	  LEVELS	  
CellROX	  Deep	  Red	  (Life	  Tech	  -­‐	  C10422)	   is	  a	  fluorogenic	  probe	  designed	  to	  measure	  
ROS	   in	   cells.	   In	   its	   reduced	   state,	   the	   probe	   is	   nonfluorescent	   or	   very	   weakly	  
fluorescent.	  Once	  it	  is	  oxidised	  within	  the	  cell	  it	  exhibits	  a	  strong	  fluorogenic	  signal.	  
CellROX	  Deep	  Red	  is	  localised	  in	  the	  cytoplasm.	  
BMDMs	   were	   seeded	   as	   described	   in	   sub-­‐section	   2.6.1.	   Cells	   were	   then	   either	  
untreated	  or	  given	  100	  ng/ml	  LPS	  for	  1	  hour	  and	  were	  allowed	  to	  incubate	  at	  37	  ˚C.	  
In	   some	   experiments,	   cells	  were	   pre-­‐treated	  with	   100	   μM	  Mito-­‐TEMPO	   or	   10	   μM	  
Apocynin	  for	  1	  hour.	  Cells	  were	  stained	  with	  5	  μM	  CellROX	  Deep	  Red	  30	  minutes	  at	  
37	  ˚C	  and	  5	  %	  CO2.	  Cells	  were	  then	  prepared	  for	  flow	  cytometry	  as	  described	  in	  sub-­‐
section	  2.6.1.	  	  
The	  excitation/emission	  for	  CellROX	  Deep	  Red	  is	  640/665	  nm.	  	  
2.6.3 PHAGOCYTOSIS	  
Fluoresbrite	   YO	  microspheres	   (Polysciences	   -­‐	   19393-­‐5)	   are	   fluorescent	   polystyrene	  
microspheres	   that	   can	   be	   used	   for	   phagocytosis	   studies.	   These	   polystyrene	   beads	  
are	   inert	   so	   they	   do	   not	   provide	   a	  metabolic	   load	   to	   the	   phagocytes.	   This	   slightly	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reductive	   approach	   has	   the	   benefit	   of	   assessing	   phagocytic	   ability	   independent	   of	  
confounding	  factors.	  
BMDMs	   were	   seeded	   as	   described	   in	   sub-­‐section	   2.6.1.	   Cells	   were	   then	   either	  
untreated	  or	  given	  100	  ng/ml	  LPS	  for	  24	  hours	  and	  were	  allowed	  to	  incubate	  at	  37	  
˚C.	  Supernatant	  was	  discarded	  and	  cells	  were	  washed	  once	  in	  PBS.	  Microspheres	  (3	  
μM)	  were	  added	  at	  a	  concentration	  of	  5-­‐6	  beads	  per	  cell	  and	  were	  incubated	  at	  37	  
˚C	  and	  5	  %	  CO2	  to	  allow	  bead	  phagocytosis	  for	  0	  to	  60	  minutes.	  A	  control	  condition	  
where	  macrophages	  were	  given	  microspheres,	  but	  kept	  on	   ice	  for	  60	  minutes,	  was	  
used	   to	   control	   for	   beads	   that	   had	  merely	   associated	  with	   the	   cells	   and	   not	   been	  
ingested.	   	  Cells	  were	  then	  prepared	  for	   flow	  cytometry	  as	  described	   in	  sub-­‐section	  
2.6.1.	  
The	  excitation/emission	  for	  Fluoresbrite	  YO	  Microspheres	  is	  529/546	  nm.	  
2.6.4 MITOCHONDRIAL	  MEMBRANE	  POTENTIAL	  	  
JC-­‐1	  Mitochondrial	  Potential	  Sensor	  (Life	  Tech	  -­‐	  T3168)	  is	  a	  cationic	  dye	  that	  exhibits	  
potential-­‐dependent	  accumulation	   in	  mitochondria.	  At	   low	  concentrations,	   the	  dye	  
exists	   as	   a	  monomer	   and	   yields	   green	   fluorescence.	   At	   higher	   concentrations,	   the	  
dye	  forms	  aggregates	  that	  yield	  red	  fluorescence.	  	  
The	   use	   of	   a	   ratiometric	   dye	   allows	   for	   the	   comparative	   measurement	   of	  
mitochondrial	   membrane	   potential	   without	   confounding	   factors	   such	   as	  
mitochondrial	   size,	   shape	   and	   density	   that	   may	   influence	   single-­‐component	  
fluorescent	  dyes.	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BMDMs	   were	   seeded	   as	   described	   in	   sub-­‐section	   2.6.1.	   Cells	   were	   then	   either	  
untreated	  or	  given	  100	  ng/ml	  LPS	  for	  24	  hours	  and	  were	  allowed	  to	  incubate	  at	  37	  
˚C.	  Supernatant	  was	  discarded	  and	  cells	  were	  washed	  once	  in	  PBS.	  Cells	  were	  stained	  
with	  2	  μM	  for	  15	  minutes	  at	  37	  ˚C	  and	  5	  %	  CO2.	  Cells	  were	  then	  prepared	  for	  flow	  
cytometry	  as	  described	  in	  sub-­‐section	  2.6.1.	  
The	  excitation/emission	   for	   JC-­‐1	  Mitochondrial	   Potential	   Sensor	   is	   485/530	   for	   the	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2.7 CHEMILUMINESCENCE	  
2.7.1 ATP	  LEVELS	  
The	   CellTiter-­‐Glo	   Luminescent	   Assay	   (Promega	   -­‐	   G7570)	   generates	   a	   luminescent	  
signal	  from	  lysed	  cells	  that	  is	  proportional	  to	  the	  amount	  of	  ATP	  present.	  The	  assay	  
relies	  on	  the	  properties	  of	  a	  thermostable	  luciferase.	  The	  luciferase	  reaction	  involves	  
the	   mono-­‐oxygenation	   of	   luciferin	   in	   the	   presence	   of	   Mg2+,	   ATP	   and	   molecular	  
oxygen.	   The	   reaction	   products	   are	   oxyluciferin,	   AMP,	   CO2	   and	   light	   emission.	   The	  
amounts	  of	  ATP	  were	  measured	  according	  to	  the	  manufacturer’s	  guidelines.	  
BMDMs	  were	  seeded	  at	  1	  x	  104	  cells/well	   into	  white	  opaque-­‐walled	  96-­‐well	  plates	  
and	  incubated	  at	  37	  ˚C	  and	  5	  %	  CO2	  over	  night.	  White	  opaque-­‐walled	  plates	  are	  used	  
for	   luminescent	   assays	   as	   the	  white	   colour	   reflects	   light	   and	   thus	  maximises	   light	  
output	  signal.	  Cells	  were	  then	  either	  untreated	  or	  given	  100	  ng/ml	  LPS	  for	  24	  hours	  
and	  were	  allowed	  to	  incubate	  at	  37	  ˚C.	  In	  some	  experiments,	  cells	  were	  pre-­‐treated	  
with	  100	  μM	  Mito-­‐TEMPO	  or	  10	  μM	  Apocynin	  for	  1	  hour.	  
The	  plate	  and	   its	   contents	  were	  equilibrated	  at	   room	  temperature	   for	  30	  minutes.	  
The	  CellTiter-­‐Glo	  Reagent	  was	  prepared	  by	  mixing	  the	  CellTiter-­‐Glo	  Buffer	  with	  the	  
CellTiter-­‐Glo	  Substrate.	  A	  volume	  of	  CellTiter-­‐Glo	  equal	  to	  the	  volume	  of	  cell	  culture	  
medium	  present	  in	  each	  well	  was	  added	  to	  the	  cells.	  The	  plates	  were	  placed	  on	  an	  
orbital	  shaker	  for	  2	  minutes	  to	  induce	  cell	  lysis	  after	  which	  the	  plates	  were	  incubated	  
at	   room	  temperature	   for	  10	  minutes	   to	  stabilise	   the	   luminescent	  signal.	  The	  signal	  
was	  recorded	  with	  a	  luminescent	  microplate	  reader	  (Tecan	  Infinite	  200	  PRO).	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2.8 CONFOCAL	  MICROSCOPY	  -­‐	  IMMUNOFLUORESCENCE	  
All	   confocal	   images	   were	   acquired	   with	   a	   laser	   scanning-­‐microscope	   LSMA	   510	  
(Zeiss)	  with	  a	  digital	  signal	  processor	  using	  the	  LSM	  software.	  	  
Glass	  cover	  slips	  (13	  mm	  Ø;	  VWR	  –	  631-­‐0150)	  were	  washed	  in	  70	  %	  ethanol,	  air-­‐dried	  
and	  then	  transferred	  into	  24-­‐well	  plates.	  WT	  and	  HVCN1-­‐/-­‐	  BMDMs	  were	  seeded	  at	  5	  
x	  104	  cells/well	  and	  incubated	  at	  37	  ˚C	  and	  5	  %	  CO2	  over	  night.	  
Cells	   were	   washed	   twice	   with	   ice-­‐cold	   PBS	   and	   fixed	   with	   4	   %	   paraformaldehyde	  
(Ecolab	   –	   416479)	   at	   room	   temperature	   for	   15	  minutes.	   Cells	   were	  washed	   twice	  
with	  PBS	  and	  then	  permeabilised	  with	  0.1	  %	  Triton	  X	  (Sigma	  –	  X100)	  in	  PBS	  at	  room	  
temperature	   for	   5	   minutes.	   Cells	   were	   washed	   again	   and	   quenched	   with	   50	   mM	  
ammonium	  chloride	  in	  PBS	  at	  room	  temperature	  for	  15	  minutes.	  After	  another	  wash	  
with	  PBS,	  cells	  were	  blocked	  with	  10	  %	  goat	  serum	  in	  PBS	  at	  room	  temperature	  for	  1	  
hour.	  Cells	  were	  then	  incubated	  with	  primary	  antibody	  or	  isotype	  control	  diluted	  in	  
blocking	  solution	  at	   room	  temperature	   for	  1	  hour	   (Table	  2	   -­‐	  5).	  Cells	  were	  washed	  
twice	  with	  PBS	  and	  then	  incubated	  with	  secondary	  antibody	   in	  blocking	  solution	  at	  
room	  temperature	  for	  1	  hour	  in	  the	  dark	  (Table	  2	  -­‐	  6).	  Cells	  were	  washed	  again	  with	  
PBS	  and	  once	  with	  water	  after	  which	  the	  cover	  slips	  were	  mounted	  on	  slides	  using	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Table	  2	  -­‐	  5	  Primary	  antibodies	  used	  for	  immunofluorescence.	  
Table	   describes	   the	  primary	   antibodies	   used	   for	   immunofluorescence	   and	   lists	   the	  
relevant	  details	  of	  each	  antibody.	  	  
	  
Antibody	   Supplier	   Cat.	  Ref.	   Dilution	  
Anti-­‐rabbit	  Alexa	  Fluor	  488	   Invitrogen	   A11008	   1:1000	  
Anti-­‐rat	  Alexa	  Fluor	  546	   Invitrogen	   A11077	   1:1000	  
	  
Table	  2	  -­‐	  6	  Secondary	  antibodies	  used	  for	  immunofluorescence.	  	  
Table	  describes	  the	  secondary	  antibodies	  used	  for	  immunofluorescence	  and	  lists	  the	  




Antibody	   Supplier	   Cat.	  Ref	   Isotype	   Dilution	  
HVCN1	   Abcam	   105344	   Rabbit	  IgG	   1:300	  
LAMP-­‐1	   Abcam	   25245	   Rat	  IgG2a	   1:200	  
Transferrin	  
receptor	  
Abcam	   60344	   Rat	  IgG2a	   1:200	  
GRP94	   Abcam	   90458	   Rat	  IgG2a	   1:200	  
MitoTracker	  
Deep	  Red	  FM	  
Life	  Tech	   M22426	   N/A	   25	  nM	  
Isotype	  control	   BD	  Biosciences	   550875	   Rabbit	  IgG	   N/A	  
Isotype	  control	   eBioscience	   14-­‐4321	   Rat	  IgG2a	   N/A	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2.9 STATISTICAL	  ANALYSIS	  
All	   data	   were	   presented	   as	   the	   mean	   of	   individual	   experiments	   with	   error	   bars,	  
representing	  the	  standard	  error	  of	   the	  mean	  (SEM);	  unless	  otherwise	  stated	   in	  the	  
figure	  legend.	  
The	   unpaired	   and	   paired	   Student’s	   t	   test	   was	   used	   as	   the	   statistical	   methods	   to	  
determine	  significant	  differences	  between	  two	  groups.	  	  
All	   p	   values	   of	   0.05	   or	   less	   were	   considered	   statistically	   significant.	   The	   level	   of	  
statistical	  significance	  was	  indicated	  by	  asterisks	  as	  follows:	  *	  p<0.05,	  **	  p<0.01	  and	  
***	  p<0.001;	  unless	  otherwise	  stated	  in	  the	  figure	  legend.	  
	  
	  	   105 
	  
	  
3 CHAPTER	  THREE:	  ELEVATED	  BASAL	  ROS	  AND	  
ATTENUATED	  RESPIRATORY	  BURST	  IN	  Hvcn1-­‐/-­‐	  
MACROPHAGES	  
CHAPTER	   THREE:	   ELEVATED	   BASAL	   ROS	   AND	  
ATTENUATED	   RESPIRATORY	   BURST	   IN	   Hvcn1-­‐/-­‐	  
MACROPHAGES	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3.1 INTRODUCTION	  
As	   described	   in	   Chapter	   1,	   voltage-­‐gated	   proton	   channels	   are	   expressed	   in	   both	  
epithelial	   and	   immune	   cells.	   Investigations	   into	   the	   role	   of	  HVCN1	   in	   a	   number	   of	  
immune	   cell	   types	   have	   found	   it	   to	   be	   involved	   in	   diverse	   functions,	   such	   as	  
nicotinamide	   adenine	   dinucleotide	   phosphate	   (NADPH)	   oxidase-­‐mediated	  
respiratory	  burst	  (DeCoursey	  et	  al.,	  2003,	  Ramsey	  et	  al.,	  2006)	  and	  histamine	  release	  
(Musset	  et	  al.,	  2008).	  
The	  majority	   of	   published	   studies	   have	   focused	   on	   the	   particular	   role	   that	  HVCN1	  
plays	   at	   the	   plasma	  membrane	   in	   the	  NADPH	   oxidase-­‐mediated	   respiratory	   burst.	  
This	   acute	   production	   of	   reactive	   oxygen	   species	   (ROS)	   is	   crucial	   for	   pathogen	  
elimination	  by	  phagocytes	  such	  as	  macrophages	  and	  neutrophils	   (Dale	  et	  al.,	  2008,	  
Segal,	  2005).	  The	  process	  of	  respiratory	  burst	  relies	  heavily	  on	  the	  recruitment	  and	  
assembly	   of	   the	   NADPH	   oxidase	   complex	   subunits	   at	   the	   plasma	   membrane	  
(Sumimoto,	   2008).	   Defects	   in	   the	   assembly	   or	   activity	   of	   the	   complex	   leads	   to	  
impaired	   pathogen	   elimination	   (Geiszt	   et	   al.,	   2001).	   In	   humans,	   mutations	   in	   the	  
NADPH	  oxidase	  components	  cause	  chronic	  granulomatous	  disease	  (CGD),	  a	  disease	  
characterised	   by	   the	   phagocytes	   of	   the	   individual	   having	   an	   impaired	   respiratory	  
burst	  and	  thus	  unable	  to	  eliminate	  pathogens.	  Patients	  are	  susceptible	  to	  recurrent	  
infections	  due	  to	  the	  decreased	  capacity	  of	  the	  immune	  system	  (Segal,	  1987).	  
Previous	   studies	   in	   several	   immune	   cell	   types	   found	   that	   ROS	   production	   was	  
significantly	  impaired	  in	  HVCN1-­‐/-­‐	  eosinophils,	  B	  cells,	  T	  cells	  and	  neutrophils	  (Zhu	  et	  
al.,	  2013,	  Capasso	  et	  al.,	  2010,	  Sasaki	  et	  al.,	  2013,	  Ramsey	  et	  al.,	  2006,	  DeCoursey	  et	  
al.,	  2003).	  However,	  it	  is	  unclear	  how	  HVCN1	  is	  involved	  in	  other	  functional	  aspects	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of	   immune	  cells	  and	  very	   little	   is	  known	  about	  downstream	  signalling	  upon	  HVCN1	  
activation.	  
The	  finding	  of	  Musset	  et	  al.	  indicated	  proton	  channels	  to	  regulate	  histamine	  release,	  
via	   a	   possible	   intracellular	   acidification	   mechanism	   in	   basophils,	   but	   this	   was	   not	  
further	   investigated	   (Musset	   et	   al.,	   2008).	   In	   addition,	   the	   Demaurex	   group	  
suggested	  HVCN1	  to	  be	  involved	  in	  regulating	  neutrophil	  migration,	  at	  least	   in	  vitro	  
(El	   Chemaly	   et	   al.,	   2010).	   Although	   the	   study	   suggested	   a	   defect	   in	   calcium	   (Ca2+)	  
entry	   in	   Hvcn1-­‐/-­‐	   neutrophils,	   no	   further	   downstream	   signalling	   defects	   were	  
analysed.	   A	   comprehensive	   study	   of	   signalling	   events	   regulated	   by	   HVCN1	   was	  
conducted	  in	  B	  cells,	  with	  HVCN1-­‐deficient	  B	  cells,	  showing	  impaired	  B	  cell	  receptor	  
(BCR)	  signalling	  (Capasso	  et	  al.,	  2010).	  
Not	  many	   studies	   have	   investigated	  where	   HVCN1	   is	   localised	   in	   immune	   cells.	   In	  
addition	   to	  being	   expressed	  on	   the	  plasma	  membrane,	   proton	   channels	  were	   also	  
detected	  in	  the	  cytosol	   in	  resting	  B	  cells	  (Capasso	  et	  al.,	  2010).	  HVCN1	  partially	  co-­‐
localised	  with	  the	  BCR	  on	  the	  plasma	  membrane	  and	  the	  proportion	  detected	  in	  the	  
cytosol	   did	   not	   co-­‐localise	   with	   endosomes,	   endoplasmic	   reticulum	   (ER),	   Golgi,	  
mitochondria,	  or	  peroxisomes	  (Capasso,	  unpublished	  observations).	  	  
The	   existence	   of	   proton	   channels	   in	   both	  murine	   (Kapus	   et	   al.,	   1993)	   and	   human	  
macrophages	   (Holevinsky	   et	   al.,	   1994)	   has	   previously	   been	   shown	   through	   patch	  
clamp	   recordings,	   however	   little	   else	   is	   known	   about	   the	   role	   of	   HVCN1	   in	  
macrophages.	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3.2 AIMS	  
This	   chapter	   describes	   my	   initial	   investigations	   into	   the	   expression	   of	   HVCN1	   in	  
macrophages	  and	  its	  potential	  involvement	  in	  their	  classical	  functions.	  My	  aims	  were	  
to	  address	  the	  following	  questions:	  
• Is	  HVCN1	  expressed	   in	  macrophages?	   Is	   the	  proton	  channel	   knocked	  out	   in	  
Hvcn1-­‐/-­‐	  macrophages?	  	  
• What	  are	  the	  basal	  ROS	  levels	  of	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages?	  What	  is/are	  
the	  source(s)	  of	  this	  basal	  ROS	  production?	  	  
• Is	  the	  respiratory	  burst	  impaired	  in	  Hvcn1-­‐/-­‐	  macrophages?	  	  
• Is	  the	  phagocytic	  capacity	  of	  Hvcn1-­‐/-­‐	  macrophages	  impaired?	  	  
• What	  is	  the	  subcellular	  localisation	  of	  HVCN1	  in	  macrophages?	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3.2.1 EXPRESSION	  OF	  HVCN1	  IN	  MACROPHAGES	  
In	  order	  to	  study	  the	  role	  of	  voltage-­‐gated	  proton	  channels	  in	  macrophages,	  we	  used	  
mice	  with	  a	  genetrap	  insertion	  within	  the	  HVCN1	  gene	  (Okochi	  et	  al.,	  2009,	  Ramsey	  
et	   al.,	   2009).	   These	   genetically	   altered	  mice	   have	   been	  widely	   used	   in	   the	  HVCN1	  
field	   of	   study.	   Quantitative	   real-­‐time	   polymerase	   chain	   reaction	   (qRT-­‐PCR)	   of	  
macrophages	   for	  Hvcn1	  messenger	   ribonucleic	  acid	   (mRNA)	  confirmed	   that	  proton	  
channel	  mRNA	  was	   produced	   in	  WT	  macrophages	  whilst	   it	   was	   absent	   in	  Hvcn1-­‐/-­‐	  
macrophages	  (Figure	  3	  -­‐1).	  
	  
	  
Figure	  3	  -­‐1	  	  Hvcn1	  is	  not	  expressed	  in	  Hvcn1-­‐/-­‐	  macrophages.	  
Hvcn1	  mRNA	  levels	   in	  untreated	  WT	  and	  Hvcn1-­‐/-­‐	  BMDMs	  relative	  to	  untreated	  WT	  
BMDMs,	  as	  measured	  by	  QRT-­‐PCR.	  18s	  mRNA	  was	  used	  as	  a	  control.	  Data	  represents	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In	  accordance	  with	   the	  mRNA	  data,	   I	   found	  HVCN1	  protein	   to	  be	  expressed	   in	  WT	  
macrophages,	   whereas	   no	   expression	   was	   detectable	   by	  Western	   Blot	   in	  Hvcn1-­‐/-­‐	  
macrophages.	  WT	  spleen	  was	  used	  as	  a	  positive	  control.	   	   (Figure	  3	  -­‐	  2).	  These	  data	  
confirm	   the	   findings	  of	   Kapus	   et	   al.	   at	   both	  mRNA	  and	  protein	   level	   (Kapus	   et	   al.,	  
1993).	  
	  
Figure	   3	   -­‐	   2	   HVCN1	   expressed	   in	  WT	   macrophages	   and	   knocked	   out	   in	  Hvcn1-­‐/-­‐	  
macrophages.	  
HVCN1	  protein	  levels	  in	  untreated	  BMDMs	  were	  measured	  by	  Western	  Blot	  analysis.	  
Actin	   was	   used	   as	   a	   loading	   control.	   Data	   are	   representative	   of	   two	   independent	  
experiments.	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As	  the	  Hvcn1-­‐/-­‐	  mice	  have	  the	  protein	  globally	  knocked	  out,	   I	  wanted	  to	  investigate	  
any	   potential	   differences	   in	   numbers	   of	   progenitors	   found	   in	   the	   bone	  marrow	  as	  
well	  as	  the	  ability	  of	  those	  progenitors	  to	  produce	  mature	  macrophages.	  Cell	  counts	  
of	  the	  bone	  marrow	  flushes	  showed	  that	  there	  were	  no	  differences	  between	  the	  two	  
groups	   (Figure	   3	   -­‐3	   A).	   Likewise,	   both	  WT	   and	  Hvcn1-­‐/-­‐	   BM	   progenitors	   produced	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Figure	  3	  -­‐	  3	  Bone	  marrow	  progenitor	  and	  macrophage	  yield.	  	  
Numbers	  of	  (A)	  BM	  progenitors	  and	  (B)	  BMDMs	  were	  counted	  from	  WT	  and	  Hvcn1-­‐/-­‐	  
mice.	  Data	  represents	  means	  ±	  SEM	  of	  three	  independent	  experiments.	  
	  
In	   addition,	   there	   were	   no	   differences	   microscopically	   between	   the	   WT	   and	   the	  
Hvcn1-­‐/-­‐	  macrophages	  (Figure	  3	  –	  4).	  
	  
	  
Figure	  3	  -­‐	  4	  Microscopic	  images	  of	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages.	  
Numbers	  of	  BM	  progenitors	  and	  BMDMs	  were	  counted	  from	  WT	  and	  Hvcn1-­‐/-­‐	  mice.	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3.2.2 ELEVATED	  BASAL	  ROS	  LEVELS	  IN	  Hvcn1-­‐/-­‐	  MACROPHAGES	  
Having	   confirmed	   that	   HVCN1	   is	   indeed	   expressed	   in	   macrophages,	   I	   wanted	   to	  
investigate	   phagocyte	   functions	   that	   the	   proton	   channel	   had	   been	   previously	  
implicated	   to	   be	   involved	   in.	   Even	   though	   decreased	   production	   of	   ROS	   in	   bone	  
marrow	  cells	  (which	  contain	  a	  small	  population	  of	  macrophages)	  from	  Hvcn1-­‐/-­‐	  mice	  
had	  been	  reported	  previously	  (Ramsey	  et	  al.,	  2009),	  the	  specific	  functional	  impact	  of	  
proton	   channel	   absence	   in	   mature	   macrophages	   had	   not	   been	   investigated.	   I	  
therefore	   assessed	   basal	   ROS	   levels	   and	   respiratory	   burst	   in	  macrophages	   lacking	  
HVCN1.	  Interestingly,	  with	  the	  use	  of	  a	  novel	  fluorogenic	  probe	  (CellROX)	  I	  observed	  
significantly	   elevated	   basal	   ROS	   in	   Hvcn1-­‐/-­‐	   macrophages	   compared	   to	   their	   WT	  
counterparts	   (Figure	  3	  -­‐	  5).	  This	  would	  suggest	  either	  dysregulated	  ROS	  production	  
or	  impaired	  scavenging	  of	  ROS.	  
	  
Figure	  1	  -­‐	  5	  Increased	  basal	  ROS	  levels	  in	  Hvcn1-­‐/-­‐	  macrophages.	  	  
ROS	   levels	   were	  measured	   in	   untreated	   BMDMs	   generated	   from	  WT	   and	  Hvcn1-­‐/-­‐	  
mice,	  shown	  as	  relative	  to	  untreated	  WT	  BMDMs.	  Data	  represents	  means	  ±	  SEM	  of	  
three	  independent	  experiments.	  *,	  p	  <	  0.05.	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It	  was	  therefore	  important	  to	  determine	  the	  source	  of	  the	  increased	  basal	  levels	  of	  
ROS	  observed	  in	  the	  Hvcn1-­‐/-­‐	  macrophages	  in	  order	  to	  understand	  whether	  this	  was	  
due	  to	  dysregulated	  ROS	  production	  at	  a	  discrete	  subcellular	  site.	  The	  two	  main	  sites	  
of	  ROS	  production	  are	  the	  NADPH	  oxidase	  complex	  and	  the	  mitochondria.	  Therefore,	  
I	   used	   a	   mitochondrial-­‐targeted	   antioxidant,	   Mito-­‐TEMPO,	   and	   a	   highly	   selective	  
NADPH	  oxidase	  inhibitor,	  Apocynin.	  
Mito-­‐TEMPO	   is	   a	   fusion	   of	   the	   antioxidant	   piperidine	   nitroxide	   (TEMPO)	   with	   the	  
lipophilic	  cation	  triphenylphosphonium,	  allowing	  Mito-­‐TEMPO	  to	  easily	  pass	  through	  
lipid	  bilayers	  and	  thus	  accumulate	  several	  hundred-­‐fold	  in	  the	  mitochondria	  where	  it	  
scavenges	   ROS	   ((Murphy	   and	   Smith,	   2007)).	   Apocynin	   is	   a	   naturally	   occurring	  
methoxy-­‐substituted	  catechol	  that	  is	  oxidised	  by	  myeloperoxidases	  within	  the	  cell	  to	  
give	   Apocynin	   dimers	   (Ximenes	   et	   al.,	   2007).	   Its	   mechanism	   of	   action	   is	   not	   well	  
defined,	   but	   it	   has	   been	   found	   to	   prevent	   the	   translocation	   of	   the	   cytosolic	  
component	   of	   the	   NADPH	   oxidase	   complex,	   p47phox,	   to	   the	   plasma	   membrane	  
(Stefanska	  and	  Pawliczak,	  2008).	  
The	  two	  compounds	  were	  firstly	  titrated	  to	  determine	  the	  optimum	  concentration	  to	  
use	  in	  experiments	  (Figure	  3	  –	  6).	  They	  were	  next	  assessed	  for	  potential	  cytotoxicity	  
at	  the	  given	  concentrations.	  Neither	  Mito-­‐TEMPO	  nor	  Apocynin	  treatment	  affected	  
cell	   viability	   (Figure	   3	   -­‐	   7)	   as	   assessed	   by	   the	   ability	   to	   reduce	   a	   water-­‐soluble	  
tetrazolium	   salt	   into	   formazan.	   Other	   NADPH	   oxidase	   inhibitors,	   such	   as	  
diphenyleneiodonium	  (DPI),	  have	  recently	  been	  found	  to	  also	  inhibit	  complex	  I	  of	  the	  
electron	  transport	  chain	  and	  as	  such	  are	  not	  specific	  inhibitors	  of	  the	  NADPH	  oxidase	  
complex	  (Lambert	  et	  al.,	  2008).	  I	  therefore	  wanted	  to	  assess	  the	  specificity	  of	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Figure	  3	  -­‐	  6	  Mito-­‐TEMPO	  and	  Apocynin	  titration.	  
ROS	   levels	   were	   measured	   in	   BMDMs	   untreated	   or	   pre-­‐treated	   for	   1	   hour	   with	  
varying	  concentrations	  of	  either	  (A)	  Mito-­‐TEMPO	  or	  (B)	  Apocynin,	  shown	  as	  relative	  
to	   untreated	   WT	   BMDMs.	   Data	   represents	   means	   ±	   SEM	   of	   three	   independent	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Apocynin	  and	  similarly	  the	  specificity	  of	  Mito-­‐TEMPO,	  to	  ensure	  that	  its	  effects	  were	  
due	   to	  mitochondrial	   ROS	   scavenging	   and	   not	   inhibition	   of	   the	   electron	   transport	  
chain	   (ETC).	   Oxygen	   consumption,	   a	  measure	   of	   ETC	   activity,	   was	   not	   affected	   by	  
either	  compound	   (Figure	  3	   -­‐	  8).	  Rotenone	  and	  Antimycin	  A,	  which	  block	  complex	   I	  
and	  complex	  III	  respectively,	  were	  used	  as	  positive	  controls	  in	  the	  assay.	  	  
	  
	  
Figure	  3	  -­‐	  7	  Mito-­‐TEMPO	  and	  Apocynin	  do	  not	  affect	  cell	  viability.	  
Percentage	   of	   viable	   BMDMs	   (expressed	   as	   percentage	   over	   vehicle)	   untreated	   or	  
pre-­‐treated	   for	   1	   hour	  with	   either	   10	  μM	  Apocynin	  or	   100	  μM	  Mito-­‐TEMPO.	  Data	  
represents	  means	  ±	  SEM	  of	  three	  independent	  experiments.	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Figure	  3	  -­‐	  8	  Mito-­‐TEMPO	  and	  Apocynin	  do	  not	  affect	  mitochondrial	  respiration.	  
Measurement	   of	   mitochondrial	   respiration	   (OCR)	   in	   BMDMs.	   The	   arrow	   indicates	  
time	  of	  addition	  of	  the	  inhibitors.	  Addition	  of	  Rotenone	  (Rot)	  and	  Antimycin	  A	  (AA),	  
which	  block	  mitochondrial	  respiration,	  was	  used	  as	  a	  control.	  Data	  represents	  means	  
±	  SEM	  of	  three	  independent	  experiments.	  
	  
The	  addition	  of	  Mito-­‐TEMPO	  reduced	  the	  basal	  ROS	  levels	  of	  Hvcn1-­‐/-­‐	  macrophages	  
to	   similar	   levels	   seen	   in	   their	   WT	   counterpart	   (Figure	   3	   -­‐	   9);	   indicating	   their	  
mitochondrial	  origin.	  In	  contrast,	  Apocynin	  did	  not	  reduce	  basal	  ROS	  levels	  and	  thus	  
confirming	   that	   the	   NADPH	   oxidase	   is	   not	   activated	   in	   quiescent	   macrophages	  
(Figure	  );	  therefore,	  the	  increase	  in	  ROS	  observed	  in	  Hvcn1-­‐/-­‐	  macrophages	  is	  indeed	  
of	  mitochondrial	  origin.	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Figure	  3	  -­‐	  9	  Mito-­‐TEMPO	  reduces	  basal	  ROS	  levels	  in	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages.	  
ROS	  levels	  were	  measured	  in	  BMDMs	  untreated	  or	  pre-­‐treated	  for	  1	  hour	  with	  either	  
10	   μM	   Apocynin	   or	   100	   μM	   Mito-­‐TEMPO,	   shown	   as	   relative	   to	   untreated	   WT	  
BMDMs.	   Data	   represents	  means	   ±	   SEM	   of	   three	   independent	   experiments.	   *,	   p	   <	  
0.05;	  ns,	  no	  significance.	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3.2.3 ATTENUATED	  REGULATION	  OF	  MITOCHONDRIAL	  ROS	  
PRODUCTION	  
I	  had	  ascertained	  that	  the	  increase	  in	  ROS	  observed	  in	  Hvcn1-­‐/-­‐	  macrophages	  was	  of	  
mitochondrial	  origin.	  However,	  the	  data	  was	  not	  conclusive	  of	  whether	  this	  was	  due	  
to	  an	  overproduction	  of	  ROS	   in	  the	  mitochondria	  or	   impairment	   in	  ROS	  scavenging	  
by	  antioxidant	  enzymes.	  It	  was	  important	  to	  investigate	  this	  further	  as	  mitochondrial	  
ROS	  play	  a	  significant	  role	  in	  signalling	  pathways	  in	  a	  number	  of	  cell	  types	  (Collins	  et	  
al.,	   2012).	   The	   current	   data	   suggest	   that	   mitochondrial	   ROS	   act	   as	   signalling	  
molecules	   to	  maintain	   homeostasis	   as	   well	   as	   adapt	   to	   stress	   (Rhee	   et	   al.,	   2000).	  
Tight	   regulation	   of	   mitochondrial	   ROS	   is	   therefore	   crucial	   in	   order	   to	   allow	   it	   to	  
participate	  in	  cell	  signalling	  pathways	  without	  causing	  redox	  stress.	  This	  is	  achieved	  
in	   several	   ways.	   Antioxidant	   enzymes,	   both	   in	   the	   cytosol	   and	   within	   the	  
mitochondria	   themselves,	   exist	   in	   order	   to	   eliminate	   ROS	   (Murphy,	   2009).	   The	  
superoxide	  dismutase	  (SOD)	  family	  of	  antioxidant	  enzymes	  can	  be	  found	  within	  the	  
mitochondria.	   The	   enzymatic	   activity	   of	   SODs	   generates	   hydrogen	   peroxide	   (H2O2)	  
from	   superoxide	   anion	   (O2-­‐),	   which	   is	   highly	   unstable	   and	   has	   a	   strong	   oxidative	  
potential.	  SOD2	  is	  found	  within	  the	  mitochondrial	  matrix	  and	  is	  one	  of	  the	  primary	  
enzyme	  that	  deals	  with	  ROS	  produced	  from	  the	  ETC	  (Sena	  and	  Chandel,	  2012).	  
Elevated	  levels	  of	  ROS	  can	  induce	  increased	  expression	  of	  SOD2	  in	  order	  to	  prevent	  
potential	  injury	  from	  oxidative	  damage	  (Miao	  and	  St	  Clair,	  2009).	  I	  therefore	  sought	  
to	  determine	  if	  the	  observed	  elevated	  basal	  ROS	  in	  Hvcn1-­‐/-­‐	  BMDMs	  might	  result	  in	  
this	  biological	  response	  by	  assessing	  the	  levels	  of	  SOD2	  protein	  expression.	  At	  steady	  
state,	   SOD2	   protein	   levels	   were	   similar	   in	   both	   cell	   types	   (Figure	   3	   -­‐	   10).	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Mitochondrial	   ROS	   have	   been	   indicated	   to	   act	   as	   signalling	   molecules	   to	   trigger	  
inflammatory	  cytokine	  production	  (Bulua	  et	  al.,	  2011,	  Nakahira	  et	  al.,	  2011,	  Zhou	  et	  
al.,	  2011),	  therefore	  LPS	  might	  regulate	  SOD2	  activity.	  LPS	  activation	  of	  macrophages	  
did	   not	   increase	   the	   expression	   of	   SOD2	   compared	   to	   untreated	   macrophages	  
(Figure	   3	   -­‐10).	   No	   difference	   in	   SOD2	   expression	   was	   observed	   between	   LPS	  
activated	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages	  (Figure	  3	  -­‐10).	  This	  was	  further	  confirmed	  by	  
densitometry	   analysis	   of	   the	   blots	   (Figure	   3	   –	   11).	   This	   would	   indicate	   that	   the	  
increase	  in	  basal	  ROS	  observed	  in	  Hvcn1-­‐/-­‐	  macrophages	  is	  due	  to	  an	  overproduction	  







Figure	   3	   -­‐	   10	   Comparable	   SOD2	   protein	   levels	   in	   untreated	   and	   activated	  
macrophages.	  
SOD2	   protein	   levels	   in	   BMDMs	   untreated	   or	   activated	  with	   100	   ng/ml	   LPS	   for	   24	  
hours	  were	  analysed	  by	  Western	  Blot.	  Actin	  was	  used	  as	  a	   loading	  control.	  Data	   is	  
representative	  of	  two	  independent	  experiments.	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Figure	   3	   -­‐	   11	   Comparable	   SOD2	   fold	   change	   in	   untreated	   and	   activated	  
macrophages.	  
Densitometry	  analysis	  of	  SOD2	  Western	  blots.	  Data	  represents	  means	  ±	  SEM	  of	  two	  
independent	  experiments.	  ns,	  no	  significance.	  
	  
Another	   important	   determinant	   of	   mitochondrial	   ROS	   production	   is	   the	  
electrochemical	   gradient	   that	   is	   generated	   across	   the	   inner	   mitochondrial	  
membrane.	   This	   gradient	   is	   highly	   dependent	   on	   the	   mitochondrial	   membrane	  
potential.	   As	   the	   electrochemical	   gradient	   and	   thus	   the	   mitochondrial	   membrane	  
potential	  increases,	  a	  parallel	  increase	  is	  observed	  in	  mitochondrial	  ROS	  production	  
(Handy	  and	  Loscalzo,	  2012).	  However,	  it	  has	  been	  proposed	  that	  an	  increase	  in	  ROS	  
production	   can	   occur	   at	   both	   extremes	   of	   high	   and	   low	  mitochondrial	  membrane	  
potential	   (Aon	   et	   al.,	   2010).	   In	   addition,	   these	   processes	   are	   closely	   linked	   to	   ETC	  
activity	   and	   as	   such	   mitochondrial	   respiration.	   A	   high	   mitochondrial	   membrane	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potential	   is	  observed	  with	  a	  high	  rate	  of	  ETC	  activity	  and	  mitochondrial	   respiration	  
(Echtay	  et	  al.,	  2002).	  
It	  was	  thus	  important	  to	  assess	  the	  state	  of	  the	  mitochondrial	  membrane	  potential	  
in	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages.	  The	  single	   fluorescent	  dyes	  available	   to	  measure	  
mitochondrial	   membrane	   potential	   are	   limited	   by	   confounding	   factors	   such	   as	  
mitochondrial	  size,	  shape	  and	  density	  (Perry	  et	  al.,	  2011).	  With	  this	  in	  mind,	  I	  used	  a	  
novel	  ratiometric	  dye	  that	  uses	  the	  ratio	  of	  two	  fluorescent	  probes	  to	  accurately	  only	  
depend	  on	  the	  mitochondrial	  membrane	  potential	  and	  not	  the	  confounding	  factors	  
described	   above	   (Tucsek	   et	   al.,	   2011).	   A	   decreased	   mitochondrial	   membrane	  
potential	   was	   observed	   in	   the	   Hvcn1-­‐/-­‐	   macrophages	   compared	   to	   their	   WT	  
counterparts	   (Figure	   3	   -­‐	   12).	   Activation	   with	   LPS	   significantly	   lowered	   the	  
mitochondrial	  membrane	  potential	   to	  a	  similar	  extent	   in	  both	  cell	   types	  (Figure	  3	   -­‐	  
12),	  as	  previously	  reported	  (Everts	  et	  al.,	  2012).	  FCCP	  was	  used	  as	  a	  positive	  control	  
of	  very	   low	  mitochondrial	  membrane	  potential	   in	  this	  assay.	  FCCP	   is	  a	   lipid	  soluble	  
ionophore,	   which	   inserts	   itself	   into	   the	   inner	   mitochondrial	   membrane	   and	  
transports	  H+	  across	  to	  the	  intermembrane	  space.	  This	  leads	  to	  an	  uncoupling	  of	  the	  
ETC	  with	  the	  ATP	  synthase,	  thus	  dissipating	  the	  mitochondrial	  membrane	  potential	  
(Joshi	  and	  Bakowska,	  2011).	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Figure	  3	  -­‐	  12	  Lowered	  mitochondrial	  membrane	  potential	  in	  Hvcn1-­‐/-­‐	  macrophages.	  
Mitochondrial	  membrane	  potential	  was	  measured	  in	  BMDMs	  untreated	  or	  activated	  
with	  100	  ng/ml	  LPS	  for	  24	  hours,	  shown	  as	  relative	  to	  untreated	  WT	  BMDMs.	  Data	  
represents	  means	  ±	  SEM	  of	  three	  independent	  experiments.	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3.2.4 IMPAIRED	  RESPIRATORY	  BURST	  IN	  Hvcn1-­‐/-­‐	  MACROPHAGES	  
Previous	  work	   in	   neutrophils	   has	   shown	   the	   essential	   role	   of	  HVCN1	   in	   facilitating	  
the	   NADPH	   oxidase-­‐mediated	   respiratory	   burst	   (Ramsey	   et	   al.,	   2009).	   This	   strong	  
ROS	   production	   is	   an	   important	   defence	   mechanism	   against	   pathogens	   as	   it	  
produces	  large	  amounts	  of	  ROS	  to	  eliminate	  pathogens	  (Dale	  et	  al.,	  2008)	  and	  I	  thus	  
wanted	  to	  assess	  the	  capacity	  of	  Hvcn1-­‐/-­‐	  macrophages	  to	  mount	  this	  response	  using	  
the	  classical	  immune	  stimulus	  LPS,	  a	  bacterial	  derived	  lipopolysaccharide.	  	  
After	   LPS	   stimulation,	  ROS	  production	   from	  Hvcn1-­‐/-­‐	  macrophages	  was	   significantly	  
lower	   compared	   to	   that	   of	   WT	   macrophages	   (Figure	   3	   -­‐	   13).	   Diminished	   ROS	  
production	   was	   observed	   in	   the	   presence	   of	   Apocynin	   in	   both	   cells	   types,	   which	  
confirmed	  that	  the	  majority	  of	  the	  LPS-­‐induced	  ROS	  were	  generated	  by	  the	  NADPH	  
oxidase	  (Figure	  3	  -­‐	  13).	  This	  is	  shown	  more	  clearly	  when	  the	  data	  are	  represented	  as	  
fold	   induction	   over	   the	   respective	   untreated	   macrophages	   (Figure	   3	   -­‐	   14.	   	   In	  
addition,	  Apocynin	  treatment	  did	  not	  affect	  cell	  viability	  after	  LPS	  treatment	  (Figure	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Figure	  3	  -­‐	  13	  Impaired	  respiratory	  burst	  in	  Hvcn1-­‐/-­‐	  macrophages.	  	  
ROS	   levels	  of	  WT	  and	  Hvcn1-­‐/-­‐	  BMDMs	   in	   response	   to	  1	  hour	   stimulation	  with	  100	  
ng/ml	   LPS.	   Data	   are	   represented	   as	   relative	   to	   untreated	   WT	   BMDMs.	   Data	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Figure	  3	  -­‐	  14	  Impaired	  respiratory	  burst	  in	  Hvcn1-­‐/-­‐	  macrophages	  (relative	  levels).	  	  
ROS	   levels	  of	  WT	  and	  Hvcn1-­‐/-­‐	  BMDMs	   in	   response	   to	  1	  hour	   stimulation	  with	  100	  
ng/ml	   LPS.	   Data	   are	   represented	   as	   fold	   induction	   over	   the	   respective	   untreated	  
macrophages.	  Data	  represents	  means	  ±	  SEM	  of	  three	  independent	  experiments.	  *,	  p	  
<	  0.05;	  ns,	  no	  significance.	  	  
	  
Figure	  3	  -­‐	  15	  Apocynin	  does	  not	  affect	  the	  viability	  of	  LPS-­‐stimulated	  macrophages.	  	  
Percentage	   of	   viable	   BMDMs	   (expressed	   as	   percentage	   over	   vehicle)	   untreated	   or	  
pre-­‐treated	   for	   1	   hour	  with	   either	   10	  μM	  Apocynin	  or	   100	  μM	  Mito-­‐TEMPO.	  Data	  
represents	  means	  ±	  SEM	  of	  three	  independent	  experiments.	  
	  
Despite	   the	   observed	   significant	   reduction	   in	   superoxide	   production	   in	   Hvcn1-­‐/-­‐	  
neutrophils,	   no	   data	   were	   available	   on	   their	   phagocytic	   capacity	   (Ramsey	   et	   al.,	  
2009).	   I	  therefore	  assessed	  whether	  HVCN1-­‐deficiency	  affected	  phagocytic	  capacity	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in	  macrophages.	  No	  differences	   in	  phagocytic	  capacity	  were	  observed	  between	  WT	  
and	   Hvcn1-­‐/-­‐	   macrophages	   at	   steady	   state	   (Figure	   3	   -­‐	   16).	   LPS	   activation	   of	  
macrophages	   increased	   the	   phagocytic	   capacity	   of	   both	   cell	   types,	   however	   no	  
differences	  were	  observed	  (Figure	  3	  -­‐	  16).	  These	  data	  would	  suggest	  that	  neither	  the	  
ability	   to	  mount	   a	   respiratory	   burst	   nor	   the	   presence	   of	   proton	   channels	   has	   any	  
involvement	  in	  the	  phagocytic	  capacity	  of	  macrophages.	  
	  
	  
Figure	   3	   -­‐	   16	   Phagocytic	   capacity	   of	   steady	   state	   and	   activated	   Hvcn1-­‐/-­‐	  
macrophages	  is	  not	  impaired.	  	  
Fluorescent-­‐labelled	  latex	  beads	  were	  given	  to	  untreated	  BMDMs	  or	  those	  activated	  
with	  100	  ng/ml	  LPS	  for	  24	  hours.	  Bead	  uptake	  was	  measured	  over	  a	  period	  of	  time.	  
BMDMs	  incubated	  at	  4	  °C	  during	  phagocytosis	  were	  used	  as	  control.	  Data	  represents	  
means	  ±	  SEM	  of	  three	  independent	  experiments.	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3.2.5 HVCN1	  IS	  LOCALISED	  ON	  THE	  PLASMA	  MEMBRANE	  IN	  
MACROPHAGES	  
As	  discussed	  previously,	  there	  is	  little	  data	  on	  the	  localisation	  of	  HVCN1	  in	  immune	  
cells.	  Electrophysiological	  investigations	  in	  immune	  cells,	  such	  as	  macrophages,	  have	  
shown	   that	  proton	  currents	  are	  mediated	  at	   the	  plasma	  membrane	   (Holevinsky	  et	  
al.,	  1994,	  Kapus	  et	  al.,	  1993).	  Other	  studies	   in	  epithelial	  cells	  have	  shown	  evidence	  
for	   proton	   channel	   expression	   on	   intracellular	   organelles	   (Schapiro	   and	   Grinstein,	  
2000,	  Li	  et	  al.,	  2010).	  	  In	  B	  cells,	  HVCN1	  was	  present	  at	  the	  plasma	  membrane	  as	  well	  
as	  in	  the	  cytoplasm	  (Capasso	  et	  al.,	  2010).	  	  
Given	   the	   observations	   made	   about	   the	   mitochondrial	   ROS	   production	   and	  
membrane	   potential	   in	   Hvcn1-­‐/-­‐	   macrophages,	   I	   next	   wanted	   to	   determine	   if	   the	  
proton	   channel	  were	  expressed	   in	   the	  mitochondria.	   Immunofluorescence	   imaging	  
showed	   that	   HVCN1	   was	   expressed	   on	   the	   plasma	   membrane	   of	   macrophages,	  
however	   it	   did	   not	   co-­‐localise	   with	   MitoTracker	   Deep	   Red	   FM,	   a	   mitochondrial	  
marker	  (Figure	  3	  -­‐	  17).	  In	  addition,	  there	  was	  no	  co-­‐localisation	  of	  HVCN1	  with	  the	  ER	  
(GRP94)	   (Figure	   3	   -­‐	   17).	   These	   results	   indicate	   that	   the	   role	   of	   HVCN1	   on	  
mitochondrial	  ROS	  and	  membrane	  potential	  is	  not	  due	  to	  direct	  function	  mediated	  in	  
the	  mitochondria.	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Figure	  3	  -­‐	  17	  HVCN1	  does	  not	  co-­‐localise	  with	  the	  mitochondria	  or	  the	  endoplasmic	  
reticulum.	  
WT	  macrophages	  were	  stained	  with	  MitoTracker	  DeepRed	  FM	  and	  GRP94	   that	  are	  
markers	   for	   the	   mitochondria	   and	   endoplasmic	   reticulum,	   respectively.	   Data	   are	  
representative	  figures	  of	  two	  independent	  experiments.	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3.3 CHAPTER	  DISCUSSION	  
Only	  two	  studies	  to	  date	  have	  investigated	  proton	  channels	  in	  macrophages	  (Kapus	  
et	  al.,	  1993,	  Holevinsky	  et	  al.,	  1994)	  and	  therefore	   little	   is	  known	  about	  the	  role	  of	  
HVCN1	  in	  these	  immune	  cells.	  These	  earlier	  studies	  have	  confirmed	  the	  existence	  of	  
proton	  channels	  in	  macrophages	  through	  patch	  clamp	  recordings.	  The	  field	  of	  proton	  
channel	  research	  has	  been	  hampered	  to	  a	  certain	  extent	  by	  the	  lack	  of	  commercially	  
available	  antibodies	  against	  HVCN1	  and	  it	  is	  only	  in	  recent	  years	  that	  such	  antibodies	  
have	   become	   available.	   The	   present	   work	   demonstrates	   for	   the	   first	   time	   the	  
expression	  of	  HVCN1	  at	  the	  protein	  level	   in	  macrophages.	  Furthermore,	   it	  confirms	  
the	  absence	  of	  HVCN1	  protein	  in	  macrophages	  from	  Hvcn1-­‐/-­‐	  mice.	  
Interestingly,	   I	   observed	   elevated	   basal	   ROS	   in	   Hvcn1-­‐/-­‐	   macrophages.	   It	   was	  
determined	   through	   pharmacological	   manipulation	   that	   they	   were	   of	   a	  
mitochondrial	  origin	  rather	  than	  due	  to	  the	  activity	  of	  the	  NADPH	  oxidase	  complex.	  
As	  discussed	  previously,	   this	  has	  been	  observed	   in	  Hvcn1-­‐/-­‐	   B	   cells	   and	  neutrophils	  
(Capasso	  et	  al.,	  2010,	  Decleva	  et	  al.,	  2013);	  an	  effect	  that	  was	  reversed	  by	  treatment	  
of	   neutrophils	   with	   gramicidin,	   a	   molecule	   that	   generates	   pores	   permeable	   to	  
protons	  and	  other	  monovalent	  cations.	  However,	   the	  observation	   in	  these	  two	  cell	  
types	  was	  not	  further	  investigated.	  
Assessment	   of	   expression	   levels	   of	   the	   mitochondrial	   antioxidant	   enzyme	   SOD2	  
showed	   similar	   expression	   at	   steady	   state	   in	   both	  WT	   and	  Hvcn1-­‐/-­‐	   macrophages.	  
This	  was	  also	  true	  after	  LPS	  activation,	  indicating	  that	  increased	  ROS	  are	  not	  inducing	  
a	   feedback	   upregulation	   of	   SOD2	   in	  macrophages.	  Whilst	   there	  might	   not	   be	   any	  
differences	   in	   the	   amount	   of	   SOD2	   enzyme,	   its	   rate	   of	   activity	  might	   be	   different.	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Investigating	   the	   specific	   activity	   of	   SOD2	  would	   provide	   a	   better	   insight	   into	   the	  
state	   of	   this	   antioxidant	   system	   in	   the	   mitochondria.	   In	   addition,	   it	   would	   be	  
important	  to	  assess	  other	  antioxidant	  enzymes,	  such	  as	  glutathione	  peroxidase	  (GPx)	  
and	  peroxiredoxins,	  and	  also	  cofactors,	  such	  as	  glutathione	  levels	  (Li	  et	  al.,	  2013).	  	  
Mitochondrial	   ROS	   production	   is	   tightly	   regulated	   by	   a	   number	   of	   factors,	   one	   of	  
those	  being	  the	  mitochondrial	  membrane	  potential.	  It	  is	  well	  described	  that	  a	  higher	  
mitochondrial	   membrane	   potential	   is	   associated	   with	   greater	   production	   of	  
mitochondrial	  ROS,	  which	  is	  associated	  with	  increased	  electron	  transport	  (Handy	  and	  
Loscalzo,	   2012).	   However,	   a	   range	   of	   agents	   that	   lower	  mitochondrial	   membrane	  
potential	   (LPS,	   ETC	   inhibitors,	   etc.)	   paradoxically	   increase	   mitochondrial	   ROS	  
production.	  The	  exact	  mechanism	  for	  this	  disparity	   is	  not	  well	  defined	  (West	  et	  al.,	  
2011,	  Everts	  et	  al.,	  2012).	  This	  appears	  to	  be	  the	  case	  in	  the	  Hvcn1-­‐/-­‐	  macrophages,	  
where	   a	   reduced	   mitochondrial	   membrane	   potential	   was	   observed	   compared	   to	  
their	   WT	   counterparts.	   A	   “redox-­‐optimised	   ROS	   balance	   hypothesis”	   has	   been	  
proposed	   to	   explain	   this	   paradox	   and	   it	   states	   that	   oxidative	   stress	   can	   occur	   at	  
either	  extremes	  of	  high	  or	  low	  mitochondrial	  potential	  (Aon	  et	  al.,	  2010).	  	  
In	   accordance	   with	   the	   literature,	   Hvcn1-­‐/-­‐	   macrophages	   displayed	   an	   impaired	  
respiratory	   burst.	   In	   neutrophils,	   the	   lack	   of	   proton	   channels	   resulted	   in	   an	  
intracellular	   acidification,	   due	   to	   the	   activity	   of	   NADPH	   oxidase	   in	   the	   absence	   of	  
charge	  and	  intracellular	  pH	  (pHi)	  compensation	  (El	  Chemaly	  et	  al.,	  2010,	  Morgan	  et	  
al.,	  2009).	  HVCN1	  extrudes	  protons	   (H+)	   that	   rapidly	  accumulate	   in	   the	  cytosol	  and	  
delivers	  them	  into	  the	  phagosome,	  where	  they	  are	  used	  in	  crucial	  chemical	  reactions	  
to	   produce	   ROS	   (Morgan	   et	   al.,	   2009).	   This	  mechanism	   is	  most	   likely	   the	   same	   in	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macrophages,	   but	   investigations	   into	   intracellular	   acidification	   during	   activation	   or	  
phagocytosis	  would	  need	  to	  be	  undertaken	  to	  confirm	  this.	  	  
Ramsey	   et	   al.	   showed	   no	   differences	   in	   the	   capacity	   of	   Hvcn1-­‐/-­‐	   neutrophils	   to	  
phagocytose	   opsonised	   bacteria	   compared	   to	   WT	   cells	   (Ramsey	   et	   al.,	   2009).	   In	  
accordance,	  my	  own	  investigations	  showed	  no	  differences	  in	  the	  phagocytic	  capacity	  
of	  WT	   and	  Hvcn1-­‐/-­‐	  macrophages.	   It	   needs	   to	   be	   noted	   that	   fluorescently-­‐labelled	  
latex	  beads	  that	  are	  classically	  used	  in	  phagocytic	  assays,	  and	  were	  also	  used	  in	  the	  
present	   study,	   do	   not	   provide	   the	   cells	   with	   a	  metabolic	   load,	   as	   the	   latex	   beads	  
cannot	  be	  degraded	  by	  the	  cells.	  On	  the	  other	  hand,	  opsonised	  bacteria	  or	  apoptotic	  
cells	  are	  more	  physiologically	  relevant	  to	  the	  phagocytic	  process	  as	  they	  do	  provide	  a	  
metabolic	   load.	   Nonetheless,	   given	   that	   no	   impairment	   was	   observed	   in	   Hvcn1-­‐/-­‐	  
neutrophil	  phagocytosing	  bacteria	  (Ramsey	  et	  al.,	  2009),	  it	  is	  likely	  that	  this	  process	  
is	  not	  linked	  to	  HVCN1	  regulation	  of	  ROS	  production	  and	  therefore	  not	  regulated	  by	  
proton	  channels.	  	  	  
Regarding	  HVCN1	  subcellular	  localisation,	  I	  observed	  it	  on	  the	  plasma	  membrane	  of	  
macrophages	  and	  could	  not	  detect	  any	  co-­‐localisation	  with	  mitochondrial	  markers.	  
Therefore,	  the	  steady	  state	  increase	  in	  mitochondrial	  ROS	  is	  not	  due	  to	  a	  direct	  role	  
of	  HVCN1	  in	  macrophages.	  It	  might	  be	  due	  to	  the	  effect	  of	  cytosolic	  charge	  and	  pH	  
balance,	  which	  might	  affect	  mitochondrial	  function.	  	  
I	   have	   presented	   here	   for	   the	   first	   time	   the	   functional	   expression	   of	   HVCN1	   in	  
macrophages	   and	   have	   found	   overproduction	   of	   mitochondrial	   ROS	   in	   Hvcn1-­‐/-­‐	  
macrophages.	  Cellular	  metabolism	  is	  closely	  linked	  to	  ROS	  production	  and	  thus	  I	  next	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4.1 INTRODUCTION	  
Previous	  studies	  discussed	  in	  Chapter	  1	  and	  my	  own	  investigations	  in	  Chapter	  3	  have	  
demonstrated	   a	   link	   between	   HVCN1	   and	   ROS	   production.	   Most	   of	   these	   studies	  
have	  focused	  on	  the	  role	  the	  proton	  channel	  plays	  in	  NADPH	  oxidase-­‐dependent	  ROS	  
production.	   Whilst	   observations	   of	   elevated	   basal	   mitochondrial	   ROS	   have	   been	  
made	  previously	  in	  HVCN1-­‐/-­‐	  B	  cells	  (Capasso	  et	  al.,	  2010)	  and,	  more	  recently,	  in	  zinc	  
(Zn2+)-­‐treated	  neutrophils	  (Decleva	  et	  al.,	  2013),	  no	  further	  investigations	  have	  been	  
undertaken	  into	  how	  the	  lack	  of	  proton	  channels	  may	  modulate	  mitochondrial	  ROS	  
or	  how	  elevated	  basal	  ROS	  levels	  may	  affect	  cellular	  processes	  such	  as	  metabolism.	  	  
To	  date,	  only	  one	  study	  has	  assessed	  the	  effects	  of	  HVCN1-­‐deficiency	  on	  metabolic	  
processes	  (Capasso	  et	  al.,	  2010).	  The	  study	  demonstrated	  that	  Hvcn1-­‐/-­‐	  B	  cells	  used	  
the	   same	   amount	   of	   oxidative	   phosphorylation	   and	   glycolysis	   as	   their	   WT	  
counterparts.	   However	   after	   BCR	   stimulation,	   B	   cells	   lacking	   HVCN1	   used	   less	  
oxidative	   phosphorylation	   and	   glycolysis	   than	   WT	   cells.	   This	   difference	   was	   not	  
apparent	  when	  B	  cells	  were	  stimulated	  with	  LPS	  or	  anti-­‐CD40.	  	  
It	   has	   been	   known	   for	   some	   time	   that	   metabolic	   profiles	   are	   closely	   linked	   to	  
macrophage	   polarisation	   and	   function.	   In	   recent	   years,	   emerging	   evidence	   has	  
suggested	   that	   the	   functional	   phenotype	   acquired	   by	  macrophages	   in	   response	   to	  
environmental	   cues	   is	   heavily	   dependent	   on	   metabolic	   processes	   (Biswas	   and	  
Mantovani,	  2012).	  	  
Classically	   activated	   macrophages,	   which	   are	   characterised	   by	   their	   pro-­‐
inflammatory	   phenotype,	   shift	   their	   metabolism	   towards	   the	   anaerobic	   glycolytic	  
CHAPTER	  FOUR	  	   CELLULAR	  BIOENERGETICS	  OF	  MACROPHAGES	  
	   135 
pathway.	   This	   shift	   is	   absent	   in	   alternatively	   activated	   macrophages,	   which	   are	  
characterised	   by	   an	   anti-­‐inflammatory	   phenotype	   (Rodriguez-­‐Prados	   et	   al.,	   2010).	  
The	   rapid	   rate	   of	   adenosine	   triphosphate	   (ATP)	   production	   by	   glycolysis	   allows	  
classically	   activated	  macrophages	   to	   cope	  with	   their	   increased	   energy	   demands	   in	  
order	   to	   trigger	   microbicidal	   functions.	   In	   contrast,	   oxidative	   metabolism	   is	   the	  
metabolic	   pathway	   favoured	   by	   alternatively	   activated	   macrophages.	   It	   generates	  
large	  amounts	  of	  ATP	  and	  thus	  provides	  sustained	  energy	  for	  the	  wound	  healing	  and	  
tissue	  remodelling	  functions	  of	  these	  macrophages	  (Odegaard	  and	  Chawla,	  2011).	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4.2 AIMS	  
This	  chapter	  describes	  my	  investigation	  to	  define	  the	  role	  of	  HVCN1	  in	  macrophage	  
metabolism.	  My	  aims	  were	  to	  address	  the	  following	  questions:	  
• Is	   mitochondrial	   respiration	   and/or	   glycolysis	   altered	   in	   Hvcn1-­‐/-­‐	  
macrophages?	  
• Are	  Hvcn1-­‐/-­‐	  macrophages	   able	   to	   produce	   comparable	   amounts	   of	   ATP,	   as	  
their	  WT	  counterparts,	  despite	  their	  intracellular	  ROS	  overproduction?	  
• Is	  the	  mitochondrial	  biomass	  similar	  in	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages?	  	  
• Does	  HVCN1-­‐deficiency	  affect	  the	  spare	  respiratory	  capacity?	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4.2.1 ATTENUATED	  MITOCHONDRIAL	  RESPIRATION	  IN	  Hvcn1-­‐/-­‐	  
MACROPHAGES	  
Since	   HVCN1	   appears	   to	   play	   a	   role	   in	   mitochondrial	   ROS	   production	   in	   Hvcn1-­‐/-­‐	  
macrophages,	   I	   next	   explored	   the	   impact	   of	   HVCN1	   deficiency	   in	   macrophage	  
metabolism.	   I	   assessed	  mitochondrial	   respiration	  and	  glycolysis	   in	  macrophages	  by	  
measuring	   oxygen	   consumption	   rate	   (OCR)	   and	   extracellular	   acidification	   rate	  
(ECAR).	  	  
Real-­‐time	   measurements	   of	   the	   OCR	   of	   WT	   and	   Hvcn1-­‐/-­‐	   macrophages	   found	  
significantly	   lower	   rates	   at	   steady	   state	   in	   cells	   lacking	   the	   proton	   channel	   (Figure	  
4-­‐1).	  However,	  activation	  with	  LPS	  decreased	  the	  OCR	  in	  both	  cell	  types	  to	  a	  similar	  
extent	   (Figure	   4-­‐1).	   This	   is	   in	   accordance	   with	   the	   decreased	   mitochondrial	  
membrane	   potential	   observed	   in	   Hvcn1-­‐/-­‐	   macrophages	   (Figure	   ),	   suggesting	   a	  
mitochondrial	  defect	  in	  these	  cells.	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Figure	  4-­‐1	  Attenuated	  mitochondrial	  respiration	  in	  Hvcn1-­‐/-­‐	  macrophages.	  
Measurement	  of	  mitochondrial	  respiration	  (OCR)	   in	  BMDMs	  untreated	  or	  activated	  
with	  100	  ng/ml	  LPS	  for	  24	  hours.	  Data	  represents	  means	  ±	  SEM	  of	  three	  independent	  
experiments.	  **,	  p	  <	  0.01;	  ***,	  p	  <	  0.001;	  ns,	  no	  significance.	  	  
	  
No	  differences	  were	  observed	  in	  the	  real-­‐time	  steady	  state	  ECAR	  of	  either	  cell	  type	  
(Figure	   4-­‐2).	   Activation	   with	   LPS	   led	   to	   an	   increase	   in	   the	   ECAR	   of	   both	  WT	   and	  
Hvcn1-­‐/-­‐	  macrophages,	  however	  the	  latter	  showed	  a	  significantly	  greater	  increase	  in	  
glycolytic	  flux	  (Figure	  4-­‐2).	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Figure	  4-­‐2	  Increased	  glycolysis	  in	  activated	  Hvcn1-­‐/-­‐	  macrophages.	  
Measurement	   of	   glycolytic	   flux	   (ECAR)	   in	   BMDMs	  untreated	   or	   activated	  with	   100	  
ng/ml	   LPS	   for	   24	   hours.	   Data	   represents	   means	   ±	   SEM	   of	   three	   independent	  
experiments.	  *,	  p	  <	  0.05;	  **,	  p	  <	  0.01;	  ***,	  p	  <	  0.001.	  
	  
Both	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages	  responded	  in	  a	  similar	  manner	  to	  LPS	  stimulation	  
by	  switching	  from	  oxidative	  metabolism	  to	  anaerobic	  glycolysis,	  which	  is	  a	  hallmark	  
of	   classical	   activation	   (Rodriguez-­‐Prados	   et	   al.,	   2010).	   This	   suggests	   that	   Hvcn1-­‐/-­‐	  
macrophages	  have	  no	  defects	  in	  inducing	  an	  increase	  in	  their	  glycolytic	  flux	  and	  thus	  
suggesting	  that	  the	  defect	  in	  the	  metabolism	  of	  these	  cells	  is	  mitochondria	  specific.	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4.2.2 DECREASED	  ATP	  LEVELS	  IN	  Hvcn1-­‐/-­‐	  MACROPHAGES	  
The	  observations	  of	  the	  metabolism	  of	  Hvcn1-­‐/-­‐	  macrophages	  in	  the	  previous	  section	  
would	  suggest	  mitochondrial	  impairment	  because	  glycolysis	  occurs	  in	  the	  cytoplasm	  
whereas	  oxidative	  phosphorylation	  occurs	  inside	  the	  mitochondria.	  I	  thus	  wanted	  to	  
investigate	   the	   potential	   impact	   this	   would	   have	   on	   cellular	   energy	   levels.	   In	  
addition,	  I	  wanted	  to	  ascertain	  that	  these	  observations	  were	  not	  due	  to	  differences	  
in	  mitochondrial	  biomass.	  	  
In	   support	   of	   altered	  mitochondrial	   respiration,	   steady	   state	  ATP	   levels	   in	  Hvcn1-­‐/-­‐	  
macrophages	   were	   significantly	   lower	   compared	   to	   their	  WT	   counterparts	   (Figure	  
4-­‐3).	  Activation	  with	   LPS	  decreased	   the	  ATP	   levels	   in	  both	   cell	   types.	   Interestingly,	  
Hvcn1-­‐/-­‐	  macrophages	  had	  lower	  ATP	  levels	  after	  LPS	  stimulation	  (Figure	  4-­‐3)	  despite	  
having	  a	  greater	  induction	  of	  glycolytic	  flux	  (Figure	  4-­‐2).	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Figure	  4-­‐3	  Attenuated	  ATP	  levels	  in	  untreated	  and	  activated	  Hvcn1-­‐/-­‐	  macrophages.	  	  
Measurement	  of	  ATP	  levels	  in	  BMDMs	  untreated	  or	  activated	  with	  100	  ng/ml	  LPS	  for	  
24	  hours,	  shown	  as	  relative	  to	  untreated	  WT	  BMDMs.	  Data	  represents	  means	  ±	  SEM	  
of	  three	  independent	  experiments.	  *,	  p	  <	  0.05;	  ***,	  p	  <	  0.001.	  
	  
I	   next	  assessed	  mitochondrial	  biomass	   in	  order	   to	   confirm	   that	   these	  observations	  
were	   not	   due	   to	   differences	   in	   numbers	   of	   mitochondria	   present	   in	   the	  
macrophages.	   I	  used	  a	  mitochondrial	  dye	   (MitoTracker	  Green	  FM)	   that	   localises	   to	  
mitochondria	   regardless	   of	   their	   membrane	   potential.	   I	   found	   similar	   levels	   of	  
mitochondrial	  biomass	  in	  the	  two	  cell	  types	  at	  the	  steady	  state	  and	  this	  was	  also	  true	  
after	   activation	   with	   LPS	   (Figure	   4-­‐4).	   Mitochondrial	   biogenesis	   was	   induced	   in	  
response	   to	   LPS	   activation	   to	   comparable	   levels	   in	  WT	   and	  Hvcn1-­‐/-­‐	   macrophages	  
(Figure	  4-­‐4),	  however	  this	  did	  not	  reach	  statistical	  significance.	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Figure	  4-­‐4	  Comparable	  mitochondrial	  biomass	  in	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages.	  	  
Mitochondrial	  biomass	  in	  BMDMs	  untreated	  or	  activated	  with	  100	  ng/ml	  LPS	  for	  24	  
hours,	  shown	  as	  relative	  to	  untreated	  WT	  BMDMs.	  Data	  represents	  means	  ±	  SEM	  of	  
three	  independent	  experiments.	  
	  
Whilst	   I	   observed	   no	   differences	   in	   mitochondrial	   biomass,	  Hvcn1-­‐/-­‐	   macrophages	  
may	  have	  acquired	  mutations	  in	  their	  mitochondrial	  DNA	  due	  to	  their	  elevated	  basal	  
mitochondrial	  ROS	  (Shokolenko	  et	  al.,	  2009).	  The	  complexes	  of	  the	  ETC	  are	  essential	  
to	  mitochondrial	  function;	  I	  therefore	  assessed	  their	  protein	  expression	  levels.	  Genes	  
found	   in	   the	   mitochondrial	   DNA	   encode	   all	   of	   the	   complex	   proteins;	   expect	   for	  
complex	  II,	  which	  is	  encoded	  by	  nuclear	  DNA	  (Bai	  et	  al.,	  2004).	  Western	  blot	  analysis	  
of	   all	   five	   complexes	   of	   the	   ETC	   showed	   comparable	   levels	   in	   WT	   and	   Hvcn1-­‐/-­‐	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macrophages,	  at	  steady	  state	  and	  after	  LPS	  activation	  (Figure	  4	  –	  5).	  This	  was	  further	  











Figure	  4-­‐5	  HVCN1	  loss	  does	  not	  affect	  protein	  expression	  of	  ETC	  complexes.	  
Protein	   levels	   of	   ETC	   complexes	   in	   untreated	   and	   LPS	   activated	   BMDMs	   were	  
measured	  by	  Western	  Blot	   analysis.	   Actin	  was	   used	   as	   a	   loading	   control.	  Data	   are	  
representative	  of	  two	  independent	  experiments.	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Figure	  4	  -­‐	  6	  HVCN1	  loss	  does	  not	  affect	  protein	  expression	  of	  ETC	  complexes.	  
Protein	  levels	  of	  ETC	  complexes	  in	  untreated	  and	  LPS	  activated	  BMDMs	  measured	  by	  
Western	  Blot	  analysis	   followed	  by	  densitometry	  analysis.	  Data	   represents	  means	  ±	  
SEM	  of	  two	  independent	  experiments.	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4.2.3 DIMINISHED	  SPARE	  RESPIRATORY	  CAPACITY	  IN	  Hvcn1-­‐/-­‐	  
MACROPHAGES	  
In	  the	  event	  of	  a	  sudden	  increase	  in	  energy	  demand	  or	  stress,	  cells	  can	  engage	  their	  
spare	  respiratory	  capacity	  (SRC).	  This	  extra	  mitochondrial	  capacity	  allows	  the	  cells	  to	  
effectively	  manage	   cellular	   stress	   such	   as	   hypoxia	   and	   low	   levels	   of	   nutrients.	   It	   is	  
believed	   to	  be	   crucial	   for	  both	   cellular	   survival	   and	   function	   (van	  der	  Windt	  et	   al.,	  
2012,	  Nicholls,	  2009).	  	  
Figure	   	   shows	   the	   real-­‐time	   OCR	   measurements	   made	   pre-­‐	   and	   post	   sequential	  
injections	   of	   Oligomycin	   A,	   FCCP,	   and	   Rotenone	   and	   Antimycin	   A.	   Oligomycin	   A	  
inhibits	   ATP	   synthase	   (complex	   V),	   which	   decreases	   the	   basal	   OCR	   of	   cells	   to	   a	  
certain	  extent.	  FCCP	  allows	   increased	  H+	  movement	  across	  the	   inner	  mitochondrial	  
membrane.	   This	   effect	   on	   the	   electrochemical	   gradient	   greatly	   increases	   the	   ETC	  
activity	   and	   thus	   the	  OCR	   (Joshi	   and	   Bakowska,	   2011).	   Rotenone	   and	  Antimycin	   A	  
inhibit	  complexes	  I	  and	  III,	  respectively.	  This	  leads	  to	  a	  complete	  inhibition	  of	  the	  ETC	  
and	  is	  followed	  by	  a	  sharp	  decline	  in	  OCR	  (Liu	  et	  al.,	  2002).	  The	  difference	  between	  
the	  maximum	  OCR,	  seen	  after	  FCCP	  addition,	  and	  the	  basal	  OCR	  is	  calculated	  as	  the	  
SRC	  (van	  der	  Windt	  et	  al.,	  2012).	  	  
I	   investigated	   this	   capacity	   in	   steady	   state	   and	   LPS	   activated	   macrophages.	   A	  
significantly	   lower	   SRC	   was	   observed	   in	   the	  Hvcn1-­‐/-­‐	  macrophages	   at	   steady	   state	  
(Figure	   4	   -­‐	   7),	   which	   agrees	   with	   my	   previous	   observations	   of	   mitochondrial	  
respiration	   (Figure	   4-­‐1).	   This	   result	   confirms	   further	   that	   mitochondria	   in	  Hvcn1-­‐/-­‐	  
macrophages	  are	  defective.	  Activation	  with	  LPS	  greatly	  reduced	  the	  SRC	  in	  both	  WT	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and	   Hvcn1-­‐/-­‐	   macrophages	   to	   comparable	   levels	   (Figure	   4	   -­‐	   7).	   Despite	   this,	   no	  
negative	  effect	  on	  cell	  survival	  was	  observed	  in	  response	  to	  LPS	  (Figure	  3	  -­‐	  7).	  
	  
	  
Figure	  4	  -­‐	  7	  Diminished	  spare	  respiratory	  capacity	  in	  Hvcn1-­‐/-­‐	  macrophages.	  
Real-­‐time	   mitochondrial	   respiration	   (OCR)	   measurements	   during	   sequential	  
treatments	  of	  BMDMs	  (untreated	  or	  activated	  with	  100	  ng/ml	  LPS	  for	  24	  hours)	  with	  
Oligomycin	  A,	  FCCP,	  and	  Rotenone	  and	  Antimycin	  A.	  Data	  represent	  means	  ±	  SEM	  of	  
three	  independent	  experiments.	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4.3 CHAPTER	  DISCUSSION	  
The	   findings	   described	   in	   Chapter	   3	   lead	  me	   to	   focus	   on	   the	  mitochondria	   and	   as	  
such,	   macrophage	   metabolism.	   HVCN1-­‐deficiency	   has	   previously	   been	   shown	   to	  
impair	  metabolism	  in	  activated	  B	  cells	  (Capasso	  et	  al.,	  2010).	  I	  sought	  to	  investigate	  
the	  impact	  of	  elevated	  basal	  ROS	  and	  attenuated	  mitochondrial	  membrane	  potential	  
on	  macrophage	  metabolism.	  	  	  
In	   agreement	   with	   the	   mitochondrial	   membrane	   potential	   data,	   Hvcn1-­‐/-­‐	  
macrophages	  in	  the	  steady	  state	  used	  significantly	  lower	  mitochondrial	  respiration	  in	  
comparison	   to	   WT	   macrophages.	   No	   differences	   were	   observed	   in	   regards	   to	  
glycolytic	  flux	  in	  the	  steady	  state.	  Both	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages	  switched	  from	  
oxidative	  metabolism	  to	  anaerobic	  glycolysis	  upon	  LPS	  stimulation,	  however	  the	  cells	  
lacking	  the	  channel	  were	  able	  to	  increase	  their	  rate	  of	  glycolysis	  to	  a	  further	  extent.	  
This	  may	   indicate	   that	   the	  Hvcn1-­‐/-­‐	  macrophages	  are	   in	   a	   state	  of	  hyper	   reactivity,	  
due	  to	  a	  greater	  volume	  of	  ROS	  signalling	  molecules,	  and	  can	  thus	  induce	  a	  greater	  
rate	   of	   glycolysis	   (Bulua	   et	   al.,	   2011).	   This	   highlights	   the	   fact	   that	   there	  might	   be	  
mitochondrial	  impairment	  in	  Hvcn1-­‐/-­‐	  macrophages	  as	  glycolysis	  occurs	  in	  the	  cytosol	  
whilst	  oxidative	  phosphorylation	  occurs	  within	  the	  mitochondrial	  matrix	  (Papa	  et	  al.,	  
2012).	  	  
Significantly	   lower	   levels	   of	   ATP	   were	   detected	   in	   Hvcn1-­‐/-­‐	   macrophages,	   which	  
supports	  the	  findings	  of	  attenuated	  mitochondrial	  respiration.	  Interestingly,	  Hvcn1-­‐/-­‐	  
cells	   had	   lower	   ATP	   levels	   even	   after	   LPS	   stimulation	   despite	   having	   a	   greater	  
induction	   of	   glycolytic	   flux.	   It	   is	   possible	   that	   the	   lower	   ATP	   levels	   are	   due	   to	   an	  
increased	  ATP	  consumption.	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I	   hypothesised	   that	   differences	   in	   mitochondrial	   biomass	   may	   give	   rise	   to	   the	  
observations	   I	   had	   made	   previously.	   A	   greater	   quantity	   of	   mitochondria	   could	  
account	   for	   the	   greater	   ROS	   production	   that	   is	   observed	   in	  Hvcn1-­‐/-­‐	  macrophages	  
whilst	   lower	   quantities	   of	   mitochondria	   could	   correlate	   with	   reduced	   levels	   of	  
mitochondrial	   respiration.	   However,	   we	   found	   similar	   levels	   of	   mitochondrial	  
biomass	  in	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages	  at	  steady	  state	  and	  after	  LPS	  activation.	  It	  
has	  been	  shown	  that	  mitochondrial	  biogenesis	  factors,	  such	  as	  proliferator-­‐activated	  
receptor-­‐ϒ	   coactivator	   1α	   (PGC1α),	   regulate	   both	   mitochondrial	   biomass	   and	   the	  
expression	  of	   several	   antioxidant	  enzymes	   in	  macrophages	   (Vats	   et	   al.,	   2006).	   It	   is	  
therefore	   thought	   that	  mitochondrial	   biomass	   is	   not	   an	   important	   factor	   in	   terms	  
regulating	  mitochondrial	  ROS.	  	  
The	  elevated	  basal	  mitochondrial	  ROS	  levels	  observed	  in	  Hvcn1-­‐/-­‐	  macrophages	  may	  
be	  present	  during	  their	  maturation	  process	  from	  monocytes.	  Mitochondrial	  DNA	  is	  in	  
close	   proximity	   to	   the	   ETC	   and	   can	   potentially	   acquire	   mutations	   in	   response	   to	  
damaging	   ROS	   (Shokolenko	   et	   al.,	   2009).	   Mitochondrial	   DNA	   encodes	   all	   of	   the	  
complex	  proteins;	  expect	  for	  complex	  II,	  which	  is	  encoded	  by	  nuclear	  DNA	  (Bai	  et	  al.,	  
2004).	  It	  was	  therefore	  imperative	  to	  assess	  the	  protein	  expression	  levels	  of	  the	  ETC	  
complexes.	  No	  differences	  in	  expression	  levels	  of	  the	  ETC	  complexes	  were	  observed	  
between	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages.	  This	  suggests	  that	  the	  mitochondrial	  defects	  
observed	  in	  the	  latter	  are	  not	  due	  to	  changes	  in	  complex	  proteins.	  It	  could	  be	  argued	  
that	   the	  activity	  of	   individual	   complex	  proteins	  might	  be	  affected	  and	  as	   such	   this	  
could	   be	   addressed	   by	   investigating	   isolated	   mitochondria	   from	   both	   types	   of	  
macrophages.	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It	   is	   important	   for	   immune	   cells	   to	   rapidly	   respond	   to	   environmental	   stimuli	   to	  
perform	  their	  functions	  and	  as	  such	  they	  need	  to	  be	  able	  to	  manage	  increased	  levels	  
of	  stress	  or	  energy	  demand.	  In	  those	  instances,	  the	  SRC	  is	  believed	  to	  be	  involved	  in	  
both	  cellular	  survival	  and	  function	  (van	  der	  Windt	  et	  al.,	  2012,	  Nicholls,	  2009).	  Hvcn1-­‐
/-­‐	   macrophages	   were	   found	   to	   have	   a	   diminished	   SRC,	   which	   provides	   further	  
confirmation	  that	   their	  mitochondria	  may	  be	  defective.	  Despite	   this,	   I	  observed	  no	  
effects	   on	   cell	   survival	   in	   response	   to	   LPS.	   It	   has	   been	   shown	   in	   other	   myeloid	  
populations	   that	   the	   loss	  of	   SRC	   following	   LPS	   stimulation	  was	   found	   to	  be	  due	   to	  
inhibition	  of	  oxidative	  phosphorylation	  by	  nitric	  oxide	  (NO),	  which	  constitutes	  part	  of	  
the	  glycolytic	  shift	  observed	  in	  myeloid	  cells	  after	  activation	  (Everts	  et	  al.,	  2012).	  
My	   investigations	   into	   the	   metabolism	   of	   Hvcn1-­‐/-­‐	   macrophages	   found	   a	  
mitochondrial	   defect	   in	   these	   cells.	   Both	   cellular	   metabolism	   and	   ATP	   production	  
was	   affected.	   With	   an	   observed	   overproduction	   of	   mitochondrial	   ROS	   and	  
attenuated	   cellular	   metabolism	   in	   Hvcn1-­‐/-­‐	   macrophages,	   I	   next	   wanted	   to	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5.1 INTRODUCTION	  
Until	  recently,	  ROS	  where	  thought	  to	  exclusively	  cause	  damaging	  effects	  on	  cellular	  
proteins	   and	   lack	   a	   physiological	   function.	   However,	   ROS	   are	   now	   appreciated	   to	  
function	  as	  signalling	  molecules	  that	  can	  modulate	  cellular	  processes	  through	  redox-­‐
dependent	  signalling	  (Sena	  and	  Chandel,	  2012).	  	  
A	   great	   deal	   of	   evidence	   indicates	   that	   ROS	   can	   regulate	   signalling	   pathways	   by	  
causing	   reversible	   protein	   modifications.	   Hydrogen	   peroxide	   oxidation	   of	   cysteine	  
groups	   can	   alter	   the	   DNA	   binding	   activity	   of	   transcription	   factors,	   protein-­‐protein	  
interactions	   and	   affect	   the	   catalytic	   activity	   of	   enzymes	   (Brandes	   et	   al.,	   2009).	  
Phosphatases	   are	   particularly	   susceptible	   to	   regulation	   by	   ROS	   as	   they	   posses	   a	  
reactive	   cysteine	   in	   their	   catalytic	   domains.	   These	   enzymes	   inhibit	   protein	   kinases	  
through	  the	  processes	  of	  dephosphorylation,	  thus	  oxidation	  of	  their	  cysteine	  residue	  
inhibits	   the	   enzymatic	   activity	   of	   phosphatases	   (Janssen-­‐Heininger	   et	   al.,	   2008).	  
Some	   notable	   examples	   of	   susceptible	   phosphatases	   are	   protein	   tyrosine	  
phosphatase	   1b	   (PTP1b)	   (Lee	   et	   al.,	   1998),	   PTEN	   (Kwon	   et	   al.,	   2004)	   and	   MAPK	  
phosphatases	  (Levinthal	  and	  Defranco,	  2005).	  	  	  	  	  	  
MAPKs	   are	   crucial	   for	   relaying	   extracellular	   signals	   to	   the	   nucleus	   and	   accomplish	  
this	  through	  a	  number	  of	  phosphorylation	  events,	  which	  are	  negatively	  regulated	  by	  
MAPK	  phosphatases	   (Cargnello	   and	  Roux,	   2011).	   Three	   subgroups	  of	  MAPKs	   exist:	  
the	   extracellular	   signal	   regulated	   kinases	   (ERKs),	   the	   JNKs,	   and	   the	   p38	   MAPKs.	  
MAPKs	  are	  involved	  in	  several	  cellular	  functions	  such	  as	  cell	  survival,	  differentiation	  
and	   inflammatory	   responses	   (Boutros	   et	   al.,	   2008).	   A	   number	   of	   studies	   have	  
demonstrated	   ROS-­‐induced	   MAPK	   activation	   and	   this	   is	   further	   evident	   as	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antioxidants	  have	  been	  shown	  to	  inhibit	  MAPK	  activation	  after	  cell	  stimulation	  (Ding	  
et	   al.,	   2010).	   ROS	   have	   also	   been	   indicated	   in	   the	   pro-­‐inflammatory	   cytokine	  
production	  of	  macrophages	  through	  their	  activation	  of	  MAPKs	  (Kasahara	  et	  al.,	  2011,	  
Emre	  et	  al.,	  2007).	  
The	  NF-­‐κB	  signalling	  pathway	  plays	  a	  highly	  important	  role	  in	  the	  immune	  system	  as	  
it	   regulates	   the	  expression	  of	  a	  number	  of	  genes	   involved	   in	   inflammation	  such	  as	  
those	   for	   cytokines	  and	  growth	   factors	   (Li	   and	  Verma,	  2002).	   The	  members	  of	   the	  
NF-­‐κB	   family	  are	   found	   in	   the	  cytoplasm	  of	  cells	  bound	  to	   IκB	   family	  proteins.	  This	  
prevents	  the	  NF-­‐κB	  proteins	  to	  translocate	  to	  the	  nucleus,	  thus	  inhibiting	  activation	  
of	   the	   pathway	   (Hayden	   and	   Ghosh,	   2004).	   NF-­‐κB	   signalling	   can	   occur	   through	   a	  
classical	   or	   alternative	   pathway.	   In	   the	   classical	   pathway	   of	   NF-­‐κB	   activation,	  
stimulation	  of	  the	  TLR4,	  for	  example,	  activates	  the	  IκB	  kinase	  (IKK)	  β	  complex.	  This	  in	  
turn	   phosphorylates	   IκB	   proteins,	   which	   are	   targeted	   for	   degradation	   by	   the	  
ubiquitin	   ligases	   (Figure	   5	   –	   0).	   In	   the	   case	   of	   the	   alternative	   activation,	   IKKα	  
phosphorylates	   the	   p100	   NF-­‐κB	   protein,	   which	   is	   processed	   by	   the	   proteasome	  
(Bonizzi	   and	   Karin,	   2004).	   Several	   novel	  mechanisms	   have	   been	   reported	   for	   ROS-­‐
induced	  NF-­‐κB	  activation	   such	  as	   tyrosine	  phosphorylation	  of	   IκB,	  activation	  of	   IKK	  
and	   serine	   phosphorylation	   of	   p65	   (Takada	   et	   al.,	   2003).	   Studies	   have	   shown	   that	  
ROS	  can	  regulate	  the	  production	  of	  cytokines,	  such	  as	  TNF,	  in	  macrophages	  through	  
its	  actions	  on	  the	  NF-­‐κB	  signalling	  pathway(Rose	  et	  al.,	  2000)	  (Bulua	  et	  al.,	  2011).	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Figure	  5	  -­‐	  0	  LPS	  activation	  of	  the	  NF-­‐κB	  signalling	  pathway.	  
LPS	   activates	   TLR4	   on	   the	   plasma	  membrane	   of	  macrophages	   and	   this	   leads	   a	   to	  
downstream	  signalling	  cascade.	  Eventually	  the	  IKK	  complexes	  is	  phosphorylated	  and	  
it	   in	   turn	  phosphorylates	   the	  NF-­‐	   κB	   complex.	   Phosphorylation	  of	   IκB	   results	   in	   its	  
ubiquitination	  and	  degradation	  by	  proteasomes.	  This	  releases	  the	  p50/p65	  complex	  
and	  allows	  it	  to	  enter	  the	  nucleus	  where	  it	  binds	  to	  the	  NF-­‐	  κB	  binding	  motif,	  which	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5.2 AIMS	  
This	   chapter	   describes	   my	   investigations	   into	   the	   impact	   of	   HVCN1-­‐deficiency	   in	  
macrophages	   on	   redox	   signalling	   pathways	   and	   potential	   effects	   on	   cytokine	  
production.	  My	  aims	  were	  to	  address	  the	  following	  questions:	  
• Does	   the	   overproduction	   of	   mitochondrial	   ROS	   observed	   in	   Hvcn1-­‐/-­‐	  
macrophages	   affect	   the	   redox	   signalling	   of	   the	   MAP	   Kinase	   and	   NF-­‐κB	  
pathways?	  	  
• What	  role	  does	  NADPH	  oxidase-­‐dependent	  ROS	  and	  mitochondrial	  ROS	  play	  
in	  macrophage	  redox	  signalling?	  	  
• Does	   the	  overproduction	  of	  mitochondrial	   ROS	  and	  attenuated	  metabolism	  
observed	  in	  Hvcn1-­‐/-­‐	  macrophages	  affect	  cytokine	  production?	  
• What	  role	  does	  NADPH	  oxidase-­‐dependent	  ROS	  and	  mitochondrial	  ROS	  play	  
in	  cytokine	  production	  in	  macrophages?	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5.2.1 ENHANCED	  REDOX	  SIGNALLING	  IN	  Hvcn1-­‐/-­‐	  MACROPHAGES	  
Given	   the	   findings	   of	   Chapters	   3	   and	   4,	   I	   wanted	   to	   investigate	   if	   elevated	  
mitochondrial	   ROS	   levels	   and	   impaired	   mitochondrial	   respiration	   would	   affect	  
cellular	  signalling	  pathways	  and	  a	  crucial	  macrophage	  function,	  cytokine	  production.	  	  
LPS	   activation	   of	   macrophages	   triggers	   a	   cascade	   of	   signalling	   that	   involves	   the	  
MAPKs	  (ERK,	  JNK,	  and	  p38)	  as	  well	  as	  the	  NF-­‐κB	  pathway	  (Emre	  et	  al.,	  2007).	  These	  
signalling	  pathways	  have	  been	  shown	   in	  macrophages	  to	  be	  redox-­‐sensitive	  and	  as	  
such	  would	  be	  susceptible	  to	  the	  increased	  mitochondrial	  ROS	  production	  observed	  
in	   the	  Hvcn1-­‐/-­‐	  macrophages.	   I	   therefore	   decided	   to	   investigate	   the	   activation	   and	  
kinetics	  of	  these	  two	  pathways.	  
Stimulation	  of	  WT	  macrophages	  with	  LPS	  resulted	  in	  the	  phosphorylation	  of	  p44/p42	  
MAPK	   within	   15	   minutes	   after	   addition	   of	   the	   stimulus.	   Phosphorylation	   of	   the	  
protein	  was	   sustained	   for	   at	   least	   15	  minutes,	   and	  was	   followed	  by	   a	  pronounced	  
decline	  in	  phosphorylation	  at	  60	  minutes	  post	  stimulation	  (Figure	  5-­‐1A).	  In	  contrast,	  
Hvcn1-­‐/-­‐	  macrophages	  showed	  a	   faster	  kinetic	   that	  was	  evident	  by	  phosphorylation	  
of	  p44/p42	  MAPK	  at	  5	  minutes	  after	  LPS	  stimulation.	  Peak	  activation	  was	  reached	  at	  
15	   minutes,	   similar	   to	   WT	   macrophages,	   but	   the	   phosphorylation	   was	   sustained	  
even	  at	  60	  minutes	  (Figure	  5-­‐1A).	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Figure	  5-­‐1	  Enhanced	  MAPK	  signalling	  in	  Hvcn1-­‐/-­‐	  macrophages	  in	  response	  to	  LPS.	  
WT	  and	  Hvcn1-­‐/-­‐	  BMDMs	  were	  treated	  with	  (A)	  100	  ng/ml	  LPS	  or	  (B)	  pre-­‐treated	  with	  
100	   μM	   Mito-­‐TEMPO	   for	   1	   hour	   before	   stimulation	   with	   100	   ng/ml	   LPS	   for	   the	  
indicated	  time	  points	  after	  which	  ERK,	  SAPK/JNK	  and	  p38	  MAPK	  phosphorylation	  was	  
measured	   by	   Western	   Blot.	   Data	   are	   representative	   of	   two	   independent	  
experiments.	  	  
	  
A	   similar	   activation	   pattern	   was	   observed	   for	   the	   SAPK/JNK	   pathway.	   For	   WT	  
macrophages	   phosphorylation	   of	   SAPK/JNK	   occurred	   at	   the	   10	   minutes	   mark,	  
reached	   peak	   activation	   at	   15	   minutes,	   and	   rapidly	   declined	   after	   reaching	   peak	  
activation.	   Almost	   complete	   de-­‐phosphorylation	   of	   SAPK/JNK	   was	   observed	   at	   60	  
minutes	   after	   LPS	   stimulation	   (Figure	   5-­‐1A).	   In	   macrophages	   lacking	   the	   proton	  
channel	  activation	  of	  the	  pathway	  occurred	  after	  5	  minutes	  and	  only	  reached	  peak	  
activation	   at	   the	   30	  minutes	  mark.	  Whilst	   there	  was	   decline	   from	   that	   time	   point	  
onwards,	  a	  great	  deal	  of	  phosphorylated	  protein	  was	  still	  observed	  after	  60	  minutes	  
(Figure	  5-­‐1A).	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No	   apparent	   differences	   in	   phosphorylation	   kinetics	   between	   WT	   and	   HVCN1-­‐/-­‐	  
macrophages	  were	  evident	  for	  the	  p38	  MAPK	  pathway.	  	  
As	   discussed	   previously,	   NF-­‐κB	   is	   a	   transcription	   factor	   that	   is	   sequestered	   in	   the	  
cytoplasm	   by	   IκBα,	   which	   is	   targeted	   for	   proteosomal	   degradation	   after	   it	   is	  
phosphorylated.	   In	  WT	  macrophages	   IκBα	  was	  phosphorylated	  after	  5	  minutes	  and	  
the	  total	  protein	  was	  completely	  degraded	  by	  10	  minutes	  (Figure	  5-­‐2A).	  However,	  in	  
Hvcn1-­‐/-­‐	  macrophages	   a	   basal	   phosphorylated	   state	   of	   IκBα	  was	   evident.	   This	   also	  
meant	   that	   the	  protein	  was	   completely	  degraded	  after	  5	  minutes	   (Figure	  5-­‐2A).	   In	  
both	   cell	   types,	   a	   phosphorylation/degradation	   ’loop’	   was	   observed,	   but	   this	  
occurred	   at	   a	   later	   time	   point	   in	   the	  Hvcn1-­‐/-­‐	  macrophages	   compared	   to	   their	  WT	  
counterpart.	  	  
	  
Figure	  5-­‐2	  Enhanced	  NF-­‐κB	  signalling	  in	  Hvcn1-­‐/-­‐	  macrophages	  in	  response	  to	  LPS.	  
WT	  and	  Hvcn1-­‐/-­‐	  BMDMs	  were	  treated	  with	  (A)	  100	  ng/ml	  LPS	  or	  (B)	  pre-­‐treated	  with	  
100	   μM	   Mito-­‐TEMPO	   for	   1	   hour	   before	   stimulation	   with	   100	   ng/ml	   LPS	   for	   the	  
indicated	  time	  points	  after	  which	  IκBα	  and	  IKKα/β	  phosphorylation	  was	  measured	  by	  
Western	  Blot.	  Data	  are	  representative	  of	  two	  independent	  experiments.	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A	  basal	   phosphorylation	  of	   IKKα/β	  was	   also	  observed	   in	   the	  Hvcn1-­‐/-­‐	  macrophages	  
(Figure	  5-­‐2).	  Considerable	  phosphorylation	  was	  sustained	  over	  the	  5	  minutes	  and	  10	  
minutes	   time	   points.	   In	   contrast,	   activation	   occurred	   at	   5	   minutes	   in	   WT	  
macrophages,	  but	  a	  great	  amount	  of	  phosphorylated	  protein	  could	  only	  be	  detected	  
at	  the	  10	  minutes	  mark	  after	  which	  there	  was	  a	  decline	  (Figure	  5-­‐2A).	  	  
Mitochondrial	  ROS	  have	  previously	  been	  reported	  to	  affect	  redox-­‐sensitive	  signalling	  
pathways	  by	  inhibiting	  phosphatases	  (Kamata	  et	  al.,	  2005,	  Murphy	  et	  al.,	  2011).	  We	  
therefore	   wanted	   to	   determine	   if	   Mito-­‐TEMPO	   could	   ‘rescue’	   the	   enhanced	  
signalling	   observed	   in	   HVCN1-­‐/-­‐	   BMDMs.	   Indeed,	   this	   antioxidant	   was	   able	   to	  
attenuate	   the	   aberrant	   signalling	   in	   these	   cells	   (Figure	   5-­‐1B	   and	   Figure	   5-­‐2B).	  
Antioxidant	  treatment	  also	  affected	  normal	  cell	  signalling	  by	  slowing	  the	  activation	  
kinetics	  of	  the	  proteins	  in	  the	  MAPK	  and	  NF-­‐κB	  pathways.	  	  
These	   results	  were	   further	   confirmed	  by	  densitometry	   analysis	   of	   the	  blots,	  which	  
showed	   significantly	   faster	   phosphorylation	   kinetics	   in	   the	   Hvcn1-­‐/-­‐	   macrophages	  
compared	   to	   their	  WT	   counterparts	   (Figure	   5	   –	   3A).	   This	   enhanced	   signalling	  was	  
abrogated	  in	  the	  presence	  of	  Mito-­‐TEMPO	  (Figure	  5	  –	  3B).	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Figure	   5	   -­‐	   3	  Densitometry	   analysis	   of	   phosphorylation	  events	   in	  WT	  and	  Hvcn1-­‐/-­‐	  
macrophages.	  	  
Densitometry	  results	  of	  phosphorylation	  events	  in	  the	  (A)	  absence	  and	  (B)	  presence	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In	   contrast,	   treatment	   with	   the	   NADPH	   oxidase	   inhibitor	   Apocynin	   did	   not	  
significantly	   affect	   signalling	   (Figure	   5	   -­‐	   4A	   and	   B).	   These	   results	   were	   further	  
confirmed	  by	  densitometry	  analysis	  of	  the	  blots,.	  
	  
	  
Figure	  5	  -­‐	  4	  Apocynin	  does	  not	  significantly	  affect	  cell	  signalling	  in	  macrophages	  in	  
response	  to	  LPS>	  
WT	   and	  Hvcn1-­‐/-­‐	   BMDMs	   were	   pre-­‐treated	   with	   100	   μM	  Mito-­‐TEMPO	   for	   1	   hour	  
before	  stimulation	  with	  100	  ng/ml	  LPS	  for	  the	  indicated	  time	  points	  after	  which	  (A)	  
ERK,	   SAPK/JNK	   and	   p38	   MAPK	   and	   (B)	   IκBα	   and	   IKKα/β	   phosphorylation	   was	  
measured	   by	   Western	   Blot.	   Data	   are	   representative	   of	   two	   independent	  
experiments.	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Figure	   5	   -­‐	   5	  Densitometry	   analysis	   of	   phosphorylation	  events	   in	  WT	  and	  Hvcn1-­‐/-­‐	  
macrophages.	  	  
Densitometry	   results	   of	   phosphorylation	  events	   in	   the	  presence	  of	  Apocynin.	  Data	  
represent	  means	  ±	  SEM	  of	  two	  independent	  experiments.	  *,	  p	  <	  0.05.	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5.2.2 INCREASED	  INFLAMMATORY	  CYTOKINE	  PRODUCTION	  IN	  Hvcn1-­‐/-­‐	  
MACROPHAGES	  
MAPKs	  are	  involved	  in	  several	  cellular	  functions	  such	  as	  cell	  survival,	  differentiation	  
and	   inflammatory	  responses	  (Boutros	  et	  al.,	  2008).	  The	  NF-­‐κB	  signalling	  pathway	   is	  
also	   very	   important	   in	  macrophages	   as	   it	   regulates	   the	   expression	  of	   a	   number	  of	  
genes	   involved	   in	   inflammation	   such	   as	   those	   for	   cytokines	   and	   growth	   factors	   (Li	  
and	  Verma,	  2002).	  To	  further	  assess	  the	  impact	  of	  the	  enhanced	  redox	  signalling	  that	  
was	   observed	   in	   Hvcn1-­‐/-­‐	   macrophages,	   I	   measured	   cytokine	   production	   in	  
macrophages	  stimulated	  with	  LPS.	  	  
I	   found	  that	  there	  was	  an	  overproduction	  of	  the	  cytokines	   IL-­‐6,	   IL-­‐10,	   IL-­‐12p40	  and	  
TNFα	  by	  the	  Hvcn1-­‐/-­‐	  macrophages	  compared	  to	  WT	  cells.	  Mito-­‐TEMPO	  significantly	  
blocked	   cytokine	   production	   in	   both	   cell	   types,	   decreasing	   production	   to	   similar	  
levels	  (Figure	  5	  –	  6).	  This	   is	  consistent	  with	  the	  ‘rescued’	  cell	  signalling	  observed	  in	  
the	  Hvcn1-­‐/-­‐	  macrophages	   in	   the	  presence	  of	  Mito-­‐TEMPO.	   In	   accordance	  with	   the	  
delayed	   signalling	   activation	   kinetics	   observed,	   there	   was	   decreased	   cytokine	  
production	  in	  WT	  macrophages.	  ROS	  have	  been	  previously	  implicated	  to	  play	  a	  role	  
in	  the	  normal	  inflammatory	  response	  to	  LPS	  stimulation	  (Finkel,	  2012).	  	  
Apocynin	   treatment	   did	   not	   affect	   IL-­‐6,	   TNFα	   or	   IL-­‐12p40	   production,	   whereas	   it	  
significantly	   attenuated	   IL-­‐10	   production	   in	   both	   WT	   and	   Hvcn1-­‐/-­‐	   macrophages	  
(Figure	   5	   –	   5).	   This	   is	   consistent	   with	   previous	   observations	   showing	   little	  
contribution	   by	   NADPH	   oxidase-­‐dependent	   ROS	   on	   inflammatory	   cytokine	  
production	  (Bulua	  et	  al.,	  2011).	  These	  results	  suggest	  a	  role	  for	  HVCN1	  in	  modulating	  
the	  intensity	  of	  the	  inflammatory	  response	  to	  LPS	  in	  macrophages.	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Figure	  5	  -­‐	  6	  Mitochondrial	  ROS	  are	  involved	  in	  LPS-­‐induced	  cytokine	  production	  in	  
macrophages.	  	  
WT	   and	   Hvcn1-­‐/-­‐	   BMDMs	   were	   untreated	   or	   pre-­‐treated	   with	   the	   indicated	  
compounds	  for	  1	  hour	  before	  activation	  with	  100	  ng/ml	  LPS	  for	  6	  hours.	  IL-­‐6,	  IL-­‐10,	  
TNFα	  and	  IL-­‐12p40	  levels	  were	  measured	  in	  culture	  supernatants.	  Statistical	  analysis	  
was	  performed	  between	  groups	   (indicated	  by	   lines)	  and	  also	   to	  untreated	  WT	  and	  
Hvcn1-­‐/-­‐	  BMDMs,	  respectively	  (indicated	  by	  */NS	  above	  bars)	  Data	  represent	  means	  




CHAPTER	  5	   REDOX-­‐SENSITIVE	  SIGNALLING	  PATHWAYS	  
	   165 
5.3 CHAPTER	  DISCUSSION	  
Redox	  signalling	  can	  occur	  when	  there	  is	  a	  change	  in	  the	  levels	  of	  ROS	  in	  a	  biological	  
system	   (Hamanaka	   and	   Chandel,	   2010).	   For	   years	   ROS	   were	   simply	   viewed	   as	  
damaging	  agents	   in	  pathology,	  but	  more	  recent	  studies	  have	  found	  that	  some	  ROS	  
can	  act	  as	  intracellular	  signalling	  molecules	  (Reth,	  2002).	  Mitochondria	  are	  therefore	  
acknowledged	   as	   important	   redox	   signalling	   nodes	   partly	   because	   of	   their	  
production	   of	   ROS,	   but	   also	   because	   of	   their	   central	   role	   in	   cellular	   metabolism	  
(Finkel,	  2012).	  
The	  MAPK	  and	  NF-­‐κB	  pathways	  are	  known	  to	  be	  redox-­‐sensitive	  signalling	  pathways	  
(Son	  et	  al.,	  2011,	  Forman	  and	  Torres,	  2002).	  Hydrogen	  peroxide	  oxidation	  of	  cysteine	  
groups	   can	   alter	   the	   DNA	   binding	   activity	   of	   transcription	   factors,	   protein-­‐protein	  
interactions	   and	   affect	   the	   catalytic	   activity	   of	   enzymes	   (Brandes	   et	   al.,	   2009).	  
Phosphatases	   are	   particularly	   susceptible	   to	   regulation	   by	   ROS	   as	   they	   posses	   a	  
reactive	   cysteine	   in	   their	   catalytic	   domains.	   These	   enzymes	   inhibit	   protein	   kinases	  
through	  the	  processes	  of	  dephosphorylation,	  thus	  oxidation	  of	  their	  cysteine	  residue	  
inhibits	   the	   enzymatic	   activity	   of	   phosphatases	   (Janssen-­‐Heininger	   et	   al.,	   2008).	  
Some	   notable	   examples	   of	   susceptible	   phosphatases	   are	   protein	   tyrosine	  
phosphatase	   1b	   (PTP1b)	   (Lee	   et	   al.,	   1998),	   PTEN	   (Kwon	   et	   al.,	   2004)	   and	   MAPK	  
phosphatases	  (Levinthal	  and	  Defranco,	  2005).	  	  	  	  	  	  
Cell	  signalling	  studies	  of	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages	  showed	  that	  the	  cells	  lacking	  
proton	  channels	  displayed	  quicker	  activation	  kinetics	  as	  well	  as	  sustained	  activation	  
compared	  to	  their	  WT	  counterparts.	  This	  was	  true	  for	  both	  the	  MAPKs	  investigated	  
and	  the	  NF-­‐κB	  signalling	  pathway.	  I	  hypothesised	  that	  the	  enhanced	  signalling	  seen	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in	   the	   Hvcn1-­‐/-­‐	   macrophages	   could	   potentially	   be	   abrogated	   with	   the	   use	   of	   a	  
mitochondrial	  ROS	  scavenger.	  In	  the	  presence	  of	  Mito-­‐TEMPO,	  I	  was	  able	  to	  ‘restore’	  
the	   signalling	   in	  Hvcn1-­‐/-­‐	   macrophages.	   However,	   as	   mitochondrial	   ROS	  molecules	  
are	   important	   redox	   signalling	   agents,	   the	   addition	   of	   Mito-­‐TEMPO	   slowed	   the	  
activation	   kinetics	  of	   both	   the	  WT	  and	   the	  Hvcn1-­‐/-­‐	  macrophages.	   Previous	   studies	  
have	   found	   similar	   results	  with	   the	   use	   of	   general	   and	  mitochondrial-­‐specific	   ROS	  
scavengers	   (Bulua	   et	   al.,	   2011).	   In	   contrast,	   treatment	   with	   Apocynin	   did	   not	  
significantly	  affect	  signalling,	  which	  is	  in	  accordance	  with	  the	  literature	  (Zhou	  et	  al.,	  
2011).	  	  
The	  MAPKs	  and	  the	  NF-­‐κB	  signalling	  pathway	  are	  important	  for	  several	  macrophage	  
functions,	  such	  as	  cytokine	  production	  (Boutros	  et	  al.,	  2008,	  Li	  and	  Verma,	  2002).	   I	  
therefore	   investigated	   the	   levels	   of	   IL-­‐6,	   IL-­‐10,	   TNF,	   and	   IL-­‐12p40.	   I	   observed	   a	  
significant	   increase	   in	   cytokine	   production	   in	   the	   Hvcn1-­‐/-­‐	   macrophages.	   In	  
accordance	   with	   the	   cell	   signalling	   data,	   the	   addition	   of	   Mito-­‐TEMPO	   ‘restored’	  
cytokine	   production	   by	   reducing	   the	   output	   to	   similar	   levels	   in	   both	   cell	   types.	   I	  
would	  expect	   that	   this	  would	  affect	  cytokine	  production	   in	  WT	  cell	  because	  of	   the	  
slowed	   cell	   signalling	  activation	   kinetics	   seen	   in	   the	  presence	  of	   the	  mitochondrial	  
ROS	   scavenger.	   Inhibition	   of	   the	   NADPH	   oxidase	   by	   Apocynin	   only	   decreased	   the	  
production	  of	   IL-­‐10	   in	  both	  cell	   type.	   	  This	   is	  an	   interesting	   result	  as	   it	   is	   generally	  
accepted	   that	   NADPH	   oxidase-­‐dependent	   ROS	   contribute	   little	   to	   inflammatory	  
cytokine	   production	   (Bulua	   et	   al.,	   2011).	   Further	   investigations	   into	   this	  would	   be	  
necessary	  to	  gain	  more	  insight	  into	  the	  mechanism.	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The	  importance	  of	  macrophages	  in	  the	  innate	  immune	  system	  has	  been	  recognised	  
for	  decades.	  Macrophages	  are	  often	  the	  first	  type	  of	  cell	  to	  encounter	  a	  pathogen	  or	  
foreign	   substance.	   They	   have	   the	   ability	   to	   ingest	   pathogens	   and	   particles	   via	  
phagocytosis,	   one	   of	   their	   most	   distinctive	   properties	   (Wynn	   et	   al.,	   2013).	  
Macrophages	   can	   detect	   these	   pathogens	   using	   a	   number	   of	   pattern	   recognition	  
receptors	   such	   as	   the	   toll-­‐like	   receptors.	   In	   addition,	   they	   have	   an	   arsenal	   of	  
antimicrobial	   effector	   mechanisms	   to	   eliminate	   pathogens	   including	   oxidation,	  
antimicrobial	   peptides	   and	   enzymatic	   degradation	   (Rees,	   2010).	   Macrophages	   are	  
also	   important	   in	  amplifying	   the	  adaptive	   immune	  response	   through	   their	  antigen-­‐
presenting	  abilities	  (Bonilla	  and	  Oettgen,	  2010).	  
Upon	   phagocyte	   activation,	   ROS	   are	   rapidly	   produced	   to	   destroy	   the	   engulfed	  
pathogen.	   The	   NADPH	   oxidase	   enzyme	   complex	   is	   crucial	   for	   the	   production	   of	   a	  
number	   of	   ROS	   such	   as	   superoxide	   and	   hydrogen	   peroxide	   (Lambeth,	   2004).	   This	  
process	  is	  highly	  dependent	  on	  voltage-­‐gated	  proton	  channels	  to	  extrude	  protons	  in	  
order	  to	  maintain	  pHi,	  as	  low	  pH	  levels	  can	  inhibit	  the	  activity	  of	  the	  NADPH	  oxidase	  
(Morgan	   et	   al.,	   2009).	   In	   addition,	   the	   extrusion	   of	   protons	   into	   the	   phagosome	  
allows	   for	   a	   number	   of	   chemical	   reactions	   to	   occur	   and	   thus	   produce	   potent	   ROS	  
(Ramsey	   et	   al.,	   2009).	   Voltage-­‐gated	   proton	   channels	   are	   thus	   involved	   in	   an	  
important	  mechanims	  of	  phagocyte-­‐mediated	  killing.	  	  	  
The	  voltage-­‐gated	  proton	  channel	  HVCN1	  is	  expressed	  in	  a	  number	  of	  immune	  cells	  
including	  granulocytes	  (Ramsey	  et	  al.,	  2009,	  Musset	  et	  al.,	  2008,	  Zhu	  et	  al.,	  2013),	  B	  
cells	  (Capasso	  et	  al.,	  2010),	  T	  cells	  (Sasaki	  et	  al.,	  2013),	  DCs	  (Szteyn	  et	  al.,	  2012)	  and	  
macrophages	   (Kapus	   et	   al.,	   1993,	   Holevinsky	   et	   al.,	   1994).	   However,	   the	   data	   on	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HVCN1	   in	  macrophages	   is	   based	   on	   electrophysiological	   studies	   that	   recorded	   ion	  
channel	   currents	   in	   the	   presence	   and	   absence	   of	   Zn2+,	   an	   unspecific	   inhibitor	   of	  
proton	  channels.	  My	  own	   investigations	   found	  HVCN1	  to	  be	  expressed	  at	  both	  the	  
mRNA	  and	  protein	   levels	   in	  murine	  macrophages,	  which	   is	   in	   accordance	  with	   the	  
electrophysiological	  data	  on	  these	  cells.	  	  
Previous	   published	   work	   has	   emphasised	   the	   crucial	   involvement	   of	   HVCN1	   in	  
NADPH	  oxidase-­‐mediated	  ROS	  production	  in	  phagocytes	  (Szteyn	  et	  al.,	  2012,	  Ramsey	  
et	  al.,	  2009)	  as	  well	  as	  in	  lymphocytes	  (Sasaki	  et	  al.,	  2013,	  Capasso	  et	  al.,	  2010).	  Of	  
note,	   elevated	   basal	   ROS	   levels	   were	   described	   in	   murine	   Hvcn1-­‐/-­‐	   B	   cells	   and	  
neutrophils	   (Capasso	  et	  al.,	  2010,	  Decleva	  et	  al.,	  2013).	   In	   the	  B	  cell	   study	  the	  ROS	  
were	   described	   as	   being	   of	   mitochondrial	   origin.	   Neither	   study	   investigated	   this	  
observation	  further.	  It	  may	  be	  that	  HVCN1-­‐deficiency	  causes	  a	  mitochondrial	  defect,	  
which	  leads	  to	  an	  overproduction	  of	  ROS.	  Indeed,	  in	  the	  Hvcn1-­‐/-­‐	  B	  cells	  attenuated	  
metabolism	  was	  observed	  upon	  BCR	  activation.	  However,	   this	  was	  not	  apparent	  at	  
steady	   state	   (Capasso	   et	   al.,	   2010).	   In	   a	   similar	   fashion,	   the	   pHi	   of	   Hvcn1-­‐/-­‐	  
neutrophils	  became	  greatly	  acidic	  upon	  activation	  (Morgan	  et	  al.,	  2009).	  It	  could	  be	  
suggested	   that	   an	   acidic	   pHi	   may	   damage	   intracellular	   organelles,	   such	   as	   the	  
mitochondria,	   leading	   to	   defects	   in	   their	   activity.	   Nonetheless,	   decreased	   pHi	   was	  
not	  observed	  at	  steady	  state.	   Interestingly,	   I	  observed	  elevated	  basal	  ROS	   levels	   in	  
murine	  Hvcn1-­‐/-­‐	  macrophages.	  I	  found	  these	  to	  be	  of	  a	  mitochondrial	  origin	  through	  
the	   use	   of	   specific	   pharmacological	   compounds.	   However,	   the	   data	   was	   not	  
instructive	  as	  to	  whether	  this	  was	  due	  to	  an	  overproduction	  of	  mitochondrial	  ROS	  or	  
due	  to	  the	  failure	  of	  antioxidant	  systems	  to	  scavenge	  the	  ROS.	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Elevated	   levels	   of	   ROS	   can	   induce	   increased	   expression	   of	   the	   mitochondrial	  
antioxidant	  enzyme	  SOD2	  in	  order	  to	  prevent	  potential	  injury	  from	  oxidative	  damage	  
(Miao	   and	   St	   Clair,	   2009).	   In	   assessing	   the	   protein	   expression	   levels	   of	   SOD2,	   I	  
observed	   no	   differences	   between	   WT	   and	   Hvcn1-­‐/-­‐	   macrophages	   at	   steady	   state.	  
Mitochondrial	   ROS	   have	   been	   indicated	   to	   act	   as	   signalling	   molecules	   to	   trigger	  
inflammatory	  cytokine	  production	  (Bulua	  et	  al.,	  2011,	  Nakahira	  et	  al.,	  2011,	  Zhou	  et	  
al.,	  2011),	  therefore	  LPS	  might	  regulate	  SOD2	  activity.	  However,	  no	  change	  in	  SOD2	  
protein	   expression	   levels	   were	   observed	   after	   LPS	   activation,	   indicating	   that	  
increased	  ROS	  are	  not	   inducing	   a	   feedback	  upregulation	  of	   SOD2	   in	  macrophages.	  
Whilst	  there	  might	  not	  be	  any	  differences	  in	  the	  amount	  of	  SOD2	  enzyme,	  its	  rate	  of	  
activity	  might	  be	  different.	  Investigating	  the	  specific	  activity	  of	  SOD2	  would	  provide	  a	  
better	   insight	   into	   the	   state	   of	   this	   antioxidant	   system	   in	   the	   mitochondria.	   In	  
addition,	   it	   would	   be	   important	   to	   assess	   other	   antioxidant	   enzymes,	   such	   as	  
glutathione	   peroxidase	   (GPx)	   and	   peroxiredoxins,	   and	   also	   cofactors,	   such	   as	  
glutathione	  levels	  (Li	  et	  al.,	  2013).	  	  
Mitochondrial	  ROS	  production	  has	  been	  described	  previously	  to	  be	  tightly	  regulated	  
by	  a	  number	  of	   factors,	  one	  of	   those	  being	  the	  mitochondrial	  membrane	  potential	  
(Echtay	  et	  al.,	  2002).	  A	  higher	  mitochondrial	  membrane	  potential	  is	  associated	  with	  
greater	   production	   of	   mitochondrial	   ROS,	   which	   is	   associated	   with	   increased	  
electron	   transport	   (Handy	   and	   Loscalzo,	   2012).	   However,	   a	   range	   of	   agents	   that	  
lower	   mitochondrial	   membrane	   potential	   (LPS,	   ETC	   inhibitors,	   etc.)	   paradoxically	  
increase	  mitochondrial	  ROS	  production.	  The	  exact	  mechanism	  for	  this	  disparity	  is	  not	  
well	  defined	  (West	  et	  al.,	  2011,	  Everts	  et	  al.,	  2012),	  however	  a	  “redox-­‐optimised	  ROS	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balance	   hypothesis”	   has	   been	   proposed	   to	   explain	   this	   paradox.	   It	   states	   that	  
oxidative	  stress	  can	  occur	  at	  either	  extremes	  of	  high	  or	  low	  mitochondrial	  potential	  
(Aon	  et	  al.,	  2010).	  This	  was	  the	  case	  in	  the	  Hvcn1-­‐/-­‐	  macrophages,	  where	  a	  reduced	  
mitochondrial	   membrane	   potential	   was	   observed	   compared	   to	   their	   WT	  
counterparts.	  These	  data	  would	  suggest	  that	  the	  increased	  basal	  ROS	  in	  the	  Hvcn1-­‐/-­‐	  
macrophages	   is	   due	   to	   an	   overproduction	   in	   the	   mitochondria	   and	   not	   due	   to	  
insufficient	  ROS	  scavenging.	  As	  mentioned	  above,	  SOD2	  is	  only	  one	  of	  a	  number	  of	  
antioxidant	   enzymes	   in	   place	   to	   scavenge	   ROS	   so	   further	   investigations	   into	   the	  
cellular	  antioxidant	  system	  would	  be	  necessary	  to	  arrive	  at	  a	  solid	  conclusion	  on	  the	  
matter.	  	  
As	   previously	   described,	   an	   impaired	   respiratory	   burst	   is	   associated	   with	  Hvcn1-­‐/-­‐	  
phagocytes.	   HVCN1	   is	   necessary	   for	   optimal	   respiratory	   burst	   in	   phagocytes	   as	   it	  
provides	   the	   charge	   compensation	   that	   is	   required	  during	   this	   process	   (Ramsey	   et	  
al.,	   2009).	   In	   accordance	   with	   the	   literature,	   Hvcn1-­‐/-­‐	   macrophages	   displayed	   an	  
impaired	   respiratory	   burst	   upon	   LPS	   activation.	   In	   neutrophils,	   the	   lack	   of	   proton	  
channels	  also	  resulted	  in	  an	  intracellular	  acidification,	  due	  to	  the	  activity	  of	  NADPH	  
oxidase	   in	   the	   absence	   of	   charge	   and	   pHi	   compensation	   (El	   Chemaly	   et	   al.,	   2010,	  
Morgan	  et	  al.,	  2009).	  HVCN1	  extrudes	  H+	  that	  rapidly	  accumulate	  in	  the	  cytosol	  and	  
delivers	  them	  into	  the	  phagosome,	  where	  they	  are	  used	  in	  crucial	  chemical	  reactions	  
to	   produce	   ROS	   (Morgan	   et	   al.,	   2009).	   This	   mechanism	   might	   be	   the	   same	   in	  
macrophages,	   but	   investigations	   into	   intracellular	   acidification	   during	   activation	   or	  
phagocytosis	  would	  need	  to	  be	  undertaken	  to	  confirm	  this.	  This	  can	  be	  accomplished	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through	   the	   use	   of	   ratiometric	   fluorescent	   indicators	   for	   intracellular	   pH,	   such	   as	  
carboxy-­‐SNARF,	  on	  either	  confocal	  microscopy	  or	  flow	  cytometry	  platforms.	  	  	  
A	   previous	   published	   study	   showed	   no	   differences	   in	   the	   capacity	   of	   Hvcn1-­‐/-­‐	  
neutrophils	  to	  phagocytose	  opsonised	  bacteria	  compared	  to	  WT	  cells	  (Ramsey	  et	  al.,	  
2009).	   In	   accordance,	   my	   own	   investigations	   showed	   no	   differences	   between	   the	  
phagocytic	   capacity	   of	   WT	   and	   Hvcn1-­‐/-­‐	   macrophages.	   It	   needs	   to	   be	   noted	   that	  
fluorescently-­‐labelled	  latex	  beads	  that	  are	  classically	  used	  in	  phagocytic	  assays,	  and	  
were	  also	  used	  in	  the	  present	  study,	  do	  not	  provide	  the	  cells	  with	  a	  metabolic	  load,	  
as	   the	   latex	  beads	  cannot	  be	  degraded	  by	   the	  cells.	  On	   the	  other	  hand,	  opsonised	  
bacteria	   or	   apoptotic	   cells	   are	   more	   physiologically	   relevant	   to	   the	   phagocytic	  
process	   as	   they	   do	   provide	   a	   metabolic	   load	   (Han	   and	   Ravichandran,	   2011).	  
Fluorescently-­‐labelled	  apoptotic	   thymocytes	   is	  another	   classical	  phagocytosis	  assay	  
used	  to	  determine	  phagocytic	  capacity.	  Nonetheless,	  given	  that	  no	  impairment	  was	  
observed	   in	  Hvcn1-­‐/-­‐	   neutrophil	   phagocytosing	   bacteria	   (Ramsey	   et	   al.,	   2009),	   it	   is	  
likely	   that	   this	   process	   is	   not	   linked	   to	   HVCN1	   regulation	   of	   ROS	   production	   and	  
therefore	  not	  regulated	  by	  proton	  channels.	  	  	  
Whilst	  electrophysiological	   studies	  of	  macrophages	  have	   indicated	   the	  presence	  of	  
HVCN1	   on	   the	   plasma	   membrane,	   no	   studies	   thus	   far	   have	   investigated	   the	  
subcellular	   localisation	  of	   the	  proton	  channel	   (Kapus	  et	  al.,	  1993,	  Holevinsky	  et	  al.,	  
1994).	  I	  observed	  it	  on	  the	  plasma	  membrane	  of	  macrophages	  and	  could	  not	  detect	  
any	  co-­‐localisation	  with	  mitochondrial	  markers.	  Therefore,	  the	  steady	  state	  increase	  
in	  mitochondrial	  ROS	  is	  not	  due	  to	  a	  direct	  role	  of	  HVCN1	  in	  macrophages.	  It	  might	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be	   due	   to	   the	   effect	   of	   cytosolic	   charge	   and	   pH	   balance,	   which	   might	   affect	  
mitochondrial	  function.	  	  
Mitochondrial	   ROS	   is	   generated	   from	   the	   ETC,	   which	   is	   located	   on	   the	   inner	  
mitochondrial	  membrane,	  during	  the	  process	  of	  OXPHOS	  (Murphy,	  2009).	  Whilst	  the	  
ETC	  is	  highly	  efficient	  in	  transporting	  electrons	  through	  the	  various	  complexes,	  there	  
is	  some	  leakage	  of	  electrons	  during	  the	  process.	  This	  leakage	  takes	  place	  at	  the	  sites	  
of	  complex	  I	  (Hirst	  et	  al.,	  2008)	  and	  complex	  III	   (Zhang	  et	  al.,	  1998),	  which	  leads	  to	  
the	   reduction	   of	   O2	   to	   form	   O2-­‐.	   Approximately	   2	   %	   of	   O2	   consumed	   by	   the	  
mitochondria	   during	   OXPHOS	   generates	   O2-­‐.	   Complex	   I	   leaks	   O2-­‐	   into	   the	  
mitochondrial	  matrix	  (Kussmaul	  and	  Hirst,	  2006)	  and	  the	  O2-­‐	  leaked	  from	  complex	  III	  
goes	  into	  both	  the	  mitochondrial	  matrix	  and	  the	  intermembrane	  space	  (Muller	  et	  al.,	  
2004).	   Cellular	   metabolism	   is	   thus	   closely	   linked	   to	   ROS	   production	   and	   it	   was	  
imperative	  to	  explore	  the	  metabolic	  state	  of	  Hvcn1-­‐/-­‐	  macrophages.	  To	  date,	  only	  one	  
study	  has	  assessed	  the	  effects	  of	  HVCN1-­‐deficiency	  on	  cellular	  metabolism	  (Capasso	  
et	  al.,	  2010).	  The	  study	  demonstrated	  that	  Hvcn1-­‐/-­‐	  B	  cells	  used	  the	  same	  amount	  of	  
mitochondrial	   respiration	   and	   glycolysis	   as	   their	   WT	   counterparts.	   However	   after	  
BCR	   stimulation,	   B	   cells	   lacking	   HVCN1	   used	   less	   mitochondrial	   respiration	   and	  
glycolysis	   than	   WT	   cells.	   This	   difference	   was	   not	   apparent	   when	   B	   cells	   were	  
stimulated	  with	  LPS	  or	  anti-­‐CD40.	  	  
My	  own	   investigations	   into	  the	  cellular	  metabolism	  of	  Hvcn1-­‐/-­‐	  macrophages	   found	  
decreased	   mitochondrial	   respiration	   in	   these	   cells	   at	   steady	   state.	   This	   is	   in	  
agreement	   with	   the	   mitochondrial	   membrane	   potential	   data,	   where	   a	   lower	  
potential	   was	   observed	   in	   Hvcn1-­‐/-­‐	   macrophages	   in	   the	   steady	   state.	   As	   the	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electrochemical	  gradient	  and	  thus	  the	  mitochondrial	  membrane	  potential	  increases,	  
a	  parallel	  increase	  is	  observed	  in	  mitochondrial	  ROS	  production	  (Handy	  and	  Loscalzo,	  
2012).	  However,	  it	  has	  been	  proposed	  that	  an	  increase	  in	  ROS	  production	  can	  occur	  
at	   both	   extremes	   of	   high	   and	   low	  mitochondrial	  membrane	   potential	   (Aon	   et	   al.,	  
2010).	   In	   addition,	   these	   processes	   are	   closely	   linked	   to	   ETC	   activity	   and	   as	   such	  
mitochondrial	   respiration.	   A	   high	   mitochondrial	   membrane	   potential	   is	   observed	  
with	  a	  high	  rate	  of	  ETC	  activity	  and	  mitochondrial	  respiration	  (Echtay	  et	  al.,	  2002).	  
Similar	   to	   WT	   macrophages,	   upon	   LPS	   activation	   Hvcn1-­‐/-­‐	   macrophages	   switched	  
their	  metabolic	  drive	  to	  glycolysis	  by	  decreasing	  their	  mitochondrial	  respiration	  and	  
increasing	  their	  glycolytic	  flux.	  However,	  Hvcn1-­‐/-­‐	  macrophages	  were	  able	  to	  reach	  a	  
significantly	  higher	   rate	  of	  glycolysis	   compared	   to	   their	  WT	  counterparts.	  This	  may	  
indicate	   that	   the	  Hvcn1-­‐/-­‐	  macrophages	   are	   in	   a	   state	   of	   hyper	   reactivity,	   due	   to	   a	  
greater	   volume	  of	  ROS	   signalling	  molecules,	   and	   can	   thus	   induce	  a	   greater	   rate	  of	  
glycolysis	   (Bulua	   et	   al.,	   2011).	   This	   highlights	   the	   fact	   that	   there	   might	   be	  
mitochondrial	  impairment	  in	  Hvcn1-­‐/-­‐	  macrophages	  as	  glycolysis	  occurs	  in	  the	  cytosol	  
whilst	  oxidative	  phosphorylation	  occurs	  within	  the	  mitochondrial	  matrix	  (Papa	  et	  al.,	  
2012).	  	  
In	   support	   of	   altered	  mitochondrial	   respiration,	   steady	   state	  ATP	   levels	   in	  Hvcn1-­‐/-­‐	  
macrophages	   were	   significantly	   lower	   compared	   to	   their	   WT	   counterparts.	  
Interestingly,	  Hvcn1-­‐/-­‐	   cells	   had	   lower	   ATP	   levels	   even	   after	   LPS	   activation	   despite	  
having	  a	  greater	  rate	  of	  glycolytic	  flux.	  It	  is	  possible	  that	  the	  lower	  ATP	  levels	  are	  due	  
to	  an	  increased	  ATP	  consumption.	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I	   hypothesised	   that	   differences	   in	   mitochondrial	   biomass	   may	   give	   rise	   to	   the	  
observations	   I	  had	  made	  about	  ROS	  production	  and	  cellular	  metabolism.	  A	  greater	  
quantity	   of	   mitochondria	   could	   account	   for	   the	   greater	   ROS	   production	   that	   is	  
observed	   in	   Hvcn1-­‐/-­‐	  macrophages	   whilst	   lower	   quantities	   of	   mitochondria	   could	  
correlate	  with	  reduced	  levels	  of	  mitochondrial	  respiration.	  However,	  I	  found	  similar	  
levels	  of	  mitochondrial	  biomass	  in	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages	  at	  steady	  state	  and	  
after	  LPS	  activation.	  This	  data	  provides	  further	  evidence	  that	  there	  is	  a	  mitochondrial	  
defect	  in	  Hvcn1-­‐/-­‐	  macrophages	  as	  the	  same	  numbers	  of	  mitochondria	  are	  producing	  
greater	   quantities	   of	   ROS	  whilst	   respiring	   at	   a	   lower	   rate.	   It	   has	   been	   shown	   that	  
mitochondrial	   biogenesis	   factors,	   such	   as	   proliferator-­‐activated	   receptor-­‐ϒ	  
coactivator	  1α	  (PGC1α),	  regulate	  both	  mitochondrial	  biomass	  and	  the	  expression	  of	  
several	   antioxidant	   enzymes	   in	   macrophages	   (Vats	   et	   al.,	   2006).	   It	   is	   therefore	  
thought	  that	  mitochondrial	  biomass	  is	  not	  an	  important	  factor	  in	  terms	  of	  regulating	  
mitochondrial	  ROS.	  	  
The	  elevated	  basal	  mitochondrial	  ROS	  levels	  observed	  in	  Hvcn1-­‐/-­‐	  macrophages	  may	  
be	  present	  during	  their	  maturation	  process	  from	  monocytes.	  Mitochondrial	  DNA	  is	  in	  
close	   proximity	   to	   the	   ETC	   and	   can	   potentially	   acquire	   mutations	   in	   response	   to	  
damaging	   ROS	   (Shokolenko	   et	   al.,	   2009).	   Mitochondrial	   DNA	   encodes	   all	   of	   the	  
complex	  proteins;	  expect	  for	  complex	  II,	  which	  is	  encoded	  by	  nuclear	  DNA	  (Bai	  et	  al.,	  
2004).	  It	  was	  therefore	  imperative	  to	  assess	  the	  protein	  expression	  levels	  of	  the	  ETC	  
complexes.	  No	  differences	  in	  expression	  levels	  of	  the	  ETC	  complexes	  were	  observed	  
between	  WT	  and	  Hvcn1-­‐/-­‐	  macrophages.	  This	  suggests	  that	  the	  mitochondrial	  defects	  
observed	  in	  the	  latter	  are	  not	  due	  to	  changes	  in	  complex	  proteins.	  It	  could	  be	  argued	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that	   the	  activity	  of	   individual	   complex	  proteins	  might	  be	  affected	  and	  as	   such	   this	  
could	   be	   addressed	   by	   investigating	   isolated	   mitochondria	   from	   both	   types	   of	  
macrophages.	  	  	  
In	  the	  event	  of	  a	  sudden	  increase	  in	  energy	  demand	  or	  stress,	  cells	  can	  engage	  their	  
SRC.	  This	  extra	  mitochondrial	  capacity	  allows	  the	  cells	  to	  effectively	  manage	  cellular	  
stress	  such	  as	  hypoxia	  and	  low	  levels	  of	  nutrients.	  It	  has	  been	  shown	  to	  be	  crucial	  for	  
both	  cellular	  survival	  and	  function	  (van	  der	  Windt	  et	  al.,	  2012,	  Nicholls,	  2009).	   It	   is	  
important	  for	   immune	  cells	  to	  rapidly	  respond	  to	  environmental	  stimuli	  to	  perform	  
their	  functions	  and	  as	  such	  they	  need	  to	  be	  able	  to	  manage	  increased	  levels	  of	  stress	  
or	   energy	   demand.	   Hvcn1-­‐/-­‐	   macrophages	   were	   found	   to	   have	   a	   diminished	   SRC,	  
which	   provides	   further	   confirmation	   that	   their	   mitochondria	   may	   be	   defective.	  
Despite	  this,	  I	  observed	  no	  effects	  on	  cell	  survival	  in	  response	  to	  LPS.	  
Until	  recently,	  ROS	  where	  thought	  to	  exclusively	  cause	  damaging	  effects	  on	  cellular	  
proteins	  and	  lack	  a	  physiological	   function	  (Sena	  and	  Chandel,	  2012).	  However,	  ROS	  
are	  now	  appreciated	  to	   function	  as	  signalling	  molecules	   that	  can	  modulate	  cellular	  
processes	   through	   redox-­‐dependent	   signalling.	   Cellular	   signalling	   is	   important	   to	  
maintain	  cell	  homeostasis	  and	  is	  also	  crucial	  for	  effector	  functions	  such	  as	  cytokine	  
production	  in	  macrophages	  (Bulua	  et	  al.,	  2011).	  	  	  
It	  is	  unclear	  how	  HVCN1	  is	  involved	  in	  other	  functional	  aspects	  of	  immune	  cells	  other	  
than	  the	  respiratory	  burst	  and	  very	  little	  is	  known	  about	  downstream	  signalling	  upon	  
HVCN1	  activation.	  A	  comprehensive	  study	  of	   signalling	  events	   regulated	  by	  HVCN1	  
was	   conducted	   with	   Hvcn1-­‐/-­‐	   B	   cells,	   showing	   impaired	   B	   cell	   receptor	   (BCR)	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signalling	   (Capasso	   et	   al.,	   2010).	   No	   other	   studies	   assessing	   the	   role	   of	   HVCN1	   in	  
immune	  cells	  has	  investigated	  downstream	  signalling	  events	  in	  Hvcn1-­‐/-­‐	  cells.	  	  
Cell	   signalling	   studies	   of	  WT	   and	  Hvcn1-­‐/-­‐	  macrophages	   fund	   that	   the	   cells	   lacking	  
proton	  channels	  displayed	  quicker	  activation	  kinetics	  as	  well	  as	  sustained	  activation	  
compared	  to	  their	  WT	  counterparts.	  This	  was	  true	  for	  both	  the	  MAPKs	  investigated	  
and	  the	  NF-­‐κB	  signalling	  pathway.	  This	  enhanced	  cell	  signalling	  was	  ‘restored’	  in	  the	  
presence	   of	   a	   mitochondrial	   ROS	   scavenger,	   thus	   suggesting	   that	   the	   aberrant	  
signalling	  was	  due	  to	  the	  overproduction	  of	  mitochondrial	  ROS.	   In	  the	  same	  event,	  
scavenging	   of	   mitochondrial	   ROS	   delayed	   the	   activation	   kinetics	   of	   the	   signalling	  
pathways	   in	   both	  WT	   and	  Hvcn1-­‐/-­‐	  macrophages.	   This	   indicates	   that	  mitochondrial	  
ROS	  can	  operate	  as	  signalling	  molecules.	  	  	  
The	   MAPKs	   and	   the	   NF-­‐κB	   signalling	   pathway	   are	   important	   for	   several	   immune	  
functions,	  such	  as	  cytokine	  production	  (Boutros	  et	  al.,	  2008,	  Li	  and	  Verma,	  2002).	   I	  
therefore	   investigated	   the	   levels	   of	   IL-­‐6,	   IL-­‐10,	   TNF,	   and	   IL-­‐12p40.	   I	   observed	   a	  
significant	   increase	   in	   cytokine	   production	   in	   the	   Hvcn1-­‐/-­‐	   macrophages.	   In	  
accordance	  with	  the	  cell	  signalling	  data,	  scavenging	  of	  mitochondrial	  ROS	  ‘restored’	  
cytokine	  production	  by	  reducing	  the	  output	  to	  similar	  levels	  in	  both	  cell	  types.	  As	  this	  
reduction	   in	  cytokine	  production	  was	  evident	   in	   the	  WT	  macrophages,	   it	  highlights	  
yet	  again	  the	  involvement	  of	  mitochondrial	  ROS	  in	  cell	  effector	  functions.	  	  
The	   data	   in	   my	   thesis	   thus	   shows	   the	   crucial	   involvement	   of	   HVCN1	   in	   the	  
respiratory	   burst	   of	   macrophages.	   It	   also	   highlights	   a	   mitochondrial	   defect	   in	   the	  
absence	   of	   HVCN1	   that	   leads	   to	   aberrant	   cell	   signalling	   and	   overproduction	   of	  
inflammatory	  cytokines.	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Given	  my	   observations,	   I	   would	   hypothesise	   that	  Hvcn1-­‐/-­‐	   macrophages	   would	   be	  
more	  efficient	  at	  eliminating	  pathogens,	  due	  to	  their	  faster	  signalling	  and	  increased	  
production	   of	   inflammatory	   cytokines.	   However,	   this	   phenotype	   could	   potentially	  
have	  a	  much	  more	  damaging	  effect	  on	  the	  surrounding	  tissues.	   It	   should	  be	  noted	  
that	   faster	   clearance	   of	   pathogens	   might	   mean	   less	   tissue	   damage	   due	   to	   pro-­‐
inflammatory	   cytokine	   production.	   It	   would	   be	   interesting	   to	   assess	   not	   only	   the	  
ability	  of	  Hvcn1-­‐/-­‐	  macrophages	  to	  clear	  pathogens,	  but	  also	  the	  rate	  at	  which	  they	  
accomplish	   it.	   That	   being	   said,	   it	   would	   be	   important	   to	   also	   assess	   Hvcn1-­‐/-­‐	  
macrophages	  in	  the	  presence	  of	  IL-­‐4,	  which	  induces	  an	  M2	  phenotype.	  Drawing	  from	  
the	  observations	  of	   the	  metabolic	   state	  of	   steady	   state	  Hvcn1-­‐/-­‐	  macrophages,	  one	  
could	   hypothesise	   that	   these	   cells	   would	   not	   be	   able	   to	   fully	   polarise	   to	   an	   M2	  
phenotype,	   which	   is	   characterised	   by	   high	   rates	   of	  mitochondrial	   respiration.	   The	  
implications	   of	   this	   would	  mean	   that	  Hvcn1-­‐/-­‐	   macrophages	  might	   fair	   better	   in	   a	  
tumour	   microenvironment,	   which	   is	   known	   to	   polorise	   macrophages	   towards	   the	  
M2	  phenotype.	  	  
At	  a	   cellular	   level,	   I	  would	  hypothesise	   that	  Hvcn1-­‐/-­‐	  macrophages	  would	  amplify	  a	  
type	  1	  response	  through	  the	  recruitment	  and	  polarisation	  of	  TH1	  cells.	  Whilst	  I	  have	  
observed	  a	  great	  amount	  of	  IL-­‐12	  secretion	  from	  these	  cells,	  it	  would	  be	  necessary	  to	  
investigate	  a	  broader	  range	  of	  cytokines	  and	  chemokines,	  such	  as	  CXCL9	  and	  CXCL10,	  
to	   gain	   a	   better	   understanding	   of	   their	   cytokine	   profile.	   In	   addition,	   it	   would	   be	  
interesting	   to	  determine	   if	   such	  polarisation	  of	  T	  cells	  would	   indeed	  occur	   through	  
the	  use	  of	  in	  vitro	  co-­‐cultures	  of	  Hvcn1-­‐/-­‐	  macrophages	  and	  T	  cells.	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In	   vivo	  models	   of	   bacterial	   infection	   could	   be	  used	   to	   investigate	   the	  number	   and	  
phenotype	   of	   activated	   T	   cells.	   At	   the	   present	   time,	   there	   are	   issues	   with	   in	   vivo	  
approaches	  using	  Hvcn1-­‐/-­‐	  mice.	  Due	   to	   the	  disrupting	  mutations	  within	   the	  Hvcn1	  
gene,	   HVCN1	   is	   absent	   in	   all	   cell	   types	   that	   express	   the	   channel.	   This	   means	  
assessing	   the	   impact	   that	  Hvcn1-­‐/-­‐	  macrophages	  would	  have	  on	   the	  outcome	  of	  an	  
infection,	   for	   example,	   would	   be	   quite	   difficult.	   However,	   this	   problem	   could	   be	  
overcome	   through	   the	   use	   of	   Cre-­‐Lox	   recombinase	   technology.	   This	   technology	  
employs	  a	  Cre	  recombinase	  enzyme	  that	  can	  recombine	  target	  sequences,	  known	  as	  
Lox	  sequences.	  Cre	   recombinase	   technology	  under	   the	  control	  of	  a	  promoter	   from	  
the	  Csfr1	  gene	  would	  provide	  a	   less	  confounding	  animal	  model	   to	  use,	  as	  CSFR1	   is	  
mainly	  expressed	  on	  myeloid	  cells.	  This	  model	  would	  allow	  for	  the	  investigation	  of	  a	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